Interation_Record_ID,Interaction_Category,MASI-Microbe-ID,Microbe-Tax-ID,Microbe-Name,MASI-Substance-chemicalD,Canonical smiles ,ATC classification,Substance-Name,Substance-Category,Substance-subCategory,Substance_Exposure_Details,Microbiota_Site,Microbe_Change,Microbe_Change_Statistics,Metabolites,Metabolism_Type,Metabolism_Enzymes,Metabolism_Effect_on_Drug,Experiment_System,Experiment_Model_Species,Model_Condition/Disease,Metabolism_Mechanism,Outcome,Reference_ID_Type,Reference_ID
PMDBI40726,Substances alter microbe abundance,PMDBM209,562,Escherichia coli,PMDBD1004,,,5-aminosalicylic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI42371,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1005,,,5-fluoro-2'-deoxyuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vivo,Caenorhabditis elegans,n.a.,n.a.,completely sterile,PMID,PMID: 30890566; PMID: 28431244
PMDBI42387,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1006,,,5-fluorocytosine,Therapeutic Substance,Approved Drug; Prodrug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase chemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42388,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1006,,,5-fluorocytosine,Therapeutic Substance,Approved Drug; Prodrug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40190,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40310,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000699998],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40449,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40590,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40713,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002546255],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40731,Substances alter microbe abundance,PMDBM209,562,Escherichia coli,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU.,n.a.,Increase,P < 0.05,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis.,PMID,PMID: 19176868
PMDBI41032,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41188,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41308,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41781,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000661825],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41887,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.71E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42029,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100844],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42194,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000491757],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42369,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,5-fluorouridine monophospate,Phosphorylation,Uracil phosphoribosyltransferase,Increase activity,In vivo,Caenorhabditis elegans,n.a.,n.a.,Lead to sterility,PMID,PMID: 30890566; PMID: 28431244
PMDBI42385,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42386,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42630,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007454688],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42950,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002535612],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43038,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43122,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002511467],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43415,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005029022],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43686,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43819,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43973,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.85E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44141,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002584087],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44461,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.27E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44630,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001979002],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45560,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD8,,,5-fluorouracil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42389,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1008,,,6-Mercaptopurine-2′-deoxyriboside,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI45197,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD10,,,Abacavir Sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000584373],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10862,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD13,,,Acecainide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI10863,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD13,,,Acecainide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI41690,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD14,,,Acenocoumarol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.21E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44868,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD14,,,Acenocoumarol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006136303],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40919,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD17,,,Acetopromazine maleate salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003467683],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41105,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD17,,,Acetopromazine maleate salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003784869],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42390,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1015,,,Actinomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40740,Substances alter microbe abundance,PMDBM233,853,Faecalibacterium prausnitzii,PMDBD1017,,,Adalimumab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI40745,Substances alter microbe abundance,PMDBM912,301302,Roseburia faecis,PMDBD1017,,,Adalimumab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI45189,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD22,,,Albendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001083172],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45467,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD22,,,Albendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003156937],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40036,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40134,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40263,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40393,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40540,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Marine medaka,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40675,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.38E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40793,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40966,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41151,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41252,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41372,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41556,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41845,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00079853],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41962,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42139,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42269,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.40E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42394,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42564,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42740,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42891,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.37E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43011,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.47E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43094,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005361641],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43185,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43349,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164611],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43644,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43757,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43915,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44081,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44237,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44399,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44564,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171847],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44767,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.85E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44917,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45067,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.22E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45245,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45371,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.47E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45509,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD24,,,Alexidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41439,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD25,,,Alfacalcidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007674264],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Acute lymphocytic leukemia (ALL),n.a.,n.a.,PMID,PMID: 29555994
PMDBI42081,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD25,,,Alfacalcidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.63E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42683,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD25,,,Alfacalcidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000508931],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43472,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD25,,,Alfacalcidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00282026],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44688,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD25,,,Alfacalcidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001149386],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45324,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD25,,,Alfacalcidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005574865],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45461,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD25,,,Alfacalcidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.93E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10842,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD26,,,Alfuzosin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI10709,Microbes metabolize substances,PMDBM349,303,Pseudomonas putida,PMDBD30,,,Altretamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Microbial N-demethylase enzymes,Lead to similar toxic effects as seen with melamine;Substrate similar(no evidence),PMID,PMID: 31184303
PMDBI42699,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD31,,,Alverine citrate salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006749194],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10920,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD32,,,Amantadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI10921,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD32,,,Amantadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI10922,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD32,,,Amantadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI10923,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD32,,,Amantadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI40889,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41067,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000394597],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41804,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.99E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42072,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42222,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43451,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001557165],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43705,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44493,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009074269],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45016,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214389],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45319,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45453,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45578,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD33,,,"Amethopterin (R,S)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41433,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007685758],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42492,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002376626],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42668,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110866],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43453,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000556732],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43706,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44670,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241562],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44851,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45018,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001543463],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45157,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45320,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160215],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45455,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD34,,,Amikacin hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10571,Microbes metabolize substances,PMDBM214,316435,Escherichia coli Nissle 1917,PMDBD36,,,Amiodarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,DEA,n.a.,n.a.,Increase Efficacy; Increase Bioavailability,In vivo,Animal model,n.a.,n.a.,"Increase bioavailability of AMI,increase plasma levels of desethylamiodarone(DEA),promote the absorption of AMI and increase the activity of CYP2C ",PMID,PMID: 30227749
PMDBI41078,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00289599],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41438,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000413539],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41664,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42498,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001134983],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42675,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.04E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43283,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000147452],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43462,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44332,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008678266],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44499,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000130393],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44678,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD37,,,Amiodarone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002565],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41916,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD39,,,Amlodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944477],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44520,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD39,,,Amlodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40915,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD40,,,Amodiaquin dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003290192],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44031,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD40,,,Amodiaquin dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.09E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44189,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD40,,,Amodiaquin dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41104,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD41,,,Amoxapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44193,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD41,,,Amoxapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008486101],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10136,Microbes metabolize substances,PMDBM140,n.a.,Clostridioides difficile,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Piglet,n.a.,n.a.,Promote colonization by opportunistic pathogens,PMID,PMID: 26972811
PMDBI40047,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002712],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40148,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40407,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00457977],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mice,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40554,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00921525],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40751,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008
PMDBI40752,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475; PMID: 8243490; PMID: 7961199
PMDBI40807,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005211253],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40980,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41266,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41384,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41570,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41741,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004980222],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41855,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41976,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42153,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42283,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42408,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42578,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42754,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42904,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43017,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43100,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43198,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43363,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000387318],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43658,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.83E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43771,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43929,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.54E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44094,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44250,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000102179],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44412,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44578,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253591],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44780,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44931,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45081,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45259,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45385,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45522,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD42,,,Amoxicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40793,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1029,,,Amoxicillin plus metronidazole,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979
PMDBI40044,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40145,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40404,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002477444],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40551,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004276717],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40804,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40977,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41263,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41381,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41567,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41854,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41973,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42150,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.36E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42280,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.14E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42405,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42575,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42751,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00023782],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42901,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.30E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43014,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43097,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43195,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.44E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43360,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43655,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.12E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43768,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43926,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44092,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44247,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.54E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44409,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44575,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138933],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44777,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44928,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.75E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45078,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45256,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45382,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45519,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD43,,,Ampicillin trihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10995,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD45,,,Anagrelide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI10997,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD45,,,Anagrelide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI10998,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD45,,,Anagrelide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI10999,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD45,,,Anagrelide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11000,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD45,,,Anagrelide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11001,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD45,,,Anagrelide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.346 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI10864,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD46,,,Anastrozole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI41674,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD47,,,Anethole-trithione,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42686,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD47,,,Anethole-trithione,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428591],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42842,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD47,,,Anethole-trithione,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44695,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD47,,,Anethole-trithione,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000981846],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44862,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD47,,,Anethole-trithione,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45173,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD47,,,Anethole-trithione,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40479,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002112696],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41069,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005675801],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41656,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41805,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006857437],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41904,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009586015],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42074,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000893552],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42670,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000493545],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42971,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150815],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43849,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44164,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45579,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD49,,,Anthralin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40215,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003977197],n.a.,n.a.,n.a.,n.a.,n.a.,Medaka fishes,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40340,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241869],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40485,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000276431],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41076,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41435,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008270317],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41660,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001204364],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44001,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001985399],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44496,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001005864],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44675,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000454054],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45581,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD63,,,Aprepitant,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008757071],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42391,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1038,,,AQ4N,Therapeutic Substance,Approved Drug; Prodrug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase cemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42392,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1039,,,Ara G hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42393,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1039,,,Ara G hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI41811,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD69,,,Aripiprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002537439],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44032,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD69,,,Aripiprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018774],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44353,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD69,,,Aripiprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008493167],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40083,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD74,,,Asenapine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003502773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42511,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD74,,,Asenapine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006518934],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43496,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD74,,,Asenapine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003655819],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40859,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40860,Substances alter microbe abundance,PMDBM57,28116,Bacteroides ovatus,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40863,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40864,Substances alter microbe abundance,PMDBM959,1305,Streptococcus sanguinis,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40865,Substances alter microbe abundance,PMDBM957,1309,Streptococcus mutans,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40866,Substances alter microbe abundance,PMDBM657,1689,Bifidobacterium dentium,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40868,Substances alter microbe abundance,PMDBM812,n.a.,Lachnospiraceae bacterium 3 1 57FAA CT1,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40869,Substances alter microbe abundance,PMDBM813,n.a.,Lachnospiraceae bacterium 7 1 58FAA,PMDBD1044,,,Aspirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40074,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000539056],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41658,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42673,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005017795],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42833,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0003577],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43279,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002062169],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43459,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000965664],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44330,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007611659],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44674,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000930375],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45019,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000919651],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45162,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD76,,,Astemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000536906],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41689,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD79,,,Atovaquone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005811135],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45190,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD79,,,Atovaquone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002191168],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40142,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-05],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40271,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40401,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40548,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40681,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40801,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40974,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41158,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008452406],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41260,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41564,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41737,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41851,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.39E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41970,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42147,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.91E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42277,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.17E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42402,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42572,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42748,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42898,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43192,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43357,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000163771],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43652,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43765,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43923,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44089,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44244,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44407,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.57E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44572,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000243363],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44774,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44925,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45075,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45253,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45379,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45516,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD80,,,Auranofin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41434,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009131895],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41655,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00063536],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41903,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009795205],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42073,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000468584],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42669,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006347589],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43277,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001196707],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43455,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000569178],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43708,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001227586],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44672,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000364452],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45159,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45457,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD81,,,Avermectin B1a,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007766915],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42101,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD82,,,Azacytidine-5,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40209,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005590073],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40331,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.94E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40612,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.49E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40734,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41064,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000761829],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41650,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.84E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41802,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000516951],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41899,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004646898],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42350,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42663,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42829,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00112447],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43445,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD83,,,Azaguanine-8,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000195813],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41672,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD85,,,Azathioprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41910,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD85,,,Azathioprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42503,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD85,,,Azathioprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00322275],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42684,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD85,,,Azathioprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000735586],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42973,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD85,,,Azathioprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007574365],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44341,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD85,,,Azathioprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171237],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45586,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD85,,,Azathioprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002817096],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40080,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD86,,,Azelastine HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43298,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD86,,,Azelastine HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007897794],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43491,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD86,,,Azelastine HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0041032],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44710,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD86,,,Azelastine HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006525874],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40014,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40106,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,n.a.,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40235,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40365,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40512,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40650,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.47E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40765,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40870,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 12111597
PMDBI40938,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41123,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41224,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41344,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41528,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41706,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41934,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42114,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42241,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42366,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42536,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42713,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42863,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42989,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43071,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43157,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43322,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00040424],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43621,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43730,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43887,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44053,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44212,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333615],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44373,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44536,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000342522],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44739,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44889,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45039,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45217,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45343,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45481,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD88,,,Azithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40873,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1049,,,Azlocillin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564
PMDBI40063,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40580,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003295689],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40842,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41015,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41293,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41409,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41605,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41878,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001584198],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42011,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42182,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42315,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42443,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42612,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42788,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42935,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43233,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.44E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43398,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016811],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43675,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43805,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43960,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44126,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44285,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44446,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44613,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216779],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44813,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44965,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45114,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45286,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45409,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45551,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD89,,,Azlocillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42838,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD91,,,Aztreonam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43050,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD91,,,Aztreonam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.99E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43133,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD91,,,Aztreonam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43857,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD91,,,Aztreonam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44338,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD91,,,Aztreonam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000688403],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45585,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD91,,,Aztreonam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41036,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41311,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41421,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41624,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42034,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42199,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.62E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42332,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.58E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42462,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42634,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42805,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.38E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42953,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43251,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43419,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000991355],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43690,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005573957],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43824,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.65E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44143,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44304,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.67E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44465,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.48E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44635,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000563638],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44831,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44983,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45131,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.16E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45302,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45429,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45562,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD93,,,Bacampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40178,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003138697],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40440,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003217095],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40581,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000945301],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40843,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001295533],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41016,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41183,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135542],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41294,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41410,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41606,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41768,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41879,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000254074],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42012,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42316,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42444,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42613,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42789,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42936,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281578],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43234,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43399,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017063],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43676,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43961,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.35E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44127,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44286,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.35E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44447,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44614,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185438],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44814,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44966,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45115,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45287,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45410,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD94,,,Bacitracin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11826,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11827,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11828,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11829,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11830,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.771 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11831,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11832,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11833,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11834,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11835,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11836,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11837,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11838,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11839,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11840,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11841,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11842,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11843,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI11844,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11845,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11846,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD98,,,Benazepril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI40091,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD99,,,Benfluorex hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007068035],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40043,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40144,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-05],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40273,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000288831],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40403,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000906821],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40550,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001659558],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40803,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40976,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.01E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41262,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41380,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.40E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41566,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41853,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41972,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42149,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42279,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42404,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42574,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42750,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42900,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43194,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43359,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001038111],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43654,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.89E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43767,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43925,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44091,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44246,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44408,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44574,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000606965],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44776,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44927,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45077,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45255,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.08E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45381,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45518,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD100,,,Benzathine benzylpenicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10844,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.828 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI40311,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160752],n.a.,n.a.,n.a.,n.a.,In vivo,Swiss mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40450,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00262628],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40591,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001233291],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40714,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000322832],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40857,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007823119],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41033,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00226359],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41309,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004146819],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41620,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41782,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41888,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42030,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42195,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42329,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000263951],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42459,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004132065],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42631,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000759868],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43416,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003862578],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43687,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007174905],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43820,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43974,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44142,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.90E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44301,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002185392],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44631,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0064412],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44828,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.42E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44980,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45300,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100118],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45426,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD101,,,Benzbromarone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40151,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40277,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40410,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mice,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40557,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40685,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750494],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40810,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.14E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40983,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41162,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000146181],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41269,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41387,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41573,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41744,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001738587],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41858,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171892],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41979,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42156,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000215531],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42286,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42411,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42581,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42757,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42907,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.17E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43201,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43366,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43659,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.48E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43774,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000270398],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43932,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44097,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44253,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44415,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44581,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000128455],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44783,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000651391],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44934,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45084,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45261,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00127379],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45387,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.44E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45525,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD102,,,Benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10866,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD103,,,Benzthiazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI40090,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD104,,,Benzydamine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000584515],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40025,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40119,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.79E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Bufo gargarizans,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40248,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000489548],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40378,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40525,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Carassius auratus,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40778,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40951,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.65E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41136,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000349651],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41237,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41357,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41541,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41836,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41947,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42126,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42254,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42379,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.85E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42549,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42726,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42876,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43000,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00405416],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43084,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43170,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43335,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209646],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43631,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.80E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43743,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43900,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44066,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44222,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44386,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00023389],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44549,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00066158],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44752,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44902,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45052,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45230,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45356,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45494,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD105,,,Benzylpenicillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40732,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007469016],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41062,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41649,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.81E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41801,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00132593],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42066,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004788164],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42488,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027457],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42827,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009131912],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43272,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43443,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00166258],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43994,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0023746],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44162,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44663,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002131008],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45010,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005475023],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45450,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD106,,,Bepridil hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008500296],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40895,Substances alter microbe abundance,PMDBM957,1309,Streptococcus mutans,PMDBD1055,,,Beta blockers,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI11496,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11498,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11499,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11500,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11501,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11502,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11503,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11504,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11505,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11506,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11507,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11508,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI11509,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI11510,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD108,,,Betamethasone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11665,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11666,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11667,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11669,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11670,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11671,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11672,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.83 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11673,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11675,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11676,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11677,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11678,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11679,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11680,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI11681,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD109,,,Betamethasone valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI43715,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD110,,,Betaxolol hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006477728],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11002,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD111,,,Bezafibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11003,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD111,,,Bezafibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11004,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD111,,,Bezafibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11005,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD111,,,Bezafibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11006,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD111,,,Bezafibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11007,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD111,,,Bezafibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11008,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD111,,,Bezafibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI10868,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD112,,,Bicalutamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.612 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI10869,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD112,,,Bicalutamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI40873,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00032003],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41049,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000280716],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41635,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41792,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002100295],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42049,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.35E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Juvenile Idiopathic Arthritis (JIA),n.a.,n.a.,PMID,PMID: 29555994
PMDBI42210,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000102773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42341,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002742893],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI42475,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42645,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42815,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43263,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43431,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165081],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44151,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002866397],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44313,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003915281],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44477,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165427],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44646,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160194],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44840,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44996,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45143,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD113,,,Bifonazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.45E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10948,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD115,,,Biperiden,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI10950,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD115,,,Biperiden,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI10951,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD115,,,Biperiden,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.583 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13498,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.102 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13499,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.027 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13500,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.233 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13501,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.813 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13502,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.878 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13503,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.22 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13505,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.752 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13506,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.091 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13507,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.989 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13508,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-12.105 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13509,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.313 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13510,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.466 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13511,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.173 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13512,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13513,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.431 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13514,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.122 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13515,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.718 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13516,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.5 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13517,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.186 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13519,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.255 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13520,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.885 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13521,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13522,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.422 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13523,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.311 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13524,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.728 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI13525,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.452 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13526,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.686 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13527,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.712 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13528,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.324 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI13529,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.654 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13530,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.456 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13531,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.716 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13532,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.49 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13533,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.584 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13534,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.081 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13535,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.328 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13536,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.122 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13537,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.549 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13538,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.863 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13539,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.547 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13540,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.23 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13541,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.41 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13542,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.369 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13543,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.192 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13544,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.472 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13545,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.201 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13546,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.266 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13547,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.587 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13548,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13549,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.678 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13550,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.639 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13551,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.854 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13552,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.863 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13553,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.33 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13554,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.0 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13556,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.324 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI13557,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.482 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13558,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.339 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13559,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.438 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13560,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.176 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13561,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.146 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13562,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.462 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13563,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.412 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13564,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.394 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13565,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.531 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13566,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.5 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13567,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.735 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13568,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.213 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13569,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.349 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13570,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.329 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13571,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.467 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13572,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.69 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13573,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD116,,,Bisacodyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.127 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI41691,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD122,,,Bosentan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10247,Microbes metabolize substances,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD123,,,Brivudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,bromovinyluracil (BVU),n.a.,n.a.,Increase Toxicity,In vivo,Mouse,"Conventional(CV),germ-free(GF)",Microbial enzymes,Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure,PMID,PMID: 30733391
PMDBI10248,Microbes metabolize substances,PMDBM57,n.a.,Bacteroides ovatus,PMDBD123,,,Brivudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,bromovinyluracil (BVU),n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,n.a.,Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure,PMID,PMID: 30733391
PMDBI13002,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.242 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13003,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.889 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13004,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI13005,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.164 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13006,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.789 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13008,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI13009,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.348 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13010,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.02 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13011,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13012,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI13013,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13014,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI13015,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.327 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13016,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13017,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13018,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.993 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13019,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13021,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.64 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI13022,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13023,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI13024,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI13025,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI13026,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13027,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13028,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI13029,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13030,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.364 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13031,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.13 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13032,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.272 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI13033,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI13034,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.023 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13035,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13036,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13037,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.911 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI13038,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.097 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13039,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.343 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13040,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.933 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13041,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.361 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13042,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13043,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.127 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13044,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI13045,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13046,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13047,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI13048,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.976 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI13049,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI13050,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13051,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.921 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13052,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.925 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI13054,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.102 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13055,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.548 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13056,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.563 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13057,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI13058,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13059,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI13060,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13061,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13062,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.157 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13063,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.198 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13064,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13065,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.066 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13066,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.099 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13067,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD125,,,Bromocriptine mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI40092,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD126,,,Bromperidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009428028],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11511,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11512,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11514,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11515,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11516,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11517,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.334 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11518,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11519,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11520,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.997 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11521,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11522,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11523,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI11524,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11525,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD128,,,Budesonide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI42975,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD129,,,Bufexamac,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00773707],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10870,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD130,,,Bupropion,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI10871,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD130,,,Bupropion,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI45200,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD131,,,Butamben,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001622822],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42506,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD132,,,Butenafine Hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.15E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43293,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD132,,,Butenafine Hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002639895],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44018,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD132,,,Butenafine Hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000999474],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44180,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD132,,,Butenafine Hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0018713],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44693,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD132,,,Butenafine Hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005890941],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45171,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD132,,,Butenafine Hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007511804],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40880,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016844],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41057,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41640,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41797,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000926063],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42055,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42213,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.75E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42344,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001497309],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42480,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42652,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42821,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43265,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43435,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00028298],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44481,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44653,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000215102],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44842,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45002,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45147,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD133,,,Butoconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10336,Microbes metabolize substances,PMDBM233,853,Faecalibacterium prausnitzii,PMDBD135,,,Butyric Acid,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Produce relatively high levels of butyrate in the gastrointestinal tract,Limit the growth of pathogenic microorganisms,PMID,PMID: 26261284
PMDBI42372,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1072,,,Camptothecin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vivo,Caenorhabditis elegans,n.a.,n.a.,production of few dead embryos,PMID,PMID: 30890566; PMID: 28431244
PMDBI10845,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD140,,,Camylofine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI10846,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD141,,,Capecitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.688 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI42374,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD141,,,Capecitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42375,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD141,,,Capecitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40024,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40118,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40247,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40377,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.95E-06],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40524,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40662,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40777,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.46E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40950,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41135,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41236,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.06E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41356,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41540,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41718,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41835,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41946,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42125,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42253,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42378,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42548,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42725,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42875,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42999,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43083,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43169,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43334,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000221545],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43742,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43899,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44065,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44221,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44385,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44548,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132494],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44751,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44901,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45051,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45229,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45355,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001009145],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45493,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD144,,,Carbadox,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41917,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD145,,,Carbenoxolone disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002796885],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42097,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD145,,,Carbenoxolone disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11009,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD146,,,Carbetapentane citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11011,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD146,,,Carbetapentane citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11012,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD146,,,Carbetapentane citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11013,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD146,,,Carbetapentane citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11014,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD146,,,Carbetapentane citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11015,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD146,,,Carbetapentane citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI10111,Microbes metabolize substances,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD147,,,Carboxymethylcellulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria,"The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome",PMID,PMID: 26972811
PMDBI11847,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11849,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11850,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11851,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11852,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11853,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11854,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11855,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11856,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11857,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11858,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11859,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11860,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI11861,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11862,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11863,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11864,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11865,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11866,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11867,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD148,,,Carisoprodol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.86 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11526,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.922 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11527,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.225 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11528,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.632 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11529,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.426 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11530,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.691 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11531,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.975 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11532,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.243 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11533,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.653 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11534,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.566 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11535,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.604 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI11536,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI11537,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.092 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11538,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.46 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11539,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.656 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11540,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.322 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI43713,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD150,,,Carvedilol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004253894],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42394,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1082,,,CB1954,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42395,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1082,,,CB1954,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40900,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1083,,,Cefaclor,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262
PMDBI41056,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41322,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41639,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42054,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42479,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42651,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004828422],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42820,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000121143],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42967,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.19E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43434,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00079504],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43841,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44480,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.59E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44652,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000751703],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44841,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45001,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009425311],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45313,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45443,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45575,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD153,,,Cefaclor hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41687,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD154,,,Cefadroxil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000723187],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44519,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD154,,,Cefadroxil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002679627],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40032,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00597968],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40130,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.29E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40259,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague-Dawley Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40389,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40536,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000923016],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40789,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40962,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41147,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001081854],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41248,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41368,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41552,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41958,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42135,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42265,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42390,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42560,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42736,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42887,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003422085],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43008,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43092,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43181,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43345,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000988593],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43640,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004079502],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43753,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43911,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44077,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44233,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44396,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44560,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686521],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44763,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44913,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45063,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45241,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45367,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45505,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD155,,,Cefazolin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40052,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000569297],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40158,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.91E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40416,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008610966],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40817,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40990,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41275,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41394,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41580,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41986,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42163,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003441605],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42292,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42418,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.81E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42587,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42763,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42914,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43022,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43105,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43208,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43373,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000401702],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43664,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43781,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43939,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44104,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44260,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000312742],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44421,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44588,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000320023],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44789,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44941,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45090,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45266,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45392,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45532,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD156,,,Cefdinir,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40927,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1085,,,Cefepime,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502
PMDBI40061,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Primigravida ICR mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40437,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001836614],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40838,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007728184],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41011,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41289,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41601,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41764,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.48E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42007,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42179,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42311,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42439,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42608,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42784,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43029,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43113,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43229,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.50E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43394,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216184],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43673,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000711793],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43802,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43958,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44122,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44281,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44442,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253591],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44609,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44809,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44962,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45110,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45282,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45405,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45549,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD157,,,Cefepime hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40453,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003029048],n.a.,n.a.,n.a.,n.a.,In vivo,Broilers,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40861,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40942,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110
PMDBI41037,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41312,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41625,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42035,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42333,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42463,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42806,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43040,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43124,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43252,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003586475],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43420,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000279971],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43825,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43975,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44144,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44305,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44466,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44636,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000177543],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44832,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45132,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45303,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45430,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45563,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD158,,,Cefixime,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40441,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD159,,,Cefmetazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40302,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40845,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41019,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41297,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41609,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41770,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42015,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42318,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42447,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42616,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42792,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42939,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.64E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43032,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43116,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43237,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43402,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001689],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43808,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43963,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44289,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44450,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44617,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000140634],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44817,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44969,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45117,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45290,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45413,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45553,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD159,,,Cefmetazole sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40958,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD160,,,Cefoperazone,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054
PMDBI40959,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD160,,,Cefoperazone,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284
PMDBI40046,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.29E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40147,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40274,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001529607],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40406,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mice,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40553,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00013257],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40806,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.71E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40979,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41265,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41383,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41569,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41740,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41975,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42152,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42282,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42407,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42577,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42753,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42903,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000290109],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43016,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43099,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43197,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43362,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384931],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43657,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43770,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43928,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44249,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000119098],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44411,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.71E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44577,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000300773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44779,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44930,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45080,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45258,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45384,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45521,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD161,,,Cefoperazone dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40054,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Enchytraeus crypticus,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40162,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40286,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00209371],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40420,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646302],n.a.,n.a.,n.a.,n.a.,In vivo,FHM; CD-1 mice,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40821,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.14E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40994,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41277,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41584,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41866,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41990,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42166,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002743209],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42296,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003205469],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42422,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42591,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42767,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43024,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.39E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43107,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43212,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000949381],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43377,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271267],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43785,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43943,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44108,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44264,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.35E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44425,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.21E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44592,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172471],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44792,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44945,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45094,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.58E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45269,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45394,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45535,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD162,,,Ceforanide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40987,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1087,,,Cefotaxime,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592
PMDBI40045,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.47E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40146,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.51E-05],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40405,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001321505],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40552,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001403982],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40805,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40978,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41264,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41382,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41568,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41739,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000524699],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41974,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42151,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.25E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42281,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42406,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42576,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42752,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.35E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42902,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001552307],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43015,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43098,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43196,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43361,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000362657],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43656,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000312424],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43769,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43927,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44093,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44248,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44410,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.81E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44576,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131781],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44778,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44929,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45079,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45257,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45383,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45520,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD163,,,Cefotaxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40300,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40438,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40840,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40993,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592
PMDBI41013,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41291,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41603,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41766,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.60E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42009,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42180,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009455871],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42313,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42441,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000977135],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42610,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42786,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42933,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001088834],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43030,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43114,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43231,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180873],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43396,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271267],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43804,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43959,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44124,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44283,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44444,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.03E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44611,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000155772],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44811,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45112,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000787021],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45284,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45407,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45550,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD164,,,Cefotetan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40180,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.19E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40844,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000358235],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41018,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.03E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41296,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41412,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41608,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42014,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42184,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42446,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42615,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42791,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42938,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006630414],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43031,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43115,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43236,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43401,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000405409],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43678,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43807,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44129,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44288,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000322932],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44449,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44616,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372124],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44816,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.12E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44968,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133971],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45116,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45289,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45412,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45552,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD165,,,Cefotiam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40999,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1088,,,Cefoxitin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592
PMDBI40424,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD166,,,Cefoxitin ,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40166,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40289,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40569,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.89E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40825,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40998,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41172,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133401],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41280,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41588,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41753,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41994,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42299,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42426,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42595,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42771,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42921,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.77E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43025,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.40E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43109,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43216,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273365],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43381,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169502],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43789,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43946,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.36E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44111,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44268,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.38E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44429,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44596,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233624],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44796,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44949,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45098,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45272,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45397,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45539,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD166,,,Cefoxitin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41024,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1090,,,Cefpodoxime Proxetil,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199
PMDBI40462,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD167,,,Cefsulodin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005294977],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41317,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41632,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.81E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41790,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003531295],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42045,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42339,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI42472,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42642,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42812,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43260,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43428,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168449],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43831,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44311,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44473,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44643,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00022602],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44837,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44992,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45141,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45308,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45437,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45569,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD167,,,Cefsulodin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006092327],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41047,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1092,,,Ceftaroline,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399
PMDBI41056,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1093,,,Ceftaroline/avibactam,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638
PMDBI40308,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.47E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40448,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004975989],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41030,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41306,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41617,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.88E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41779,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42026,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42191,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42326,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42456,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001689],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42627,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42800,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43037,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43121,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43245,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43412,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407345],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43817,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43971,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44139,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44298,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000334037],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44458,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44627,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333791],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44825,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45297,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45423,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45559,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD168,,,Ceftazidime pentahydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41065,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1094,,,Ceftazidime/avibactam,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639
PMDBI41073,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1095,,,Ceftibuten,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366; PMID: 7961199
PMDBI41091,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1097,,,Ceftriaxone,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 1800369; PMID: 3992209; PMID: 11020259
PMDBI41110,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1098,,,Cefuroxime,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592
PMDBI40434,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD169,,,Cefuroxime ,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003534694],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41116,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1099,,,Cefuroxime axetil,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 8618110; PMID: 7961199
PMDBI40060,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00010915],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Primigravida ICR mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40835,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41008,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41286,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41404,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41598,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.12E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42004,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42176,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42308,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42436,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42605,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42781,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43027,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.75E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43111,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43226,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43391,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168435],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43671,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43799,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43955,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44120,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44278,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.53E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44439,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44606,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132382],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44806,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44959,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45107,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45279,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45402,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45547,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD169,,,Cefuroxime sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40342,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000250272],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40488,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40895,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41079,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41665,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42499,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44500,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45583,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD172,,,"Cephalosporanic acid, 7-amino",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001967198],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40414,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD174,,,Cephalothin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001022261],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40156,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.52E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40281,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40815,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.94E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40988,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41274,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41392,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41578,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41984,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42161,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.01E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42290,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42416,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42585,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42761,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42912,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006144696],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43021,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43104,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43206,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43371,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168984],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43663,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686529],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43779,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43937,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44102,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44258,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.52E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44419,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44586,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135328],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44787,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44939,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45088,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45265,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45391,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45530,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD174,,,Cephalothin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41152,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1103,,,Cephazolin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592
PMDBI12260,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12261,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12262,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.957 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12263,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12264,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12265,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI12266,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI12267,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.811 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12268,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI12269,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12270,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12271,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12272,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12273,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12274,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12276,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI12277,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12278,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12279,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12280,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12281,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12282,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12283,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12284,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.687 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI12285,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12286,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12287,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12288,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD175,,,Cetirizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI40093,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD179,,,Chlorcyclizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000594816],n.a.,n.a.,n.a.,n.a.,In vivo,Rabbit,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11016,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD181,,,Chlormezanone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11018,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD181,,,Chlormezanone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI11019,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD181,,,Chlormezanone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11020,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD181,,,Chlormezanone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11021,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD181,,,Chlormezanone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11022,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD181,,,Chlormezanone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI41440,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD182,,,Chlorotrianisene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003982696],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41676,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD182,,,Chlorotrianisene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004929581],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42507,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD182,,,Chlorotrianisene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149994],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42844,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD182,,,Chlorotrianisene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008706801],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44864,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD182,,,Chlorotrianisene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002425866],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45175,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD182,,,Chlorotrianisene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001283709],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40172,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40295,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105033],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40430,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187809],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40575,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40699,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40831,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.60E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41004,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.21E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41177,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41594,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.10E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41759,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41874,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42000,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42174,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42305,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42432,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164863],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42601,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42777,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42927,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019363],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43222,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43387,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034623],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43669,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686521],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43795,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44117,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44274,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44435,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142897],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44602,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44802,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.09E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44955,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.40E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45104,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.61E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45544,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD183,,,Chloroxine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40087,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD184,,,Chlorpheniramine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003216147],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40078,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD185,,,Chlorpromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000323877],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40910,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD185,,,Chlorpromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157656],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41096,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD185,,,Chlorpromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42086,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD185,,,Chlorpromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000926722],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44022,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD185,,,Chlorpromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003429568],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44182,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD185,,,Chlorpromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003605615],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40075,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40621,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001963588],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40743,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000462902],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI41083,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000380382],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42501,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006089512],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44010,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000776517],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44174,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00216403],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44337,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD186,,,Chlorprothixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003321156],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40004,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Wild-type and Ahr-/- mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40095,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40224,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40354,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40501,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40639,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40754,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40927,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41112,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41213,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41333,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41517,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41695,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41814,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41923,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42104,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42230,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42355,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42525,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42702,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42852,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42978,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43060,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43146,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.02E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43311,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43610,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43719,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43876,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44042,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44201,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000204718],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44362,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44525,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135092],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44728,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.08E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44878,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45028,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45206,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45332,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45470,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD187,,,Chlortetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40349,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD193,,,Cilnidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009528998],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41912,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD193,,,Cilnidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001096233],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44025,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD193,,,Cilnidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002695836],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44184,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD193,,,Cilnidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009525141],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45327,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD193,,,Cilnidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009376224],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10971,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD194,,,Cimetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI10972,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD194,,,Cimetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI10973,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD194,,,Cimetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI10974,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD194,,,Cimetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI10975,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD194,,,Cimetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI10976,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD194,,,Cimetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI41102,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD196,,,Cinnarizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004182486],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41685,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD196,,,Cinnarizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001296087],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42513,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD196,,,Cinnarizine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001760582],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42091,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD197,,,Cinoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43054,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD197,,,Cinoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43136,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD197,,,Cinoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44186,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD197,,,Cinoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41176,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1118,,,Ciprofloxacin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 2941281; PMID: 2940965; PMID: 2934338
PMDBI40104,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40233,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003986644],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40363,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40510,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40648,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40763,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40936,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00052783],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41121,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41222,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41342,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41526,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41704,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41823,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41932,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42113,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.42E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42239,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00030367],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42364,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42534,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42711,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42861,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42987,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43069,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43155,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43320,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000898138],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43619,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43728,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43885,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44051,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44210,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006006895],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44371,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002785984],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44534,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000416305],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44737,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283578],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44887,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000314817],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45037,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45215,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45341,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45479,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD199,,,Ciprofloxacin hydrochloride monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42376,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD200,,,Cladribine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42377,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD200,,,Cladribine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40016,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40108,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,n.a.,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40237,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40367,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.75E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40514,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Ldlr-/- mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40652,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.57E-05],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40767,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40940,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.86E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41125,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41226,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41227,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 12111597; PMID: 10716083
PMDBI41346,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41530,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41708,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41936,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42116,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42243,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42368,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42538,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42715,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42865,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42990,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43073,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43159,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43324,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43623,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.47E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43732,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43889,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.62E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44055,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44214,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44375,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44538,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141125],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44741,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44891,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45041,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45219,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45345,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45483,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD201,,,Clarithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41259,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1121,,,Clarithromycin plus metronidazole,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979
PMDBI41260,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1121,,,Clarithromycin plus metronidazole,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 11552917
PMDBI43868,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD202,,,Clavulanate potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000334219],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44867,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD202,,,Clavulanate potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008071607],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12038,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI12039,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12040,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI12042,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12043,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI12044,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12045,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12046,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12047,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.575 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12048,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12049,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12050,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12051,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI12052,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI12053,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12054,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12055,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI12056,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI12057,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI12058,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI12059,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12060,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD203,,,Clemastine fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI10847,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD204,,,Clemizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI41645,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42062,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42216,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034551],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42347,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110855],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42486,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42659,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42825,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43269,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43441,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166388],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43703,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001957133],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44486,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44660,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142009],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44846,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45008,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45153,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD205,,,Clemizole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273281],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40109,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40238,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40368,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40515,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40653,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40768,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40941,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.12E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41126,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41227,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41273,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132
PMDBI41347,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.07E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41531,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41709,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41826,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41937,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42117,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42244,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42369,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42539,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42716,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42866,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42991,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43074,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43160,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43325,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000935714],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43624,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43733,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43890,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44056,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44215,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44376,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44539,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000468263],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44742,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44892,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45042,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150969],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45220,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45346,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45484,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD206,,,Clinafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40015,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.04E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40107,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40236,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.23E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40366,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40513,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40651,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.99E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40766,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40939,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41124,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41225,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41345,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41529,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41707,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41825,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000619008],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41935,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42115,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42242,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42367,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42537,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.78E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42714,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42864,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43072,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000619485],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43158,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43323,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355776],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43622,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43731,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43888,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44054,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44213,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44374,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44537,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131781],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44740,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44890,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45040,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45218,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45344,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45482,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD208,,,Clindamycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40181,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Hannover rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40303,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40442,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40583,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40706,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.06E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40846,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41020,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41185,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.60E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41610,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.62E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41771,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41881,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000247101],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42016,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42185,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42319,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42617,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42793,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42940,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006477672],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43238,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43403,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000163962],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43809,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44130,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44290,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44451,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000964707],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44618,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000178834],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44818,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44970,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45118,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45554,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD209,,,Clioquinol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42396,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1124,,,Clofarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42397,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1124,,,Clofarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI43300,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD211,,,Clofilium tosylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00386463],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43493,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD211,,,Clofilium tosylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000200168],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44517,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD211,,,Clofilium tosylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000254099],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44712,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD211,,,Clofilium tosylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004885272],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40334,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00888111],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40737,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008333416],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41654,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003454674],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42491,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002315632],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42667,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003489629],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43276,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000409922],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43452,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001929889],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43997,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008757232],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44494,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281831],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44669,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000236766],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45017,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133859],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45454,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD212,,,"Clomiphene citrate (Z,E)",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009110665],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44359,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD213,,,Clomipramine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000642265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11454,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11455,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11456,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11457,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11458,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11459,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.427 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11460,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11461,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11462,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11463,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11464,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11465,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11466,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11467,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD215,,,Clonidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12130,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12131,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12133,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12134,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12135,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12136,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12137,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.368 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12138,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12139,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12140,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12141,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12142,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12143,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12144,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12145,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12146,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12147,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.416 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12148,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12149,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12150,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12151,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12152,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12153,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD216,,,Clopidogrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.972 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI40143,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40272,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40402,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.09E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40549,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40682,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40802,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40975,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41159,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41261,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41379,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41565,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41738,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41852,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41971,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42148,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.91E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42278,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42403,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42573,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42749,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42899,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43193,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43358,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271581],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43653,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43766,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43924,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44090,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44245,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44573,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000179188],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44775,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44926,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45076,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45254,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45380,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45517,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD217,,,Closantel,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40186,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001339048],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Hannover rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40306,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40446,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187916],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40587,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007729025],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40711,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000758779],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40853,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41027,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41303,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.15E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41417,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001890094],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41615,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41776,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42023,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42190,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.21E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42324,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100937],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42453,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42624,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42798,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43243,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43410,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202747],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43969,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001800915],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44136,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.64E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44296,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005092649],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44456,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002911093],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44625,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000635361],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44823,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44976,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.82E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45125,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45420,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD218,,,Clotrimazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006108494],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40066,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.70E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Primigravida ICR mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40187,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001689365],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40854,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000146112],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41028,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000134609],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41304,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41418,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41616,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.28E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41777,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42024,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42325,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42454,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42625,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42799,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.46E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43244,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43411,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000982525],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43682,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43815,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44137,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003097339],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44297,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.09E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44457,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44626,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000508555],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44824,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44977,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45126,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45295,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45421,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD219,,,Cloxacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40070,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.60E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40198,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40600,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001083172],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40722,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006561372],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41046,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009344181],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41631,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42641,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00343082],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42811,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004285355],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42961,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000483527],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43045,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43128,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43259,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003395309],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43427,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922821],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44149,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44310,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002523703],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44472,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142269],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44642,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001187417],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45140,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244933],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45568,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD224,,,Colistin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42471,Microbes metabolize substances,PMDBM647,357276,Bacteroides dorei,PMDBD1129,,,Corticosteroids,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI10071,Microbes metabolize substances,PMDBM42,n.a.,Bacteroides fragilis,PMDBD231,,,CTLA-4 blockade,Therapeutic Substance,Drug Class,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Blockade  immunotherapy ,PMID,PMID: 26972811
PMDBI10072,Microbes metabolize substances,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD231,,,CTLA-4 blockade,Therapeutic Substance,Drug Class,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Blockade  immunotherapy ,PMID,PMID: 26972811
PMDBI10874,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD234,,,Cyclobenzaprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI40082,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD235,,,Cyclobenzaprine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001347342],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40913,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD235,,,Cyclobenzaprine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004347253],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41100,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD235,,,Cyclobenzaprine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00597968],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45588,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD235,,,Cyclobenzaprine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008100327],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41210,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD236,,,Cyclopenthiazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922821],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10202,Microbes metabolize substances,PMDBM376,n.a.,Segmented filamentous bacteria,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Gram-positive commensals mediate accumulation of TH17 and TH1-cell response,PMID,PMID: 28270698
PMDBI10204,Microbes metabolize substances,PMDBM347,287,Pseudomonas aeruginosa,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,"Fed a diet(high in protein, l-leucine, fish oil and specific oligosaccharides)",n.a.,Reduce incidence and severity of Pseudomonas aeruginosa translocation,PMID,PMID: 28270698
PMDBI10205,Microbes metabolize substances,PMDBM202,1354,Enterococcus hirae,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Inoculated with MCA205 tumours;microbiota-depleted,As an orchestrator of cyclophosphamide effects,n.a.,PMID,PMID: 28270698
PMDBI10206,Microbes metabolize substances,PMDBM83,487174,Barnesiella intestinihominis,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Inoculated with MCA205 tumours;microbiota-depleted,As an orchestrator of cyclophosphamide effects,n.a.,PMID,PMID: 28270698
PMDBI10207,Microbes metabolize substances,PMDBM202,1354,Enterococcus hirae,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs,PMID,PMID: 28270698
PMDBI10208,Microbes metabolize substances,PMDBM277,1622,Lactobacillus murinus,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs,PMID,PMID: 28270698
PMDBI10209,Microbes metabolize substances,PMDBM274,33959,Lactobacillus johnsonii,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs,PMID,PMID: 28270698
PMDBI10484,Microbes metabolize substances,PMDBM376,n.a.,Segmented filamentous bacteria,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Immunomodulation,Gram‑positive commensals mediate accumulation of TH 17 and TH 1‑cell response,PMID,PMID: 28270698
PMDBI10486,Microbes metabolize substances,PMDBM202,1354,Enterococcus hirae,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Translocation,Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs,PMID,PMID: 28270698
PMDBI10487,Microbes metabolize substances,PMDBM277,1622,Lactobacillus murinus,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Translocation,Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs,PMID,PMID: 28270698
PMDBI10488,Microbes metabolize substances,PMDBM274,33959,Lactobacillus johnsonii,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Translocation,Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs,PMID,PMID: 28270698
PMDBI10924,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI10925,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI10926,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI10927,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI40704,Substances alter microbe abundance,PMDBM157,29347,Clostridium scindens,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Reduced diversity,PMID,PMID: 31675176
PMDBI40708,Substances alter microbe abundance,PMDBM912,301302,Roseburia faecis,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,Reduced diversity,PMID,PMID: 31675176
PMDBI41358,Substances alter microbe abundance,PMDBM702,n.a.,Clostridium cluster XIVa,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide.,PMID,PMID: 24264990; PMID: 29789015
PMDBI42427,Microbes metabolize substances,PMDBM620,626932,Alistipes indistinctus,PMDBD237,,,Cyclophosphamide,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI41443,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD238,,,Cyclosporin A,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003650878],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41678,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD238,,,Cyclosporin A,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004008817],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42088,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD238,,,Cyclosporin A,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44513,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD238,,,Cyclosporin A,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.40E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45587,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD238,,,Cyclosporin A,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00310105],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40922,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD239,,,Cyproheptadine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001175749],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11682,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11683,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11685,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11686,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11687,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11688,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11689,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11690,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11691,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11692,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11693,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11694,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11695,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11696,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11697,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI11698,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD240,,,Cyproterone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI42398,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1136,,,Cytarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42399,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1136,,,Cytarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42227,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD243,,,Dacarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000695859],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI13136,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13137,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13138,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.29 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13139,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13140,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.012 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13141,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.172 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI13143,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.805 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13144,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.544 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13145,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.099 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13146,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.901 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13147,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.527 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13148,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.834 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13149,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.318 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI13150,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13151,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.254 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI13152,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.623 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13153,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.624 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13154,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.772 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI13155,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.139 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13157,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.913 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13158,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.237 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13159,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.912 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13160,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.35 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13161,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.388 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13162,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.995 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13163,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.165 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13164,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13165,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.826 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13166,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.035 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13167,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.009 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13168,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.493 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13169,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.68 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI13170,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.212 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13171,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.48 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13172,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.371 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13173,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.315 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13174,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.112 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13175,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.335 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13176,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI13177,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.617 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13178,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13179,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13180,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.285 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13181,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.181 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13182,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.454 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI13183,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13184,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.594 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13185,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.994 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI13186,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.247 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13188,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.43 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13189,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.818 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13190,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.465 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13191,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.732 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13192,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI13193,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.789 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13194,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI13195,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.135 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13196,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13197,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.187 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13198,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.772 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13199,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.917 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13200,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.995 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13201,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.67 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13202,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.352 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13203,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13204,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.655 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13205,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD246,,,Danazol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.937 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI43872,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD247,,,Dantrolene sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002634804],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43503,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD248,,,Darifenacin hydrobromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001015196],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10977,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD249,,,Dasatinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI10979,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD249,,,Dasatinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.327 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI10980,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD249,,,Dasatinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.961 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI10981,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD249,,,Dasatinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI10982,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD249,,,Dasatinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI42431,Microbes metabolize substances,PMDBM42,817,Bacteroides fragilis,PMDBD249,,,Dasatinib,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42432,Microbes metabolize substances,PMDBM660,78346,Bifidobacterium ruminantium,PMDBD249,,,Dasatinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42400,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1142,,,Daunorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42401,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1142,,,Daunorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40179,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001045178],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40582,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40705,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00323688],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41017,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003081374],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41184,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003770771],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41295,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41411,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41607,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41769,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41880,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001440752],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42013,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283455],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42183,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42317,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002397008],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42445,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42614,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42790,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42937,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43235,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005040288],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43400,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001199846],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43677,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43806,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43962,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44128,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.81E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44287,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00773707],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44448,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44615,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44815,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44967,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000895076],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45288,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45411,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD250,,,Daunorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12318,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12319,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.667 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI12320,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI12322,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.773 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12323,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.084 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12324,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.485 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12325,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.916 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12326,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI12327,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12328,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.073 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12329,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.272 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12330,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.27 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12331,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12332,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12333,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.231 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12334,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12335,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.913 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12336,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.389 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12337,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI12338,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.315 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12339,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.262 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12340,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12341,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12342,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.852 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12343,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.786 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12344,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12345,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.797 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12346,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12347,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD252,,,Deflazacort,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.926 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI44522,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD254,,,Demecarium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207856],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40009,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40100,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40229,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40359,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40506,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40644,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40759,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40932,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41117,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41218,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41338,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41522,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41700,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41819,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41928,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42109,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42235,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42360,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42530,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42707,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42857,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42983,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43065,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43151,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.99E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43316,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017063],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43615,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.43E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43724,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43881,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44047,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44206,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000937349],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44367,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44530,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183647],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44733,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44883,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45033,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45211,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45337,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.83E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45475,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD255,,,Demeclocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43306,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD256,,,Deptropine citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002434065],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40183,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.53E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40585,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006747737],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40708,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000478376],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40848,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000108547],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41022,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001280508],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41299,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41413,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41611,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42018,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42187,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005301499],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42321,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117411],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42448,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42619,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000849895],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42942,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43239,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009240568],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43405,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372795],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43680,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43811,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001063906],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43965,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44132,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44452,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44620,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000424954],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44819,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159192],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44971,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45120,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007772802],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45292,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750268],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45415,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45555,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD257,,,Dequalinium dichloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11089,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11090,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.605 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11091,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11092,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11093,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11094,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.363 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11095,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11096,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11097,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI42433,Microbes metabolize substances,PMDBM157,29347,Clostridium scindens,PMDBD259,,,Dexamethasone,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,Dexamethasone side chain cleavage,n.a.,Drug metabolism,In vitro,High-throughput incubation assays,n.a.,n.a.,Microbiota species involved in ALL chemotherapeutics metabolism,PMID,PMID: 31675176
PMDBI40170,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40293,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40428,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.62E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40573,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40698,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40829,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41002,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41175,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41592,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41757,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41872,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41998,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42172,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42303,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42430,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42599,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42775,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42925,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43220,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43385,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170513],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43793,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43950,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44115,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44272,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.04E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44433,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44600,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202857],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44800,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44953,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.24E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45102,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.81E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45274,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45399,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45543,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD260,,,Diacerein,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI13276,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13277,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.109 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13278,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.531 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13279,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.103 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13280,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.76 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13281,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.572 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13282,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.686 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13283,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.301 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13284,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.649 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13285,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.671 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13286,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI13287,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.733 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13288,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.947 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI13289,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.983 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13290,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.5 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13291,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.028 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13292,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.156 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13294,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.609 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13295,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.062 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13296,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.408 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13297,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13298,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.373 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13299,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.668 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13300,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.97 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13301,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.147 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13302,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.801 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13303,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13304,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.671 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13305,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.378 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13306,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.635 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13307,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13308,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.38 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13309,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.096 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13310,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.521 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13311,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.22 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13312,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.556 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13313,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13314,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.423 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13315,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.089 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13316,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13317,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.92 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13318,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.898 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13319,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.645 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13320,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI13321,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.183 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13322,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13323,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.166 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13324,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.863 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13325,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.529 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13326,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.676 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13327,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.927 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13328,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI13330,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.259 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13331,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.117 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13332,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.366 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13333,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.709 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13334,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13335,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.065 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13336,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.642 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13337,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.583 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13338,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.576 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13339,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13340,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13341,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI13342,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.595 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13343,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.215 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13344,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.392 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13345,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.268 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13346,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.246 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13347,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD261,,,Diacetamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.28 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI40491,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00184996],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40620,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009510718],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41906,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007631742],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42079,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005776539],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42677,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009519216],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44008,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000137683],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44173,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44335,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45323,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD262,,,Diclazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008913545],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10381,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD263,,,Diclofenac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,Diclofenac glucuronide,Hydrolysis to diclofenac,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 27591027; PMID: 24780296; PMID: 22328575
PMDBI40062,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.08E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40176,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40579,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000650497],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40839,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41012,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41181,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000376726],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41290,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41407,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41602,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41765,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42008,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42312,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42440,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42609,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42785,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42932,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000963399],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43230,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43395,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271872],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43674,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43803,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44123,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44282,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.27E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44443,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44610,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000175753],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44810,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44963,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45111,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45283,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45406,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD264,,,Dicloxacillin sodium salt hydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11023,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD266,,,Dicyclomine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11024,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD266,,,Dicyclomine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11025,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD266,,,Dicyclomine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11026,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD266,,,Dicyclomine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11027,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD266,,,Dicyclomine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11028,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD266,,,Dicyclomine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11029,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD266,,,Dicyclomine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI43307,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD267,,,Dicyclomine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002806708],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40207,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003741022],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40329,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000539738],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40472,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000671946],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40609,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40731,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41060,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002426018],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41199,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001467284],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41646,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000470942],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42063,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006417648],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42348,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008553647],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43843,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.48E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43992,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44159,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44321,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005071009],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45448,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD273,,,Diethylstilbestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004139029],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12061,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.55 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12063,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.44 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12064,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI12065,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12066,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.987 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12067,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12068,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12069,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12070,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.86 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12071,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12072,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.05 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12073,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12074,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI12075,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.045 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI12076,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12077,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.149 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12078,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI12079,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.351 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12080,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI12081,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12082,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12083,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD274,,,Diflorasone diacetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI42421,Microbes metabolize substances,PMDBM186,84112,Eggerthella lenta,PMDBD276,,,Digoxin,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,dihydrodigoxin,Reduction,Cardiac glycoside reductase,Reduce bioavailability; Decrease activity,In vivo,Mouse,n.a.,n.a.,"Digoxin is converted to the inactive metabolite dihydrodigoxin by Eggerthella lenta, limiting the amount of active drug that is absorbed into the systemic circulation.",PMID,PMID: 23869020
PMDBI44871,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD280,,,Diloxanide furoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009077749],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10760,Microbes metabolize substances,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Germ-free(GF),Bt4096 encodes an enzyme that metabolizes diltiazem,n.a.,PMID,PMID: 31235939
PMDBI11389,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11391,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11392,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11393,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11394,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.781 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11395,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11396,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.207 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11397,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11398,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.677 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11399,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.654 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11400,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.964 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11401,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD281,,,Diltiazem,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI43308,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD282,,,Dimethisoquin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004750396],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10848,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD285,,,Diphenylpyraline,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI10896,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD286,,,Dipyridamole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI10898,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD286,,,Dipyridamole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.805 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI40040,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002343758],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40138,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40267,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002053979],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40397,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40544,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40677,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40797,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.76E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40970,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41155,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41256,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41376,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41560,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41733,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41966,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42143,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000158672],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42273,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000601093],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42398,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42568,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42744,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42895,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.70E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43189,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000200215],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43353,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0004071],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43648,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43761,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43919,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44085,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44403,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44568,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000323156],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44770,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44921,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45071,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45249,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45375,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45512,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD287,,,Dirithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42226,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD288,,,Disulfiram,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001296427],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10899,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD289,,,Doxazosin mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI10901,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD289,,,Doxazosin mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI43873,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD289,,,Doxazosin mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008264925],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42378,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42422,Microbes metabolize substances,PMDBM258,573,Klebsiella pneumoniae,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug inactivation,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42435,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug inactivation,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42436,Microbes metabolize substances,PMDBM211,679895,Escherichia coli BW25113,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,7-deoxydoxorubicinol; 7-deoxydoxorubicinolone,n.a.,n.a.,Reduced toxicity,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 30890566; PMID: 29160065
PMDBI42437,Microbes metabolize substances,PMDBM258,573,Klebsiella pneumoniae,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 30890566; PMID: 29160065
PMDBI42438,Microbes metabolize substances,PMDBM905,575,Raoultella planticola,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug inactivation,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42439,Microbes metabolize substances,PMDBM905,575,Raoultella planticola,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,7-deoxydoxorubicinol; 7-deoxydoxorubicinolone,reductive deglycosylation,n.a.,reduced toxicity,In vitro,High-throughput incubation assays,n.a.,n.a.,"For cancer patients, inactivation of doxorubicin by gut microbes could result in a decrease in active doxorubicin levels, potentially altering the efficacy of chemotherapeutic treatment and the severity of side effects.",PMID,PMID: 30890566; PMID: 29160065
PMDBI42940,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vivo,Caenorhabditis elegans,n.a.,n.a.,No effect on Caenorhabditis elegans,PMID,PMID: 30890566; PMID: 28431244
PMDBI42955,Microbes metabolize substances,PMDBM768,469008,Escherichia coli BL21(DE3),PMDBD290,,,Doxorubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 30890566; PMID: 29160065
PMDBI41320,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41429,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41636,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000106944],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41794,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41895,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001734051],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42051,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00294464],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42212,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.70E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42477,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42647,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000769478],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42817,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003450843],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42965,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43699,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.55E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43836,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43985,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213793],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44479,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.32E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44648,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838187],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45145,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000240309],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45312,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45441,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD291,,,Doxorubicin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41373,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1170,,,Doxycycline,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619
PMDBI40003,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.32E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40094,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40223,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40353,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40500,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40638,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40753,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.82E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40926,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.98E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41111,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41212,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41332,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41516,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41694,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41813,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41922,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42103,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42229,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42354,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.79E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI42524,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42701,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42851,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42977,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43059,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43145,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43310,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000409003],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43609,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43718,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43875,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44041,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44200,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000337554],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44361,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44524,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000406033],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44727,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44877,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45027,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45205,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45331,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45469,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD292,,,Doxycycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11134,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11135,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11136,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11137,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11138,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11139,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11140,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11141,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.868 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11142,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11143,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD293,,,Drospirenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11081,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD294,,,Duloxetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11082,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD294,,,Duloxetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11084,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD294,,,Duloxetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11085,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD294,,,Duloxetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11086,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD294,,,Duloxetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11087,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD294,,,Duloxetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11088,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD294,,,Duloxetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.843 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI40175,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009959859],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40299,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000269368],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40436,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000416203],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40703,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001858081],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40837,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180117],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41010,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.28E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41288,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41406,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41600,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41763,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004717236],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42006,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42178,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.83E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42310,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00013664],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42438,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42607,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42783,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42931,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43228,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.37E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43393,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43672,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43801,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002400165],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43957,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000199681],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44121,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44280,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.14E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44441,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002297368],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44608,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166421],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44808,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44961,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45109,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45281,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45404,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD295,,,Ebselen,Therapeutic Substance,Investigational Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000623909],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40221,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD296,,,Eburnamonine (-),Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002903472],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40455,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002511467],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40864,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41040,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41628,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41786,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.33E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42038,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42202,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42336,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.98E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42466,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42637,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42809,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42955,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001653916],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43255,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43423,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207066],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43692,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002834728],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43978,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000192316],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44146,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001809617],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44308,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003414426],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44469,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183536],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44639,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000665366],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44835,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44986,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45135,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45433,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD297,,,Econazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004177971],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40339,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003048825],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40484,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.27E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40893,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002422736],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41074,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009732678],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43458,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005069808],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43852,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006094828],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44000,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44168,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44329,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001747188],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44855,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD298,,,Efavirenz,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002032],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10902,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD302,,,Enalapril maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI10903,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD302,,,Enalapril maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI10904,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD302,,,Enalapril maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI41652,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42069,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000451654],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42220,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027896],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42489,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.98E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42665,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42830,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43274,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.87E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43448,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001010013],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44667,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001194454],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44850,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45013,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.81E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45156,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110537],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45317,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD303,,,Enilconazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009673022],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40184,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.25E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40305,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005817323],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40444,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Piglet,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40586,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40709,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40850,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41024,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41186,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41774,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.10E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41883,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003421461],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42020,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.05E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42450,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426771],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42621,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42795,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006943422],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42944,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43034,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43118,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43407,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001718902],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43813,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43966,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003167824],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44293,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000348442],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44622,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004538411],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44973,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002313221],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45122,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001391235],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45417,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001329469],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45556,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD304,,,Enoxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI13068,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.539 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13069,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.594 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13070,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.053 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13071,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.579 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI13072,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.15 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13074,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.121 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13075,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.363 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13076,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.878 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13077,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.194 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13078,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.106 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI13079,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.731 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13080,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.636 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI13081,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI13082,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.532 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13083,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.365 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13084,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13085,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.004 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13086,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.445 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI13088,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.171 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13089,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.7 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13090,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI13091,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13092,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.008 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13093,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13094,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.342 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13095,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.631 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13096,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.282 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13097,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.099 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13098,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.865 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13099,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13100,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.119 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13101,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.964 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13102,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.665 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13103,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13104,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.393 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13105,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.315 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13106,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.548 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13107,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.281 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13108,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI13109,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.034 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13110,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.254 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13111,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.375 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13112,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.213 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13113,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.255 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13114,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.258 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13115,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI13116,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.842 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13117,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.076 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13119,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13120,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13121,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.063 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13122,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.104 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13123,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.135 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13124,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13125,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.42 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13126,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13127,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.58 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13128,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.77 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13129,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.83 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13130,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.775 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13131,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.56 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13132,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.334 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13133,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.788 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13134,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.839 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13135,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.877 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI41075,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006752846],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41659,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41806,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.10E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42496,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009152734],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42674,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207101],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42834,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43280,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003959654],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44856,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45163,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD306,,,Entacapone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41686,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD310,,,Epirizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44716,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD310,,,Epirizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003382732],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45185,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD310,,,Epirizole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11402,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11403,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11404,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11405,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI11406,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11407,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI11408,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11409,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI11410,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11411,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.601 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11412,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11413,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11414,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD311,,,Ergonovine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.655 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI10928,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD312,,,Ergotamine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.956 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI10929,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD312,,,Ergotamine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI10930,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD312,,,Ergotamine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.23 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI10931,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD312,,,Ergotamine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.969 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI44869,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD313,,,Erlotinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005683558],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45191,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD313,,,Erlotinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002028454],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40212,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00431781],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40336,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006648497],n.a.,n.a.,n.a.,n.a.,In vitro,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40480,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.97E-05],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41070,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42075,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00147683],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42671,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000199681],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43456,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002436407],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44165,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000997738],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44328,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007431509],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44853,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45160,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD316,,,Estradiol Valerate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575241],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42402,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1182,,,Estramustine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42519,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD317,,,Estropipate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009514871],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11145,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11146,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI11147,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11148,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11149,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11150,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11151,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11152,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11153,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD318,,,Eszopiclone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI41679,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD320,,,Ethaverine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42845,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD320,,,Ethaverine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.84E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43487,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD320,,,Ethaverine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004729501],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44705,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD320,,,Ethaverine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001686706],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45178,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD320,,,Ethaverine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10956,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD321,,,Ethopropazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI10958,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD321,,,Ethopropazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI10959,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD321,,,Ethopropazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI10960,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD321,,,Ethopropazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI40214,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40338,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.49E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40482,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000437689],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40616,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40740,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.27E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40891,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41072,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41203,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43851,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43999,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44167,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD322,,,Ethopropazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10849,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD323,,,Ethoxzolamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11268,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11269,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11270,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11271,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11272,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11273,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11274,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11275,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11276,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11277,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11278,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI11279,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD324,,,Etodolac,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI40632,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD325,,,Etofenamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000304871],n.a.,n.a.,n.a.,n.a.,In vivo,Human,Obese,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44035,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD325,,,Etofenamate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338854],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41681,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD326,,,Etomidate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009471157],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44708,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD326,,,Etomidate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008448038],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44865,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD326,,,Etomidate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002512885],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45181,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD326,,,Etomidate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42379,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD327,,,Etoposide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42380,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD327,,,Etoposide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42942,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD327,,,Etoposide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vivo,Caenorhabditis elegans,n.a.,n.a.,No effect on Caenorhabditis elegans,PMID,PMID: 30890566; PMID: 28431244
PMDBI42098,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD328,,,Etretinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000341198],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11225,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11226,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11227,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11228,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11229,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11230,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11231,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11232,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11233,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI11234,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD329,,,Ezetimibe,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI43714,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD330,,,Fadrozole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007672282],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12348,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.603 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12349,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.022 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12350,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.84 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12351,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12352,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.199 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12353,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.744 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12354,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.635 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12355,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.919 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12356,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.957 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12357,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.857 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI12358,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.998 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12359,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.783 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12360,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.331 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12361,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.225 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12362,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12363,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.791 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12364,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12365,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.383 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12366,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12367,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.95 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12368,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.474 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12369,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.096 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12370,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.639 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12371,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.397 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12372,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.783 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12373,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.554 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12374,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.872 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12375,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.353 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12376,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.818 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12377,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.942 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12378,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD331,,,Famciclovir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.097 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11889,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11890,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11891,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11892,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11893,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11894,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11895,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11896,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11897,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11898,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11899,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11900,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11902,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11903,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11904,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11905,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11906,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11907,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.562 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11908,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.725 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11909,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI44197,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD333,,,Famprofazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004960818],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11733,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11734,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11736,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11737,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11738,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11739,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11740,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11741,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.703 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11742,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11743,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11744,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11745,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11746,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11747,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11748,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11749,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11750,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD334,,,Febuxostat,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI40205,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112711],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40326,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324943],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40470,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40729,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008429051],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40881,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008277451],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41058,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004419106],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41897,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202694],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42057,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.46E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42654,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001136075],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43990,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44156,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44318,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00027388],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44655,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002287279],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44843,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004078377],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45148,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009028298],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45315,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008363427],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45445,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD335,,,Felodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004629765],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41688,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD336,,,Fenbendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002022672],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45188,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD336,,,Fenbendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001339],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40634,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD337,,,Fenbufen,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006136783],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40899,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.81E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41082,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41908,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006460559],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42680,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003648773],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43287,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009434026],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43468,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004664749],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44336,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008811167],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44684,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD338,,,Fendiline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003134602],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11030,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD340,,,Fenofibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11031,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD340,,,Fenofibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11032,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD340,,,Fenofibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.516 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11033,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD340,,,Fenofibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.559 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11034,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD340,,,Fenofibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11035,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD340,,,Fenofibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.308 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11036,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD340,,,Fenofibrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.855 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11601,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11602,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11603,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11604,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.747 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11605,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11606,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11607,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.816 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11608,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11609,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11610,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11611,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11612,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11613,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11614,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11615,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.922 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11616,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD341,,,Fenspiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI41919,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD342,,,Fentiazac,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000634437],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43141,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD350,,,Fexofenadine HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008281463],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11280,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11281,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.735 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11282,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11283,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11284,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11285,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11286,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.039 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11287,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11288,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11289,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11290,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11291,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD352,,,Finasteride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI40483,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40892,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005217961],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41073,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001913202],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42076,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42494,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42972,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43049,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43132,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45580,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD353,,,Fleroxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40012,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40103,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40232,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.45E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40362,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.15E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40509,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40647,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.51E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40762,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40935,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41120,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41221,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41341,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41525,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41703,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41822,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41931,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42112,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42238,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42363,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42533,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42710,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42860,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42986,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43068,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43154,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43319,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172554],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43618,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.09E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43727,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43884,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44050,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44209,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44370,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44533,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151221],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44736,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44886,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45036,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45214,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45340,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45478,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD354,,,Florfenicol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10192,Microbes metabolize substances,PMDBM300,2100,Mycoplasma hyorhinis,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Bacterium encode a thymidine phosphorylase,Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds,PMID,PMID: 28270698
PMDBI40199,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.64E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40320,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.89E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40463,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.82E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40601,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40723,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40872,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41048,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159192],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41192,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42047,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.43E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42208,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42962,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001923619],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43046,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.38E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43129,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43832,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43983,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44312,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187809],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44475,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.83E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44994,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45309,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45439,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD355,,,Floxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40065,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000121136],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40849,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41023,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000585698],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41300,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41414,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41612,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41773,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.47E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42019,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42188,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000964707],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42322,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42449,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42620,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42794,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42943,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000136718],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43240,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43406,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001039356],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43681,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000949493],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43812,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44133,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005381005],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44292,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129378],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44453,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44621,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000833633],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44820,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44972,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45121,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.83E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45293,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.08E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45416,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD356,,,Flucloxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11468,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11470,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11471,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11472,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11473,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11474,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI11475,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11476,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11477,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.484 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11478,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11479,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11480,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11481,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD357,,,Fluconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI10382,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD358,,,Flucytosine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,5-fluorouracil,Deamination,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 27591027; PMID: 12714804; PMID: 3729334
PMDBI10746,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD358,,,Flucytosine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,5-FU,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Deamination by bacteria,n.a.,PMID,PMID: 3729334
PMDBI43712,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD358,,,Flucytosine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007454192],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10515,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD359,,,Fludarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Direct chemical modification,n.a.,PMID,PMID: 28642381
PMDBI43142,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD359,,,Fludarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00022021],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42403,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1198,,,Fludarabine de phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42404,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1198,,,Fludarabine de phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40629,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD360,,,Flufenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000601342],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43867,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD360,,,Flufenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838187],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44030,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD360,,,Flufenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001149242],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44187,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD360,,,Flufenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008821497],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40191,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40312,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001030079],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40451,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000504227],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40593,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40715,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40859,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002015009],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41034,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000266312],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41189,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.60E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41622,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007130854],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41784,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00027409],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41889,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000380382],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42032,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42197,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002583972],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42331,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007412673],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42951,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43039,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43123,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43249,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008468237],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43822,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004208369],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44303,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44463,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009830868],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44633,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007277845],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45561,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD361,,,Flumequine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44725,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD362,,,Flunarizine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004676065],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40633,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD363,,,Flunixin meglumine,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001747188],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43870,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD363,,,Flunixin meglumine,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691593],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43143,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD364,,,Fluorometholone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005527231],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11154,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11155,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11156,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.188 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11157,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11159,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.029 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11160,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11161,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11162,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11163,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD367,,,Fluphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI43485,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD368,,,Fluphenazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003104732],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44027,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD368,,,Fluphenazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005572399],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44347,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD368,,,Fluphenazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001603792],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44512,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD368,,,Fluphenazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00250842],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44703,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD368,,,Fluphenazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005479453],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43502,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD369,,,Fluspirilen,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009483084],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44723,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD369,,,Fluspirilen,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000392987],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10905,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD370,,,Fluvoxamine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI10907,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD370,,,Fluvoxamine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI40027,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000289729],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40124,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40253,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40383,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40530,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40667,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40783,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40956,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41141,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41242,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41362,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41546,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41723,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41841,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004692789],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41952,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42130,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42259,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.52E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42384,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42554,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42730,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42881,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43005,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43089,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43175,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.49E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43339,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43748,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43905,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44071,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44227,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44390,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44554,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166377],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44757,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44907,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45057,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141893],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45235,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45361,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00357394],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45499,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD374,,,Furaltadone hydrochloride,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40022,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.62E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40116,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40245,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40375,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40522,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40660,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40775,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40948,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41133,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41234,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41354,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41538,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41716,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41833,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41944,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42123,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42251,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42376,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42546,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42723,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42873,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42997,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43081,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43167,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.00E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43332,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000162753],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43740,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43897,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44063,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44219,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.33E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44383,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44546,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000239345],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44749,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44899,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45049,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45227,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.45E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45353,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45491,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD375,,,Furazolidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40149,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40275,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40408,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.95E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mice,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40555,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40683,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000393088],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40808,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40981,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.58E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41160,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41267,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41385,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41571,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.77E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41742,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41856,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.64E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41977,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42154,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42284,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42409,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42579,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42755,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42905,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43199,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.50E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43364,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000382397],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43772,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43930,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44095,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44251,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103492],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44413,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.92E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44579,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233624],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44781,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44932,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45082,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.65E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45260,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45386,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45523,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD376,,,Fusidic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.16E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40121,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Cyprinus carpio,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40250,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40380,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40527,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40664,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40780,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40953,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41138,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41239,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41359,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41543,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41720,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41838,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41949,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42128,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42256,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42381,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42551,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42727,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000227146],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42878,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43002,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43086,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43172,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43633,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43745,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43902,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44068,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44224,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.80E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44388,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.18E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44551,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000536192],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44754,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.45E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44904,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172471],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45054,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000778131],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45232,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45358,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45496,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD380,,,Gatifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43303,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD381,,,GBR 12909 dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004498],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44717,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD381,,,GBR 12909 dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007394277],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45024,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD381,,,GBR 12909 dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000891288],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10516,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Direct chemical modification,n.a.,PMID,PMID: 28642381
PMDBI41469,Substances alter microbe abundance,PMDBM140,1496,Peptoclostridium difficile,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,gemcitabine injection once per week for 3 weeks,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Pancreatic ductal adenocarcinoma xenografted,n.a.,n.a.,PMID,PMID: 29473096; PMID: 29789015
PMDBI41470,Substances alter microbe abundance,PMDBM209,562,Escherichia coli,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,gemcitabine injection once per week for 3 weeks,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Pancreatic ductal adenocarcinoma xenografted,n.a.,n.a.,PMID,PMID: 29473096; PMID: 29789015
PMDBI41474,Substances alter microbe abundance,PMDBM32,85831,Bacteroides acidifaciens,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,gemcitabine injection once per week for 3 weeks,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Pancreatic ductal adenocarcinoma xenografted,n.a.,n.a.,PMID,PMID: 29473096; PMID: 29789015
PMDBI41478,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,gemcitabine injection once per week for 3 weeks,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Pancreatic ductal adenocarcinoma xenografted,n.a.,n.a.,PMID,PMID: 29473096; PMID: 29789015
PMDBI41480,Substances alter microbe abundance,PMDBM819,1605,Lactobacillus animalis,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,gemcitabine injection once per week for 3 weeks,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Pancreatic ductal adenocarcinoma xenografted,n.a.,n.a.,PMID,PMID: 29473096; PMID: 29789015
PMDBI42096,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.50E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42381,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42382,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42440,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug inactivation,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI44356,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD384,,,Gemcitabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000437895],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44715,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD388,,,Gentamicine sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008614335],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45184,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD388,,,Gentamicine sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001548607],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45329,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD388,,,Gentamicine sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009968201],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44874,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD398,,,Glafenine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11235,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11236,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11237,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11238,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11239,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11240,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11241,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11242,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11243,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11244,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11245,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD399,,,Gliclazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11098,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11099,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11100,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11101,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11102,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11103,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11104,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11105,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11106,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD400,,,Glipizide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI41920,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD401,,,Gliquidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006069732],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10366,Microbes metabolize substances,PMDBM227,n.a.,Eubacterium sp. GLH,PMDBD407,,,Glycyrrhizic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,18-β-glycyrrhetinic acid,n.a.,n.a.,Increase Efficacy,n.a.,n.a.,n.a.,Hydrolysis,Increased activity,PMID,PMID: 26569070
PMDBI42520,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD416,,,Guanadrel sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008720694],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43296,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD417,,,Halofantrine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001229724],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43484,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD417,,,Halofantrine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002281473],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44510,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD417,,,Halofantrine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007614793],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44702,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD417,,,Halofantrine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000894084],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45022,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD417,,,Halofantrine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006930773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40084,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD418,,,Haloperidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006623603],n.a.,n.a.,n.a.,n.a.,n.a.,Rodent,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42974,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD418,,,Haloperidol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00721154],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40912,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD419,,,Haloprogin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426281],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41099,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD419,,,Haloprogin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41810,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD419,,,Haloprogin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005736582],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44349,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD419,,,Haloprogin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003972536],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40035,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40133,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40262,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40392,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40539,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40674,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40792,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40965,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41150,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41251,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41371,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41555,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41730,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41844,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.32E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41961,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42138,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42268,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42393,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42563,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42739,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42890,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43010,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006329494],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43184,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43348,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43643,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43756,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43914,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44080,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44236,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44563,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159446],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44766,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44916,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45066,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45244,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45370,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45508,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD423,,,Hexachlorophene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40201,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40322,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40465,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40603,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40725,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40876,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002181305],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41052,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002638689],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41194,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41321,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41637,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.35E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42052,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001729015],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42342,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000130388],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43837,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43986,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.94E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44153,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44315,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0028704],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44649,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003185447],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44998,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009586657],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45442,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD424,,,Hexestrol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027956],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41673,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD425,,,Hexetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42841,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD425,,,Hexetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003042737],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43294,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD425,,,Hexetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000285174],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43477,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD425,,,Hexetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000769692],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44694,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD425,,,Hexetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000580982],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45172,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD425,,,Hexetidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160806],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40219,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD431,,,Hycanthone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004412596],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40626,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD431,,,Hycanthone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006642697],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41807,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD431,,,Hycanthone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000289776],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42685,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD431,,,Hycanthone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005921662],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43862,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD431,,,Hycanthone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001979002],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44506,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD431,,,Hycanthone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000688404],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40220,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD433,,,Hydrocortisone base,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008623045],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45589,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD433,,,Hydrocortisone base,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008929837],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10710,Microbes metabolize substances,PMDBM393,211046,Styrax aureus,PMDBD434,,,Hypochlorite,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Human,cutaneous T cell lymphoma,n.a.,Reduce the amount of bacteria,PMID,PMID: 18835065; PMID: 31186074
PMDBI42516,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD436,,,Ibutilide fumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005740186],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42405,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1232,,,Idarubicin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI11911,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11912,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.96 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11913,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11914,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11915,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11916,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.876 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11917,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11918,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11919,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.089 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11920,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11921,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11922,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11924,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11925,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11926,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11927,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11928,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11929,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.988 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11930,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI42093,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004608193],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42224,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000661483],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44033,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD437,,,Idebenone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003822923],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40496,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD438,,,Idoxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007141128],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40627,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD438,,,Idoxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000352557],n.a.,n.a.,n.a.,n.a.,In vivo,Human,Obese,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43051,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD438,,,Idoxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000843474],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43864,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD438,,,Idoxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001120241],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44346,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD438,,,Idoxuridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006327976],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10876,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD439,,,Imatinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI42441,Microbes metabolize substances,PMDBM39,28111,Bacteroides eggerthii,PMDBD439,,,Imatinib,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42442,Microbes metabolize substances,PMDBM75,821,Bacteroides vulgatus,PMDBD439,,,Imatinib,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42443,Microbes metabolize substances,PMDBM648,46506,Bacteroides stercoris,PMDBD439,,,Imatinib,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug metabolism,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42444,Microbes metabolize substances,PMDBM869,387661,Parabacteroides johnsonii,PMDBD439,,,Imatinib,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug activation,In vitro,n.a.,n.a.,n.a.,Microbiota as ALL chemotherapy response biomarker,PMID,PMID: 31675176
PMDBI40055,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507548],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Primigravida ICR mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40163,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40287,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000812744],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40421,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.57E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40566,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40693,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000174956],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40822,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40995,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41170,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41278,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41396,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41585,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41751,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00012308],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41991,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42167,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000469876],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mice,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42423,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42592,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42768,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42918,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001496762],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43108,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43213,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43378,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000412089],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43786,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44265,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333376],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44426,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44593,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00033814],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44793,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44946,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000798186],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45095,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45270,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45395,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45536,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD440,,,Imipenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41107,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD441,,,Imiquimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005790619],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11482,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11483,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11484,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11485,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11486,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11487,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11488,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11489,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11490,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11491,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11492,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11493,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11494,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11495,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD446,,,Indomethacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.78 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI41507,Substances alter microbe abundance,PMDBM233,853,Faecalibacterium prausnitzii,PMDBD1239,,,Infliximab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI41512,Substances alter microbe abundance,PMDBM912,301302,Roseburia faecis,PMDBD1239,,,Infliximab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI43716,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD449,,,Iocetamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.86E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42693,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD450,,,Iohexol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.15E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44718,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD450,,,Iohexol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004750711],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45025,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD450,,,Iohexol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002666464],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44357,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD451,,,Iopanoic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000901834],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11541,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11542,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11543,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11544,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.428 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11545,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11546,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11547,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11548,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11549,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11550,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11551,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11552,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11553,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11554,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11555,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD454,,,Irbesartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI10221,Microbes metabolize substances,PMDBM392,1308,Streptococcus thermophilus,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10222,Microbes metabolize substances,PMDBM140,n.a.,Clostridioides difficile,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,Increase abundance of bacteria,Cause diarrhoea;,PMID,PMID: 28270698
PMDBI10223,Microbes metabolize substances,PMDBM269,1579,Lactobacillus acidophilus,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10224,Microbes metabolize substances,PMDBM279,1590,Lactobacillus plantarum,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10225,Microbes metabolize substances,PMDBM278,1597,Lactobacillus paracasei,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10226,Microbes metabolize substances,PMDBM94,1685,Bifidobacterium breve,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10227,Microbes metabolize substances,PMDBM100,216816,Bifidobacterium longum,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10228,Microbes metabolize substances,PMDBM271,1585,Lactobacillus delbrueckii subsp. bulgaricus,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10229,Microbes metabolize substances,PMDBM103,1682,Bifidobacterium longum subsp. infantis,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,"Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis",PMID,PMID: 28270698
PMDBI10439,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,SN-38 glucuronide ,Glucuronide hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
PMDBI10440,Microbes metabolize substances,PMDBM42,n.a.,Bacteroides fragilis,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,SN-38 glucuronide ,Glucuronide hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
PMDBI10441,Microbes metabolize substances,PMDBM386,1311,Streptococcus agalactiae,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,SN-38 glucuronide ,Glucuronide hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
PMDBI10442,Microbes metabolize substances,PMDBM153,n.a.,Clostridium perfringens,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,SN-38 glucuronide ,Glucuronide hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
PMDBI10577,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,SN-38,n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,"Hydrolysis of the glycosidicbon,bacterial b-glucuronidases",Increase toxicity,PMID,PMID: 30227749
PMDBI10578,Microbes metabolize substances,PMDBM75,821,Bacteroides vulgatus,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,SN-38,n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,"Hydrolysis of the glycosidicbon,bacterial b-glucuronidases",Increase toxicity,PMID,PMID: 30227749
PMDBI10579,Microbes metabolize substances,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,SN-38,n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,"Hydrolysis of the glycosidicbon,bacterial b-glucuronidases",Increase toxicity,PMID,PMID: 30227749
PMDBI10637,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Β-glucuronidases,Enhance the irinotecan toxicity,PMID,PMID: 30338735
PMDBI10638,Microbes metabolize substances,PMDBM75,821,Bacteroides vulgatus,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Β-glucuronidases,Enhance the irinotecan toxicity,PMID,PMID: 30338735
PMDBI10639,Microbes metabolize substances,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Β-glucuronidases,Enhance the irinotecan toxicity,PMID,PMID: 30338735
PMDBI41513,Substances alter microbe abundance,PMDBM140,1496,Peptoclostridium difficile,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,Irinotecan (125 mg/kg×3 days),n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Fisher 344 rat,Colon cancer,n.a.,n.a.,PMID,PMID: 22844397; PMID: 29789015
PMDBI41515,Substances alter microbe abundance,PMDBM317,186804,Clostridium cluster XI,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug,Irinotecan (125 mg/kg×3 days),n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Fisher 344 rat,Colon cancer,n.a.,n.a.,PMID,PMID: 22844397; PMID: 29789015
PMDBI42383,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42384,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42491,Microbes metabolize substances,PMDBM203,1547,Clostridium ramosum,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,SN-38,Glucuronide hydrolysis,Bacterial β-glucuronidases,Metabolize prodrug to active form; Increase toxicity,In vitro,High-throughput incubation assays,n.a.,n.a.,"Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial β-glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy.",PMID,PMID: 21789126; PMID: 21051639
PMDBI42492,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,SN-38,Glucuronide hydrolysis,Bacterial β-glucuronidases,Metabolize prodrug to active form; Increase toxicity,In vitro,High-throughput incubation assays,n.a.,n.a.,"Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial β-glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy.",PMID,PMID: 21789126; PMID: 21051639
PMDBI42493,Microbes metabolize substances,PMDBM75,821,Bacteroides vulgatus,PMDBD455,,,Irinotecan,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,SN-38,Glucuronide hydrolysis,Bacterial β-glucuronidases,Metabolize prodrug to active form; Increase toxicity,In vitro,High-throughput incubation assays,n.a.,n.a.,"Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial β-glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy.",PMID,PMID: 21789126; PMID: 21051639
PMDBI10850,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD456,,,Irsogladine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI40185,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001902308],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40445,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000385531],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40710,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001275288],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40852,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103719],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41026,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41302,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838051],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41416,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0065524],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41614,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41775,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41884,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004646157],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42022,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42189,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42323,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42452,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42623,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42797,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42946,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000206272],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43242,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43409,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000350754],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43968,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44135,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44295,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00048278],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44455,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44624,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133224],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44822,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.08E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44975,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45124,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.11E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45419,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD459,,,Isoconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003205469],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11037,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD463,,,Itraconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.527 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11039,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD463,,,Itraconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11040,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD463,,,Itraconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.067 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11041,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD463,,,Itraconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11042,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD463,,,Itraconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.136 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11043,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD463,,,Itraconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.204 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11165,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11166,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11167,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11168,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11169,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11170,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11171,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11172,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI11173,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD469,,,Ketorolac tromethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI41329,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD470,,,Lacidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704978],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41911,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD470,,,Lacidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001391325],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42084,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD470,,,Lacidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00390871],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42687,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD470,,,Lacidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009136971],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44696,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD470,,,Lacidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006991061],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45463,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD470,,,Lacidipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007635661],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10026,Microbes metabolize substances,PMDBM258,573,Klebsiella pneumoniae,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,"Monosaccharides; lactate, acetate; butyrate",Hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli),PMID,PMID: 26569070
PMDBI10027,Microbes metabolize substances,PMDBM199,n.a.,Enterococcus faecalis,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,"Monosaccharides; lactate, acetate; butyrate",Hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli),PMID,PMID: 26569070
PMDBI10028,Microbes metabolize substances,PMDBM176,28141,Cronobacter sakazakii,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,"Monosaccharides; lactate, acetate; butyrate",Hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli),PMID,PMID: 26569070
PMDBI10029,Microbes metabolize substances,PMDBM198,37734,Enterococcus casseliflavus,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,"Monosaccharides; lactate, acetate; butyrate",Hydrolysis,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli),PMID,PMID: 26569070
PMDBI10177,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,fructose and galactose,n.a.,n.a.,Increase Efficacy,n.a.,n.a.,n.a.,Hydrolysis of enzymes of the intestinal bacteria,Lead to laxative effect of lactulose,PMID,PMID: 27485182
PMDBI10289,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,"fructose,galactose",n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs,PMID,PMID: 25926432
PMDBI10367,Microbes metabolize substances,PMDBM258,573,Klebsiella pneumoniae,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,Monosaccharides,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Hydrolysis,"Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)",PMID,PMID: 26569070
PMDBI10368,Microbes metabolize substances,PMDBM199,n.a.,Enterococcus faecalis,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,Monosaccharides,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Hydrolysis,"Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)",PMID,PMID: 26569070
PMDBI10369,Microbes metabolize substances,PMDBM176,28141,Cronobacter sakazakii,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,Monosaccharides,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Hydrolysis,"Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)",PMID,PMID: 26569070
PMDBI10370,Microbes metabolize substances,PMDBM198,37734,Enterococcus casseliflavus,PMDBD471,,,Lactulose,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,Monosaccharides,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Hydrolysis,"Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)",PMID,PMID: 26569070
PMDBI41670,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD472,,,Lansoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42682,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD472,,,Lansoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42839,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD472,,,Lansoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43471,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD472,,,Lansoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00073008],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44687,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD472,,,Lansoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000428798],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44859,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD472,,,Lansoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000152827],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45168,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD472,,,Lansoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41516,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1249,,,Latamoxef,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592
PMDBI41522,Substances alter microbe abundance,PMDBM106,28026,Bifidobacterium pseudocatenulatum,PMDBD1250,,,Laxatives,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41523,Substances alter microbe abundance,PMDBM116,40520,Ruminococcus obeum,PMDBD1250,,,Laxatives,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41525,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD1250,,,Laxatives,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41527,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD1250,,,Laxatives,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41538,Substances alter microbe abundance,PMDBM648,46506,Bacteroides stercoris,PMDBD1250,,,Laxatives,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41539,Substances alter microbe abundance,PMDBM716,116085,Coprococcus catus,PMDBD1250,,,Laxatives,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41540,Substances alter microbe abundance,PMDBM643,1118061,Bacteroidales bacterium ph8,PMDBD1250,,,Laxatives,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42849,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD473,,,Leflunomide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002219157],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45194,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD473,,,Leflunomide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42447,Microbes metabolize substances,PMDBM186,84112,Eggerthella lenta,PMDBD476,,,Levodopa,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,m-tyramine,n.a.,molybdenum-dependent dehydroxylase,Decreases bioavailability; Increase toxicity,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 31196984; PMID: 32409589
PMDBI42448,Microbes metabolize substances,PMDBM199,1351,Enterococcus faecalis,PMDBD476,,,Levodopa,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,dopamine,decarboxylation,Gut bacterial tyrosine decarboxylases,Decreases bioavailability,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 31196984; PMID: 30659181; PMID: 32409589
PMDBI42449,Microbes metabolize substances,PMDBM201,1352,Enterococcus faecium,PMDBD476,,,Levodopa,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,dopamine,decarboxylation,Gut bacterial tyrosine decarboxylases,Decreases bioavailability,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 31196984; PMID: 30659181; PMID: 32409589
PMDBI41566,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1257,,,Levofloxacin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920
PMDBI11994,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11996,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.579 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11997,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.565 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11998,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.571 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11999,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.148 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12000,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI12001,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12002,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12003,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI12004,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12005,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI12006,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12007,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.605 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12008,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12009,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12010,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12011,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12012,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12013,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.846 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12014,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI12015,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD477,,,Levonorgestrel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI43494,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD479,,,Lidoflazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001454241],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44188,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD479,,,Lidoflazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44518,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD479,,,Lidoflazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44713,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD479,,,Lidoflazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008916378],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11556,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11557,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.6 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11558,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11559,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.215 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11560,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11561,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.342 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11562,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.623 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11563,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.764 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11564,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.722 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11565,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.787 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11566,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.253 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11567,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.544 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11568,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.018 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11569,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.902 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11570,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD482,,,Linagliptin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.569 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI40031,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40128,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40257,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40387,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40534,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40671,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40787,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40960,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41145,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41246,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41366,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41550,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41727,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41956,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42133,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42263,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42388,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42558,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42734,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42885,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43179,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43343,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43638,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43752,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43909,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44075,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44231,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44394,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232154],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44558,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691798],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44761,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44911,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45061,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45239,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45365,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45503,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD483,,,Lincomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40018,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40111,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40240,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40370,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Drosophila melanogaster,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40517,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40655,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40770,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40943,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41128,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41229,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41349,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41533,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41579,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762
PMDBI41711,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.54E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41828,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41939,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42119,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42246,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42371,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42541,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42718,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42868,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43076,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007723953],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43162,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43327,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273851],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43626,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43735,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43892,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44058,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44216,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.55E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44378,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44541,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169425],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44744,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44894,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45044,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45222,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45348,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45486,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD484,,,Linezolid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10851,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD488,,,Lofexidine ,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI40447,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD489,,,Lomefloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40188,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40307,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40588,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40712,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40855,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.26E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41029,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41187,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41305,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41778,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001362],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41885,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001423006],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42025,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42455,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42626,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005069808],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42947,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43036,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43120,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43683,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000198677],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43816,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43970,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000153415],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44138,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.30E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45296,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006240123],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45422,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000279971],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45558,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD489,,,Lomefloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40918,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD491,,,Loperamide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007377276],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43498,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD491,,,Loperamide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002894824],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40851,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001729015],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41025,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41301,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41415,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41587,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475
PMDBI41588,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174
PMDBI41613,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42021,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42451,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42622,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42796,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42945,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43035,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43119,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43241,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009959859],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43408,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000230873],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43814,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43967,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44134,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44294,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44454,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44623,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00015842],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44821,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44974,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45123,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207669],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45294,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45418,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45557,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD493,,,Loracarbef,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11415,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11416,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11417,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11418,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11419,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11420,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11421,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11422,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11423,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11424,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11425,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.63 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11426,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11427,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD495,,,Losartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI40624,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD502,,,Loxapine succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157443],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40746,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD502,,,Loxapine succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000612907],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40902,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD502,,,Loxapine succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.92E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41087,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD502,,,Loxapine succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43859,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD502,,,Loxapine succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.54E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44012,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD502,,,Loxapine succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44177,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD502,,,Loxapine succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40195,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.26E-05],n.a.,n.a.,n.a.,n.a.,In vitro,SHIME intestinal environment mimic model,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40459,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40597,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40720,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40868,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41044,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42042,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42205,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42338,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI42470,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42958,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43258,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43425,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001026634],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43828,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43982,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44836,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44989,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009392496],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45138,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45306,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001859804],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45435,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45566,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD504,,,Lymecycline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44870,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD505,,,Lynestrenol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000228354],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45196,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD505,,,Lynestrenol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003709083],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40467,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD506,,,Mafenide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000612559],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40203,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129582],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40324,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40605,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40727,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244742],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40878,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0035891],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41054,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000178054],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41196,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000631183],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41796,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009606166],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42343,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003535641],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42649,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.19E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42818,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0084923],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43839,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43987,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407345],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44650,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003522489],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44999,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009222294],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45574,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD506,,,Mafenide hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000124422],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11769,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11770,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI11772,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11773,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11774,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11775,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11776,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11777,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11778,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11779,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.864 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11780,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11781,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11782,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11783,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11784,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11785,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.752 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI11786,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.802 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11787,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD511,,,Mebendazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI40085,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD513,,,"Mebhydroline 1,5-naphtalenedisulfonate",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43499,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD513,,,"Mebhydroline 1,5-naphtalenedisulfonate",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002495343],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40008,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40099,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40228,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Health Newborn infants,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40358,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40505,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40643,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40758,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40931,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41116,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41217,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41337,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41521,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41699,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41818,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41927,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42108,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42234,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42359,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42529,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.69E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42706,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.40E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42856,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42982,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43064,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43150,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43315,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000974908],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43614,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43723,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43880,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.59E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44046,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44205,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44366,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44529,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000477981],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44732,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44882,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45032,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45210,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45336,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45474,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD514,,,Meclocycline sulfosalicylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40350,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD515,,,Meclofenamic acid sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000537636],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40497,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD515,,,Meclofenamic acid sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008962491],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40628,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD515,,,Meclofenamic acid sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006173365],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44026,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD515,,,Meclofenamic acid sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003019082],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44185,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD515,,,Meclofenamic acid sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000845062],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41084,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001419173],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41669,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00037081],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41909,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001293302],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42502,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43289,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001303223],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43470,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009134219],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44686,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001403155],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45460,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD516,,,Meclozine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002196121],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10932,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD517,,,Mefloquine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI10933,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD517,,,Mefloquine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI10934,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD517,,,Mefloquine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI10935,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD517,,,Mefloquine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.995 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI40474,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008623045],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40733,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007503786],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40885,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007710688],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41063,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005806766],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42662,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000296205],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42828,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361304],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43444,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002765864],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43846,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000732883],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43995,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44323,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44488,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103252],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44664,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00061337],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45011,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD518,,,Mefloquine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000473573],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11973,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11974,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11976,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11977,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11978,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.024 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11979,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11980,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11981,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11982,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI11983,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11984,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11985,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11986,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11987,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11988,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11989,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11990,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11991,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11992,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11993,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD519,,,Megestrol acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13574,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.295 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13575,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.788 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13576,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.796 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13577,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.658 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13578,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.571 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13579,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.068 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13581,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.441 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13582,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.52 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13583,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.869 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13584,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.412 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13585,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.969 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13586,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.142 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13587,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.785 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13588,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.529 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13589,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI13590,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.657 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13591,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.488 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13592,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.949 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13593,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.2 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13595,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.673 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13596,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.432 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13597,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.41 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13598,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.326 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13599,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.147 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13600,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.965 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13601,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.968 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13602,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.823 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13603,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.304 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13604,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.47 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13605,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13606,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.297 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13607,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.973 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13608,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.704 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13609,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.711 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13610,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.726 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13611,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.622 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13612,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.618 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13613,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.254 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13614,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.301 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13615,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.758 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13616,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.454 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13617,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.289 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13618,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.754 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13619,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.645 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13620,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.417 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13621,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13622,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13623,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13624,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.905 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13625,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.588 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13626,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.235 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI13627,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13628,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.954 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13629,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.768 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13630,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.734 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13632,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.074 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13633,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.528 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13634,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.385 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13635,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.445 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13636,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.393 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13637,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.216 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13638,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.383 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13639,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.233 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13640,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.234 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13641,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.345 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13642,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13643,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.014 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13644,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.95 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13645,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.492 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13646,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.196 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13647,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.862 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13648,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.808 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13649,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD520,,,Melphalan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.753 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI10878,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD521,,,Memantine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI10879,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD521,,,Memantine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI42406,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1275,,,Menadione,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40174,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40296,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002594892],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40432,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.27E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40577,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40701,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40833,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003325765],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41006,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000321397],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41179,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41284,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000201053],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41402,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.92E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41596,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.59E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41760,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41875,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42002,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005474974],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42307,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.42E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42434,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42603,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42779,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43224,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43389,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168628],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43797,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43953,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646374],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44119,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034437],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44276,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44437,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44604,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018563],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44804,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44957,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45106,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45277,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD522,,,Merbromin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0005815],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40028,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40125,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40254,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40384,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40531,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40668,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.42E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40784,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40957,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41142,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41243,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41363,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000153485],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41547,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41612,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390
PMDBI41724,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.79E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41953,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42260,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42385,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42555,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42731,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42882,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43006,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43090,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43176,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43340,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43749,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43906,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44072,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44228,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44391,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.84E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44555,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133365],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44758,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44908,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45058,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.68E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45236,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45362,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45500,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD524,,,Meropenem,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10393,Microbes metabolize substances,PMDBM347,287,Pseudomonas aeruginosa,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10394,Microbes metabolize substances,PMDBM134,546,Citrobacter freundii,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10395,Microbes metabolize substances,PMDBM256,571,Klebsiella oxytoca,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10396,Microbes metabolize substances,PMDBM257,574,Klebsiella pneumoniae subsp. ozaenae,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10397,Microbes metabolize substances,PMDBM295,582,Morganella morganii,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10399,Microbes metabolize substances,PMDBM378,623,Shigella flexneri,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10400,Microbes metabolize substances,PMDBM408,666,Vibrio cholerae,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10401,Microbes metabolize substances,PMDBM324,703,Plesiomonas shigelloides,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10402,Microbes metabolize substances,PMDBM132,35703,Citrobacter amalonaticus,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10403,Microbes metabolize substances,PMDBM259,39831,Klebsiella pneumoniae subsp. rhinoscleromatis,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI10404,Microbes metabolize substances,PMDBM133,67824,Citrobacter farmeri,PMDBD525,,,Mesalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,N-acetyl-5-aminosalicylic acid,Acetylation,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
PMDBI40750,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD526,,,Mesoridazine besylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001895632],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40917,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD526,,,Mesoridazine besylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000861551],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41103,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD526,,,Mesoridazine besylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000191026],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11316,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11318,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11319,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11320,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11321,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11322,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI11323,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11324,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11325,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11326,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11327,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD528,,,Metaxalone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI43869,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD529,,,Metergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002160053],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44521,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD529,,,Metergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002585901],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40697,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Type 2 diabetes,n.a.,metformin promotes in vivo the growth of the bacterial species,PMID,PMID: 25038099
PMDBI40698,Substances alter microbe abundance,PMDBM703,69824,Clostridium cocleatum,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Type 2 diabetes,n.a.,metformin promotes in vivo the growth of the bacterial species,PMID,PMID: 25038099
PMDBI41628,Substances alter microbe abundance,PMDBM168,411903,Collinsella aerofaciens ATCC 25986,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41629,Substances alter microbe abundance,PMDBM168,411903,Collinsella aerofaciens ATCC 25986,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41630,Substances alter microbe abundance,PMDBM169,521003,Collinsella intestinalis DSM 13280,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41631,Substances alter microbe abundance,PMDBM169,521003,Collinsella intestinalis DSM 13280,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41633,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41636,Substances alter microbe abundance,PMDBM192,500639,Enterobacter cancerogenus ATCC 35316,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.455607077, FDR-p value=8.24019E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41637,Substances alter microbe abundance,PMDBM192,500639,Enterobacter cancerogenus ATCC 35316,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.530215106, FDR-p value=2.92612E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41641,Substances alter microbe abundance,PMDBM209,562,Escherichia coli,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41647,Substances alter microbe abundance,PMDBM342,471874,Providencia stuartii ATCC 25827,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.37429031, FDR-p value=0.006587299",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41648,Substances alter microbe abundance,PMDBM342,471874,Providencia stuartii ATCC 25827,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41650,Substances alter microbe abundance,PMDBM38,547042,Bacteroides coprophilus DSM 18228 = JCM 13818,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41651,Substances alter microbe abundance,PMDBM38,547042,Bacteroides coprophilus DSM 18228 = JCM 13818,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41658,Substances alter microbe abundance,PMDBM42,817,Bacteroides fragilis,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,"newly diagnosed individuals with T2D who received oral metformin hydrochloride treatment (1000 mg b.i.d, Merck Serono) for 3 d.",n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,"metformin acts in part through a B. fragilis-GUDCA-intestinal FXR axis to improve metabolic dysfunction, including hyperglycemia.",PMID,PMID: 30397356
PMDBI41663,Substances alter microbe abundance,PMDBM710,1511,Clostridium sticklandii,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.632748187, FDR-p value=1.04667E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41664,Substances alter microbe abundance,PMDBM710,1511,Clostridium sticklandii,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.53115063, FDR-p value=6.68753E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41666,Substances alter microbe abundance,PMDBM746,88431,Dorea longicatena,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41667,Substances alter microbe abundance,PMDBM736,177439,Desulfotalea psychrophila LSv54,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41668,Substances alter microbe abundance,PMDBM736,177439,Desulfotalea psychrophila LSv54,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41669,Substances alter microbe abundance,PMDBM735,188626,Dermacoccus sp. Ellin185,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.408391853, FDR-p value=0.002834337",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41670,Substances alter microbe abundance,PMDBM735,188626,Dermacoccus sp. Ellin185,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.505327642, FDR-p value=0.002245307",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41671,Substances alter microbe abundance,PMDBM741,198628,Dickeya dadantii 3937,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.80251936, FDR-p value=0.047280665",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41672,Substances alter microbe abundance,PMDBM741,198628,Dickeya dadantii 3937,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.267692359, FDR-p value=0.005809229",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41673,Substances alter microbe abundance,PMDBM737,207559,Desulfovibrio alaskensis G20,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.700365998, FDR-p value=0.023893497",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41674,Substances alter microbe abundance,PMDBM737,207559,Desulfovibrio alaskensis G20,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41675,Substances alter microbe abundance,PMDBM873,218491,Pectobacterium atrosepticum SCRI1043,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.305509866, FDR-p value=0.024240865",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41676,Substances alter microbe abundance,PMDBM873,218491,Pectobacterium atrosepticum SCRI1043,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41677,Substances alter microbe abundance,PMDBM924,218493,Salmonella bongori NCTC 12419,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.265290612, FDR-p value=0.002107056",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41678,Substances alter microbe abundance,PMDBM924,218493,Salmonella bongori NCTC 12419,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.380107218, FDR-p value=0.000710559",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41679,Substances alter microbe abundance,PMDBM664,243160,Burkholderia mallei ATCC 23344,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41680,Substances alter microbe abundance,PMDBM664,243160,Burkholderia mallei ATCC 23344,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41681,Substances alter microbe abundance,PMDBM882,243265,Photorhabdus luminescens subsp. laumondii TTO1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.025852269, FDR-p value=0.013302006",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41682,Substances alter microbe abundance,PMDBM882,243265,Photorhabdus luminescens subsp. laumondii TTO1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41683,Substances alter microbe abundance,PMDBM825,257314,Lactobacillus johnsonii NCC 533,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.869448838, FDR-p value=0.011460102",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41684,Substances alter microbe abundance,PMDBM825,257314,Lactobacillus johnsonii NCC 533,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41685,Substances alter microbe abundance,PMDBM665,269482,Burkholderia vietnamiensis G4,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41686,Substances alter microbe abundance,PMDBM665,269482,Burkholderia vietnamiensis G4,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41687,Substances alter microbe abundance,PMDBM685,290338,Citrobacter koseri ATCC BAA-895,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.322795865, FDR-p value=0.001184309",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41688,Substances alter microbe abundance,PMDBM685,290338,Citrobacter koseri ATCC BAA-895,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.550284088, FDR-p value=0.000191515",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41689,Substances alter microbe abundance,PMDBM693,290402,Clostridium beijerinckii NCIMB 8052,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.935456291, FDR-p value=1.68244E-09",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41690,Substances alter microbe abundance,PMDBM693,290402,Clostridium beijerinckii NCIMB 8052,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.180967822, FDR-p value=1.63819E-06",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41691,Substances alter microbe abundance,PMDBM621,293826,Alkaliphilus metalliredigens QYMF,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.396739312, FDR-p value=0.008992925",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41692,Substances alter microbe abundance,PMDBM621,293826,Alkaliphilus metalliredigens QYMF,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41693,Substances alter microbe abundance,PMDBM827,314315,Lactobacillus sakei subsp. sakei 23K,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41694,Substances alter microbe abundance,PMDBM827,314315,Lactobacillus sakei subsp. sakei 23K,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41695,Substances alter microbe abundance,PMDBM993,316273,Xanthomonas campestris pv. vesicatoria str. 85-10,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.785442807, FDR-p value=0.001647526",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41696,Substances alter microbe abundance,PMDBM993,316273,Xanthomonas campestris pv. vesicatoria str. 85-10,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41697,Substances alter microbe abundance,PMDBM935,318167,Shewanella frigidimarina NCIMB 400,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41698,Substances alter microbe abundance,PMDBM935,318167,Shewanella frigidimarina NCIMB 400,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41699,Substances alter microbe abundance,PMDBM622,350688,Alkaliphilus oremlandii OhILAs,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.404113177, FDR-p value=0.012985681",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41700,Substances alter microbe abundance,PMDBM622,350688,Alkaliphilus oremlandii OhILAs,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.268766679, FDR-p value=0.029253235",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41701,Substances alter microbe abundance,PMDBM647,357276,Bacteroides dorei,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41702,Substances alter microbe abundance,PMDBM669,360107,Campylobacter hominis ATCC BAA-381,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41703,Substances alter microbe abundance,PMDBM669,360107,Campylobacter hominis ATCC BAA-381,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41704,Substances alter microbe abundance,PMDBM705,386415,Clostridium novyi NT,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.399368333, FDR-p value=0.022167527",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41705,Substances alter microbe abundance,PMDBM705,386415,Clostridium novyi NT,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.284918994, FDR-p value=0.029253235",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41706,Substances alter microbe abundance,PMDBM996,393305,Yersinia enterocolitica subsp. enterocolitica 8081,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.120033541, FDR-p value=0.006748256",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41707,Substances alter microbe abundance,PMDBM996,393305,Yersinia enterocolitica subsp. enterocolitica 8081,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.401555425, FDR-p value=0.001114606",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41708,Substances alter microbe abundance,PMDBM782,393480,Fusobacterium nucleatum subsp. polymorphum ATCC 10953,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41709,Substances alter microbe abundance,PMDBM782,393480,Fusobacterium nucleatum subsp. polymorphum ATCC 10953,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41710,Substances alter microbe abundance,PMDBM656,398513,Bifidobacterium bifidum NCIMB 41171,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41711,Substances alter microbe abundance,PMDBM656,398513,Bifidobacterium bifidum NCIMB 41171,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41712,Substances alter microbe abundance,PMDBM930,399741,Serratia proteamaculans 568,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.055616701, FDR-p value=0.044674306",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41713,Substances alter microbe abundance,PMDBM930,399741,Serratia proteamaculans 568,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41716,Substances alter microbe abundance,PMDBM936,399804,Shewanella putrefaciens 200,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.430097656, FDR-p value=0.000474933",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41717,Substances alter microbe abundance,PMDBM936,399804,Shewanella putrefaciens 200,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41718,Substances alter microbe abundance,PMDBM995,406817,Xenorhabdus nematophila ATCC 19061,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.359407385, FDR-p value=0.013649734",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41719,Substances alter microbe abundance,PMDBM995,406817,Xenorhabdus nematophila ATCC 19061,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41720,Substances alter microbe abundance,PMDBM994,406818,Xenorhabdus bovienii SS-2004,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.228183644, FDR-p value=0.044674306",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41721,Substances alter microbe abundance,PMDBM994,406818,Xenorhabdus bovienii SS-2004,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41722,Substances alter microbe abundance,PMDBM893,411467,Pseudoflavonifractor capillosus ATCC 29799,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-0.438854387, FDR-p value=0.029026142",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41723,Substances alter microbe abundance,PMDBM893,411467,Pseudoflavonifractor capillosus ATCC 29799,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41724,Substances alter microbe abundance,PMDBM655,411481,Bifidobacterium adolescentis L2-32,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.742138652, FDR-p value=0.010221867",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41725,Substances alter microbe abundance,PMDBM655,411481,Bifidobacterium adolescentis L2-32,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41727,Substances alter microbe abundance,PMDBM830,420890,Lactococcus garvieae Lg2,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41728,Substances alter microbe abundance,PMDBM830,420890,Lactococcus garvieae Lg2,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41729,Substances alter microbe abundance,PMDBM824,440497,Lactobacillus jensenii 1153,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.215894228, FDR-p value=0.047280665",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41730,Substances alter microbe abundance,PMDBM824,440497,Lactobacillus jensenii 1153,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41731,Substances alter microbe abundance,PMDBM641,441769,Bacillus coahuilensis m4-4,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.031673872, FDR-p value=0.009194719",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41732,Substances alter microbe abundance,PMDBM641,441769,Bacillus coahuilensis m4-4,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.078729007, FDR-p value=0.005809229",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41733,Substances alter microbe abundance,PMDBM696,445337,Clostridium botulinum C str. Eklund,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.695314834, FDR-p value=0.000183528",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41734,Substances alter microbe abundance,PMDBM696,445337,Clostridium botulinum C str. Eklund,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.299844607, FDR-p value=0.022714196",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41735,Substances alter microbe abundance,PMDBM692,445973,Clostridium bartlettii DSM 16795,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.643594699, FDR-p value=1.25224E-09",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41736,Substances alter microbe abundance,PMDBM692,445973,Clostridium bartlettii DSM 16795,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.230344191, FDR-p value=3.86591E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41737,Substances alter microbe abundance,PMDBM712,445975,Collinsella stercoris DSM 13279,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41738,Substances alter microbe abundance,PMDBM712,445975,Collinsella stercoris DSM 13279,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41739,Substances alter microbe abundance,PMDBM984,450749,Veillonella sp. 6_1_27,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41740,Substances alter microbe abundance,PMDBM984,450749,Veillonella sp. 6_1_27,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41741,Substances alter microbe abundance,PMDBM707,451755,Clostridium perfringens E str. JGS1987,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.683428005, FDR-p value=0.000160155",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41742,Substances alter microbe abundance,PMDBM707,451755,Clostridium perfringens E str. JGS1987,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.689121212, FDR-p value=0.029059088",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41743,Substances alter microbe abundance,PMDBM706,451756,Clostridium perfringens CPE str. F4969,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.47198195, FDR-p value=3.86591E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41744,Substances alter microbe abundance,PMDBM706,451756,Clostridium perfringens CPE str. F4969,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.15525023, FDR-p value=0.003081898",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41745,Substances alter microbe abundance,PMDBM708,457396,Clostridium sp. 7_2_43FAA,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.595495199, FDR-p value=1.74946E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41746,Substances alter microbe abundance,PMDBM708,457396,Clostridium sp. 7_2_43FAA,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.755719438, FDR-p value=0.000178937",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41747,Substances alter microbe abundance,PMDBM918,457412,Ruminococcus sp. 5_1_39BFAA,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=0.601222601, FDR-p value=0.035744039",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41748,Substances alter microbe abundance,PMDBM918,457412,Ruminococcus sp. 5_1_39BFAA,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=0.644897181, FDR-p value=0.019241663",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41749,Substances alter microbe abundance,PMDBM765,465817,Erwinia tasmaniensis Et1/99,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.599688661, FDR-p value=0.001225249",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41750,Substances alter microbe abundance,PMDBM765,465817,Erwinia tasmaniensis Et1/99,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.449901175, FDR-p value=3.63324E-06",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41753,Substances alter microbe abundance,PMDBM783,469606,Fusobacterium nucleatum subsp. vincentii 4_1_13,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41754,Substances alter microbe abundance,PMDBM783,469606,Fusobacterium nucleatum subsp. vincentii 4_1_13,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41755,Substances alter microbe abundance,PMDBM940,471855,Slackia heliotrinireducens DSM 20476,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41756,Substances alter microbe abundance,PMDBM940,471855,Slackia heliotrinireducens DSM 20476,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41757,Substances alter microbe abundance,PMDBM694,498214,Clostridium botulinum A3 str. Loch Maree,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.075608857, FDR-p value=0.000211621",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41758,Substances alter microbe abundance,PMDBM694,498214,Clostridium botulinum A3 str. Loch Maree,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.749316365, FDR-p value=0.002715502",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41759,Substances alter microbe abundance,PMDBM704,500633,Clostridium hiranonis DSM 13275,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41760,Substances alter microbe abundance,PMDBM704,500633,Clostridium hiranonis DSM 13275,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41761,Substances alter microbe abundance,PMDBM688,500640,Citrobacter youngae ATCC 29220,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.852298241, FDR-p value=0.000320929",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41762,Substances alter microbe abundance,PMDBM688,500640,Citrobacter youngae ATCC 29220,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.955117605, FDR-p value=0.00026017",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41763,Substances alter microbe abundance,PMDBM767,502347,Escherichia albertii TW07627,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.559216276, FDR-p value=0.000171663",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41764,Substances alter microbe abundance,PMDBM767,502347,Escherichia albertii TW07627,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.644468481, FDR-p value=0.000155853",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41765,Substances alter microbe abundance,PMDBM908,506534,Rheinheimera sp. A13L,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.163610081, FDR-p value=0.010593629",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41766,Substances alter microbe abundance,PMDBM908,506534,Rheinheimera sp. A13L,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.282398293, FDR-p value=0.005103239",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41767,Substances alter microbe abundance,PMDBM808,507522,Klebsiella pneumoniae 342,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.02111568, FDR-p value=0.00034365",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41768,Substances alter microbe abundance,PMDBM808,507522,Klebsiella pneumoniae 342,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=4.522142971, FDR-p value=5.02008E-09",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41769,Substances alter microbe abundance,PMDBM608,525245,Actinomyces coleocanis DSM 15436,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.462058179, FDR-p value=0.037370083",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41770,Substances alter microbe abundance,PMDBM608,525245,Actinomyces coleocanis DSM 15436,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41771,Substances alter microbe abundance,PMDBM720,525262,Corynebacterium jeikeium ATCC 43734,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41772,Substances alter microbe abundance,PMDBM720,525262,Corynebacterium jeikeium ATCC 43734,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41773,Substances alter microbe abundance,PMDBM721,525263,Corynebacterium lipophiloflavum DSM 44291,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.887722054, FDR-p value=0.01941076",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41774,Substances alter microbe abundance,PMDBM721,525263,Corynebacterium lipophiloflavum DSM 44291,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.213645212, FDR-p value=0.003944251",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41775,Substances alter microbe abundance,PMDBM722,525264,Corynebacterium pseudogenitalium ATCC 33035,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41776,Substances alter microbe abundance,PMDBM722,525264,Corynebacterium pseudogenitalium ATCC 33035,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41777,Substances alter microbe abundance,PMDBM724,525268,Corynebacterium striatum ATCC 6940,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.937531565, FDR-p value=0.01941076",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41778,Substances alter microbe abundance,PMDBM724,525268,Corynebacterium striatum ATCC 6940,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.332867835, FDR-p value=0.003071288",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41779,Substances alter microbe abundance,PMDBM817,525306,Lactobacillus acidophilus ATCC 4796,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.692905134, FDR-p value=0.033240142",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41780,Substances alter microbe abundance,PMDBM817,525306,Lactobacillus acidophilus ATCC 4796,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.913457198, FDR-p value=0.013709185",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41781,Substances alter microbe abundance,PMDBM820,525310,Lactobacillus brevis subsp. gravesensis ATCC 27305,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.293771827, FDR-p value=0.029253235",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41782,Substances alter microbe abundance,PMDBM820,525310,Lactobacillus brevis subsp. gravesensis ATCC 27305,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41783,Substances alter microbe abundance,PMDBM823,525326,Lactobacillus gasseri JV-V03,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.189352734, FDR-p value=0.004093915",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41784,Substances alter microbe abundance,PMDBM823,525326,Lactobacillus gasseri JV-V03,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41785,Substances alter microbe abundance,PMDBM828,525365,Lactobacillus ultunensis DSM 16047,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.772985275, FDR-p value=0.009779385",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41786,Substances alter microbe abundance,PMDBM828,525365,Lactobacillus ultunensis DSM 16047,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41787,Substances alter microbe abundance,PMDBM834,525367,Listeria grayi DSM 20601,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41788,Substances alter microbe abundance,PMDBM834,525367,Listeria grayi DSM 20601,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41789,Substances alter microbe abundance,PMDBM950,525376,Staphylococcus epidermidis W23144,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.374785171, FDR-p value=0.044870479",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41790,Substances alter microbe abundance,PMDBM950,525376,Staphylococcus epidermidis W23144,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41791,Substances alter microbe abundance,PMDBM906,533247,Raphidiopsis brookii D9,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.588467041, FDR-p value=0.010704071",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41792,Substances alter microbe abundance,PMDBM906,533247,Raphidiopsis brookii D9,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41793,Substances alter microbe abundance,PMDBM700,536227,Clostridium carboxidivorans P7,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.320074187, FDR-p value=0.00392092",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41794,Substances alter microbe abundance,PMDBM700,536227,Clostridium carboxidivorans P7,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41795,Substances alter microbe abundance,PMDBM698,536233,Clostridium botulinum E1 str. 'BoNT E Beluga',PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.802220104, FDR-p value=5.02008E-09",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41796,Substances alter microbe abundance,PMDBM698,536233,Clostridium botulinum E1 str. 'BoNT E Beluga',PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.356574993, FDR-p value=3.86591E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41797,Substances alter microbe abundance,PMDBM848,546263,Neisseria elongata subsp. glycolytica ATCC 29315,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.561060703, FDR-p value=0.00252331",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41798,Substances alter microbe abundance,PMDBM848,546263,Neisseria elongata subsp. glycolytica ATCC 29315,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41799,Substances alter microbe abundance,PMDBM849,546266,Neisseria mucosa ATCC 25996,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.939340536, FDR-p value=0.001544492",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41800,Substances alter microbe abundance,PMDBM849,546266,Neisseria mucosa ATCC 25996,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.063888827, FDR-p value=0.000843551",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41801,Substances alter microbe abundance,PMDBM983,546273,Veillonella dispar ATCC 17748,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41802,Substances alter microbe abundance,PMDBM983,546273,Veillonella dispar ATCC 17748,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41803,Substances alter microbe abundance,PMDBM659,547043,Bifidobacterium pseudocatenulatum DSM 20438 = JCM 1200,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41804,Substances alter microbe abundance,PMDBM659,547043,Bifidobacterium pseudocatenulatum DSM 20438 = JCM 1200,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41805,Substances alter microbe abundance,PMDBM674,553178,Capnocytophaga gingivalis ATCC 33624,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.510785896, FDR-p value=0.032299347",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41806,Substances alter microbe abundance,PMDBM674,553178,Capnocytophaga gingivalis ATCC 33624,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.521956757, FDR-p value=0.035377676",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41807,Substances alter microbe abundance,PMDBM668,553220,Campylobacter gracilis RM3268,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41808,Substances alter microbe abundance,PMDBM668,553220,Campylobacter gracilis RM3268,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41809,Substances alter microbe abundance,PMDBM781,556263,Fusobacterium necrophorum D12,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.627931551, FDR-p value=0.019241663",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41810,Substances alter microbe abundance,PMDBM781,556263,Fusobacterium necrophorum D12,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41811,Substances alter microbe abundance,PMDBM744,561229,Dickeya zeae Ech1591,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.910451267, FDR-p value=0.043895048",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41812,Substances alter microbe abundance,PMDBM744,561229,Dickeya zeae Ech1591,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.971726928, FDR-p value=0.031075441",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41813,Substances alter microbe abundance,PMDBM874,561231,Pectobacterium wasabiae WPP163,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.3812479, FDR-p value=0.01941076",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41814,Substances alter microbe abundance,PMDBM874,561231,Pectobacterium wasabiae WPP163,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41815,Substances alter microbe abundance,PMDBM889,563008,Prevotella oris C735,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41816,Substances alter microbe abundance,PMDBM889,563008,Prevotella oris C735,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41817,Substances alter microbe abundance,PMDBM759,565654,Enterococcus casseliflavus EC10,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.183354227, FDR-p value=0.043895048",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41818,Substances alter microbe abundance,PMDBM759,565654,Enterococcus casseliflavus EC10,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41819,Substances alter microbe abundance,PMDBM743,579405,Dickeya dadantii Ech703,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.114542755, FDR-p value=0.039417774",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41820,Substances alter microbe abundance,PMDBM743,579405,Dickeya dadantii Ech703,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.501949726, FDR-p value=0.008015127",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41821,Substances alter microbe abundance,PMDBM818,585524,Lactobacillus amylolyticus DSM 11664,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.773792802, FDR-p value=0.013709185",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41822,Substances alter microbe abundance,PMDBM818,585524,Lactobacillus amylolyticus DSM 11664,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41823,Substances alter microbe abundance,PMDBM742,590409,Dickeya dadantii Ech586,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.467930302, FDR-p value=0.025565282",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41824,Substances alter microbe abundance,PMDBM742,590409,Dickeya dadantii Ech586,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41825,Substances alter microbe abundance,PMDBM697,592027,Clostridium botulinum D str. 1873,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.809632604, FDR-p value=2.33067E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41826,Substances alter microbe abundance,PMDBM697,592027,Clostridium botulinum D str. 1873,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.863663383, FDR-p value=0.00138343",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41827,Substances alter microbe abundance,PMDBM868,592316,Pantoea sp. At-9b,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.765848702, FDR-p value=0.048292655",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41828,Substances alter microbe abundance,PMDBM868,592316,Pantoea sp. At-9b,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.382110424, FDR-p value=0.002681787",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41829,Substances alter microbe abundance,PMDBM881,596315,Peptostreptococcus stomatis DSM 17678,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-0.977184181, FDR-p value=0.027617344",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41830,Substances alter microbe abundance,PMDBM881,596315,Peptostreptococcus stomatis DSM 17678,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41831,Substances alter microbe abundance,PMDBM887,596327,Porphyromonas uenonis 60-3,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41832,Substances alter microbe abundance,PMDBM887,596327,Porphyromonas uenonis 60-3,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41833,Substances alter microbe abundance,PMDBM789,626369,Granulicatella elegans ATCC 700633,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41834,Substances alter microbe abundance,PMDBM789,626369,Granulicatella elegans ATCC 700633,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41835,Substances alter microbe abundance,PMDBM902,629259,Pseudomonas syringae pv. morsprunorum str. M302280,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.934384014, FDR-p value=0.029620989",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41836,Substances alter microbe abundance,PMDBM902,629259,Pseudomonas syringae pv. morsprunorum str. M302280,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41837,Substances alter microbe abundance,PMDBM699,632245,Clostridium butyricum E4 str. BoNT E BL5262,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.617949905, FDR-p value=1.85148E-08",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41838,Substances alter microbe abundance,PMDBM699,632245,Clostridium butyricum E4 str. BoNT E BL5262,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.356166923, FDR-p value=3.86591E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41839,Substances alter microbe abundance,PMDBM860,633147,Olsenella uli DSM 7084,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41840,Substances alter microbe abundance,PMDBM860,633147,Olsenella uli DSM 7084,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41841,Substances alter microbe abundance,PMDBM764,634500,Erwinia billingiae Eb661,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.691049642, FDR-p value=0.00252331",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41842,Substances alter microbe abundance,PMDBM764,634500,Erwinia billingiae Eb661,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.888477517, FDR-p value=0.000683858",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41843,Substances alter microbe abundance,PMDBM747,634503,Edwardsiella ictaluri 93-146,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.087120925, FDR-p value=0.021796713",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41844,Substances alter microbe abundance,PMDBM747,634503,Edwardsiella ictaluri 93-146,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41845,Substances alter microbe abundance,PMDBM686,637910,Citrobacter rodentium ICC168,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.660488871, FDR-p value=4.16674E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41846,Substances alter microbe abundance,PMDBM686,637910,Citrobacter rodentium ICC168,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.677704858, FDR-p value=2.02091E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41847,Substances alter microbe abundance,PMDBM730,639282,Deferribacter desulfuricans SSM1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.315385139, FDR-p value=0.022255128",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41848,Substances alter microbe abundance,PMDBM730,639282,Deferribacter desulfuricans SSM1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41849,Substances alter microbe abundance,PMDBM751,640513,Enterobacter asburiae LF7a,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.32807204, FDR-p value=0.011456502",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41850,Substances alter microbe abundance,PMDBM751,640513,Enterobacter asburiae LF7a,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.797095531, FDR-p value=0.001075253",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41851,Substances alter microbe abundance,PMDBM917,641112,Ruminococcus flavefaciens FD-1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-0.97431946, FDR-p value=0.009565832",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41852,Substances alter microbe abundance,PMDBM917,641112,Ruminococcus flavefaciens FD-1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41853,Substances alter microbe abundance,PMDBM939,649764,Slackia exigua ATCC 700122,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41854,Substances alter microbe abundance,PMDBM939,649764,Slackia exigua ATCC 700122,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41855,Substances alter microbe abundance,PMDBM739,653733,Desulfurispirillum indicum S5,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.115968801, FDR-p value=0.024240865",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41856,Substances alter microbe abundance,PMDBM739,653733,Desulfurispirillum indicum S5,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41857,Substances alter microbe abundance,PMDBM769,656449,Escherichia coli TW10509,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.567658358, FDR-p value=0.000191515",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41858,Substances alter microbe abundance,PMDBM769,656449,Escherichia coli TW10509,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.721061424, FDR-p value=0.000129651",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41859,Substances alter microbe abundance,PMDBM919,657323,Ruminococcus sp. SR1/5,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41860,Substances alter microbe abundance,PMDBM919,657323,Ruminococcus sp. SR1/5,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41861,Substances alter microbe abundance,PMDBM723,662755,Corynebacterium resistens DSM 45100,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41862,Substances alter microbe abundance,PMDBM723,662755,Corynebacterium resistens DSM 45100,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41863,Substances alter microbe abundance,PMDBM954,663952,Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41864,Substances alter microbe abundance,PMDBM954,663952,Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41865,Substances alter microbe abundance,PMDBM929,667129,Serratia odorifera DSM 4582,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.211691931, FDR-p value=0.017934627",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41866,Substances alter microbe abundance,PMDBM929,667129,Serratia odorifera DSM 4582,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.329116737, FDR-p value=0.011449719",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41867,Substances alter microbe abundance,PMDBM990,675811,Vibrio furnissii CIP 102972,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.248372349, FDR-p value=0.024240865",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41868,Substances alter microbe abundance,PMDBM990,675811,Vibrio furnissii CIP 102972,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41869,Substances alter microbe abundance,PMDBM793,679897,Helicobacter mustelae 12198,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=4.130588109, FDR-p value=0.0007715",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41870,Substances alter microbe abundance,PMDBM793,679897,Helicobacter mustelae 12198,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=4.569821736, FDR-p value=0.000106099",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41871,Substances alter microbe abundance,PMDBM914,680646,Rothia mucilaginosa DY-18,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.199480889, FDR-p value=0.035377676",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41872,Substances alter microbe abundance,PMDBM914,680646,Rothia mucilaginosa DY-18,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41873,Substances alter microbe abundance,PMDBM725,693216,Cronobacter turicensis z3032,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.45720173, FDR-p value=0.00252331",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41874,Substances alter microbe abundance,PMDBM725,693216,Cronobacter turicensis z3032,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.963526975, FDR-p value=0.000106099",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41875,Substances alter microbe abundance,PMDBM640,699184,Bacillus cereus SJ1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.178117422, FDR-p value=0.004656101",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41876,Substances alter microbe abundance,PMDBM640,699184,Bacillus cereus SJ1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.750279107, FDR-p value=0.000246599",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41877,Substances alter microbe abundance,PMDBM718,700015,Coriobacterium glomerans PW2,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41878,Substances alter microbe abundance,PMDBM718,700015,Coriobacterium glomerans PW2,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41879,Substances alter microbe abundance,PMDBM755,701347,Enterobacter lignolyticus SCF1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.050390527, FDR-p value=0.00639885",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41880,Substances alter microbe abundance,PMDBM755,701347,Enterobacter lignolyticus SCF1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.443474267, FDR-p value=0.000474933",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41881,Substances alter microbe abundance,PMDBM835,702453,Listeria seeligeri FSL N1-067,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41882,Substances alter microbe abundance,PMDBM835,702453,Listeria seeligeri FSL N1-067,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41883,Substances alter microbe abundance,PMDBM605,707232,Acinetobacter haemolyticus ATCC 19194,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.320471234, FDR-p value=0.000595034",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41884,Substances alter microbe abundance,PMDBM605,707232,Acinetobacter haemolyticus ATCC 19194,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41885,Substances alter microbe abundance,PMDBM822,712938,Lactobacillus fermentum CECT 5716,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.348898935, FDR-p value=0.037504396",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41886,Substances alter microbe abundance,PMDBM822,712938,Lactobacillus fermentum CECT 5716,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41887,Substances alter microbe abundance,PMDBM763,716540,Erwinia amylovora ATCC 49946,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.249706167, FDR-p value=0.037264707",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41888,Substances alter microbe abundance,PMDBM763,716540,Erwinia amylovora ATCC 49946,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.872804342, FDR-p value=0.002834337",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41889,Substances alter microbe abundance,PMDBM753,716541,Enterobacter cloacae subsp. cloacae ATCC 13047,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.407318727, FDR-p value=0.000352065",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41890,Substances alter microbe abundance,PMDBM753,716541,Enterobacter cloacae subsp. cloacae ATCC 13047,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.432745788, FDR-p value=0.000211621",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41891,Substances alter microbe abundance,PMDBM754,718254,Enterobacter cloacae subsp. cloacae NCTC 9394,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.659961714, FDR-p value=4.8626E-06",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41892,Substances alter microbe abundance,PMDBM754,718254,Enterobacter cloacae subsp. cloacae NCTC 9394,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=4.038769728, FDR-p value=3.86591E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41893,Substances alter microbe abundance,PMDBM701,720554,Clostridium clariflavum DSM 19732,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41894,Substances alter microbe abundance,PMDBM701,720554,Clostridium clariflavum DSM 19732,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41895,Substances alter microbe abundance,PMDBM904,741091,Rahnella sp. Y9602,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.724851882, FDR-p value=0.000257223",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41896,Substances alter microbe abundance,PMDBM904,741091,Rahnella sp. Y9602,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41897,Substances alter microbe abundance,PMDBM903,745277,Rahnella aquatilis CIP 78.65 = ATCC 33071,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.132822941, FDR-p value=0.012098214",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41898,Substances alter microbe abundance,PMDBM903,745277,Rahnella aquatilis CIP 78.65 = ATCC 33071,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41899,Substances alter microbe abundance,PMDBM776,748224,Faecalibacterium cf. prausnitzii KLE1255,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-0.728616189, FDR-p value=0.023392474",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41900,Substances alter microbe abundance,PMDBM776,748224,Faecalibacterium cf. prausnitzii KLE1255,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41901,Substances alter microbe abundance,PMDBM894,748280,Pseudogulbenkiania sp. NH8B,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.427383556, FDR-p value=0.044870479",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41902,Substances alter microbe abundance,PMDBM894,748280,Pseudogulbenkiania sp. NH8B,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41903,Substances alter microbe abundance,PMDBM948,754026,Staphylococcus aureus subsp. aureus MRSA177,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.325157575, FDR-p value=0.013709185",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41904,Substances alter microbe abundance,PMDBM948,754026,Staphylococcus aureus subsp. aureus MRSA177,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41905,Substances alter microbe abundance,PMDBM662,759914,Brachyspira pilosicoli 95/1000,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41906,Substances alter microbe abundance,PMDBM662,759914,Brachyspira pilosicoli 95/1000,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41907,Substances alter microbe abundance,PMDBM796,760142,Hippea maritima DSM 10411,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-1.415675601, FDR-p value=0.047280665",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41908,Substances alter microbe abundance,PMDBM796,760142,Hippea maritima DSM 10411,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41909,Substances alter microbe abundance,PMDBM958,760570,Streptococcus parasanguinis ATCC 15912,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.134677832, FDR-p value=0.044674306",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41910,Substances alter microbe abundance,PMDBM958,760570,Streptococcus parasanguinis ATCC 15912,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41911,Substances alter microbe abundance,PMDBM609,762963,Actinomyces sp. oral taxon 170 str. F0386,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41912,Substances alter microbe abundance,PMDBM609,762963,Actinomyces sp. oral taxon 170 str. F0386,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41913,Substances alter microbe abundance,PMDBM646,762984,Bacteroides clarus YIT 12056,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.168360159, FDR-p value=0.029253235",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41914,Substances alter microbe abundance,PMDBM646,762984,Bacteroides clarus YIT 12056,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41917,Substances alter microbe abundance,PMDBM658,871562,Bifidobacterium dentium ATCC 27679,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41918,Substances alter microbe abundance,PMDBM658,871562,Bifidobacterium dentium ATCC 27679,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41919,Substances alter microbe abundance,PMDBM614,878320,Aeromonas caviae Ae398,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.440430469, FDR-p value=0.024240865",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41920,Substances alter microbe abundance,PMDBM614,878320,Aeromonas caviae Ae398,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41921,Substances alter microbe abundance,PMDBM877,879308,Peptoniphilus sp. oral taxon 375 str. F0436,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=0.421746652, FDR-p value=0.049124707",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41922,Substances alter microbe abundance,PMDBM877,879308,Peptoniphilus sp. oral taxon 375 str. F0436,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41923,Substances alter microbe abundance,PMDBM985,879309,Veillonella sp. oral taxon 158 str. F0412,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41924,Substances alter microbe abundance,PMDBM985,879309,Veillonella sp. oral taxon 158 str. F0412,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41925,Substances alter microbe abundance,PMDBM925,882884,"Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980",PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.529077443, FDR-p value=0.00037212",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41926,Substances alter microbe abundance,PMDBM925,882884,"Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980",PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.626655863, FDR-p value=0.000171663",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41927,Substances alter microbe abundance,PMDBM821,888027,Lactobacillus delbrueckii subsp. lactis DSM 20072,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.868633697, FDR-p value=0.028170194",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41928,Substances alter microbe abundance,PMDBM821,888027,Lactobacillus delbrueckii subsp. lactis DSM 20072,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41929,Substances alter microbe abundance,PMDBM847,888742,Neisseria bacilliformis ATCC BAA-1200,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41930,Substances alter microbe abundance,PMDBM847,888742,Neisseria bacilliformis ATCC BAA-1200,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41933,Substances alter microbe abundance,PMDBM772,903814,Eubacterium limosum KIST612,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41934,Substances alter microbe abundance,PMDBM772,903814,Eubacterium limosum KIST612,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41935,Substances alter microbe abundance,PMDBM926,909945,Salmonella enterica subsp. enterica serovar Dublin str. SD3246,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.61522486, FDR-p value=0.00026017",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41936,Substances alter microbe abundance,PMDBM926,909945,Salmonella enterica subsp. enterica serovar Dublin str. SD3246,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.788588462, FDR-p value=5.97097E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41937,Substances alter microbe abundance,PMDBM991,911104,Weissella cibaria KACC 11862,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.964812413, FDR-p value=0.043895048",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41938,Substances alter microbe abundance,PMDBM991,911104,Weissella cibaria KACC 11862,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41939,Substances alter microbe abundance,PMDBM695,929506,Clostridium botulinum BKT015925,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-3.819744919, FDR-p value=5.29255E-05",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41940,Substances alter microbe abundance,PMDBM695,929506,Clostridium botulinum BKT015925,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Decrease,"log2FC=-2.755940694, FDR-p value=0.003267857",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41941,Substances alter microbe abundance,PMDBM604,980514,Acinetobacter baumannii TCDC-AB0715,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.547944979, FDR-p value=0.024240865",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41942,Substances alter microbe abundance,PMDBM604,980514,Acinetobacter baumannii TCDC-AB0715,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41943,Substances alter microbe abundance,PMDBM901,996285,Pseudomonas stutzeri DSM 4166,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.546250033, FDR-p value=0.008015127",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41944,Substances alter microbe abundance,PMDBM901,996285,Pseudomonas stutzeri DSM 4166,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41945,Substances alter microbe abundance,PMDBM806,1006551,Klebsiella oxytoca KCTC 1686,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.795582236, FDR-p value=0.00026017",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41946,Substances alter microbe abundance,PMDBM806,1006551,Klebsiella oxytoca KCTC 1686,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.672789777, FDR-p value=2.2381E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41947,Substances alter microbe abundance,PMDBM750,1028307,Enterobacter aerogenes KCTC 2190,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.354538187, FDR-p value=0.003574388",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41948,Substances alter microbe abundance,PMDBM750,1028307,Enterobacter aerogenes KCTC 2190,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.842625114, FDR-p value=0.000191515",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41949,Substances alter microbe abundance,PMDBM826,1040964,Lactobacillus ruminis SPM0211,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41950,Substances alter microbe abundance,PMDBM826,1040964,Lactobacillus ruminis SPM0211,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41951,Substances alter microbe abundance,PMDBM752,1045856,Enterobacter cloacae EcWSU1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.12259286, FDR-p value=0.024051055",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41952,Substances alter microbe abundance,PMDBM752,1045856,Enterobacter cloacae EcWSU1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.169148203, FDR-p value=0.018165801",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41953,Substances alter microbe abundance,PMDBM616,1050720,Agrobacterium tumefaciens F2,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41954,Substances alter microbe abundance,PMDBM616,1050720,Agrobacterium tumefaciens F2,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41955,Substances alter microbe abundance,PMDBM891,1051006,Propionibacterium acnes SK182B-JCVI,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41956,Substances alter microbe abundance,PMDBM891,1051006,Propionibacterium acnes SK182B-JCVI,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41957,Substances alter microbe abundance,PMDBM960,1051074,Streptococcus thermophilus JIM 8232,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41958,Substances alter microbe abundance,PMDBM960,1051074,Streptococcus thermophilus JIM 8232,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41959,Substances alter microbe abundance,PMDBM837,1064535,Megasphaera elsdenii DSM 20460,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41960,Substances alter microbe abundance,PMDBM837,1064535,Megasphaera elsdenii DSM 20460,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41961,Substances alter microbe abundance,PMDBM955,1069533,Streptococcus infantarius subsp. infantarius CJ18,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41962,Substances alter microbe abundance,PMDBM955,1069533,Streptococcus infantarius subsp. infantarius CJ18,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41963,Substances alter microbe abundance,PMDBM895,1089456,Pseudomonas aeruginosa NCGM2.S1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=1.761073416, FDR-p value=0.047280665",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41964,Substances alter microbe abundance,PMDBM895,1089456,Pseudomonas aeruginosa NCGM2.S1,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=3.594793617, FDR-p value=7.95032E-07",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41966,Substances alter microbe abundance,PMDBM867,1123863,Pantoea ananatis LMG 5342,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.708788524, FDR-p value=0.000596366",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41967,Substances alter microbe abundance,PMDBM867,1123863,Pantoea ananatis LMG 5342,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,Increase,"log2FC=2.823475384, FDR-p value=0.00037212",n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Altered gut microbiota mediates some of metformin’s antidiabetic effects.,PMID,PMID: 28530702
PMDBI41968,Substances alter microbe abundance,PMDBM829,1423814,Lactobacillus vaginalis ATCC 49540,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,2 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI41969,Substances alter microbe abundance,PMDBM829,1423814,Lactobacillus vaginalis ATCC 49540,PMDBD530,,,Metformin,Therapeutic Substance,Approved Drug,4 months of metformin treatment vs control,n.a.,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 28530702
PMDBI40010,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.84E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40101,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40230,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40360,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40507,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR),Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40645,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.51E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Bufo gargarizans,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40760,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40933,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000104443],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41118,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.29E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41219,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41339,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41523,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41701,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41820,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41929,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42110,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42236,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42361,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42531,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42708,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42858,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42984,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43066,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43152,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43317,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001033647],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43616,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43725,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43882,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44048,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44207,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002795386],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44368,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44531,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001195925],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44734,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44884,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45034,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.82E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45212,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45338,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45476,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD531,,,Methacycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42697,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD532,,,Methantheline bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008706801],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45198,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD533,,,Methiazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164286],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41437,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000977939],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41663,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00025014],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42497,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003241472],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43282,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000587621],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43461,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001925619],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43854,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004225506],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44003,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004049483],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44331,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000263044],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44498,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271321],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44677,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD534,,,Methiothepin maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000672828],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40887,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41066,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.82E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41803,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117098],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42071,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253827],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42221,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42944,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vivo,Caenorhabditis elegans,n.a.,n.a.,No effect on Caenorhabditis elegans,PMID,PMID: 30890566; PMID: 28431244
PMDBI43449,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001928589],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43704,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44491,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006374774],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45014,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005149904],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45318,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45452,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45577,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD535,,,Methotrexate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41109,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD536,,,Methotrimeprazine maleat salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006991298],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10881,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD538,,,Methsuximide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI40169,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro; In vivo(Rat),Human; Rats,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40292,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40427,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40572,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Cirrhosis,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40697,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000390662],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40828,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000191748],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41001,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41281,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41399,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41591,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41756,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000196949],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41871,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185668],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41997,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42302,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.11E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42429,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42598,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42774,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42924,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43219,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.91E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43384,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164898],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43667,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.19E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43792,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43949,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44114,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.37E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44271,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44432,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44599,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131961],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44799,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271654],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44952,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45101,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45273,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001708248],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45398,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45542,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD539,,,Methyl benzethonium chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10952,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD541,,,Methylphenidate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI10954,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD541,,,Methylphenidate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI10955,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD541,,,Methylphenidate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI10882,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD542,,,Methysergide maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI10883,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD542,,,Methysergide maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI10852,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD543,,,Metitepine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI40217,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005682417],n.a.,n.a.,n.a.,n.a.,n.a.,Medaka fishes,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40343,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00665058],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40619,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109489],n.a.,n.a.,n.a.,n.a.,In vivo,Japanese quail,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40742,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI40898,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41081,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43856,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000994849],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44007,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44172,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD544,,,Metixene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10884,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD545,,,Metoprolol tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI10885,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD545,,,Metoprolol tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.328 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11586,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.013 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11587,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.989 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11588,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.126 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11589,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11590,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11591,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11592,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11593,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11594,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.052 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11595,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11596,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11597,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.833 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11598,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11599,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11600,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD547,,,Mevastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI40189,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002157434],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40309,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00055263],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40856,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005367666],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41031,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000197672],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41619,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41780,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001159592],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42028,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.43E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42193,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.98E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42328,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42458,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42629,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42802,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42949,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001003844],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43247,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43414,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43685,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003529462],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43972,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007636386],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44140,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170427],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44300,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944356],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44460,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44629,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001943],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44827,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44979,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45128,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45299,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001963582],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45425,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD548,,,Miconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006471536],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11107,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11109,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11110,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11111,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11112,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11113,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11114,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11115,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI40916,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002824993],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41915,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404149],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44191,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD549,,,Mifepristone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.97E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40007,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40098,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.82E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40227,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.37E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40357,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40504,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40642,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.55E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40757,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40930,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41115,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41216,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41336,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41520,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41698,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41817,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41926,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42107,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42233,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42358,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42528,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42705,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42855,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42981,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43063,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43149,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43314,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214078],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43613,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43722,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43879,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44045,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44204,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.42E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44365,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183397],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44528,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44731,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44881,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.10E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45031,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45209,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45335,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45473,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD552,,,Minocycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42407,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1299,,,Mitomycin C,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI44036,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD554,,,Mitotane,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003007578],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44721,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD554,,,Mitotane,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003977147],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42408,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1300,,,Mitoxantrone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI45592,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD555,,,Mometasone furoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40429,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD556,,,Monensin sodium,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40171,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003263891],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40294,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40574,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002632027],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40830,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507497],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41003,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41176,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009577361],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41282,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41400,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41593,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41758,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41873,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.37E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41999,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42173,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42304,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42431,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42600,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42776,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42926,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.72E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43221,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43386,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43668,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.81E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43794,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43951,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44116,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.21E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44273,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00193131],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44434,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44601,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00015911],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44801,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44954,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45103,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45275,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45400,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD556,,,Monensin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41907,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000869382],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42080,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42678,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000234948],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43466,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007492184],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44009,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44682,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000673509],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45021,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000958761],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45459,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD558,,,Montelukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40623,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD559,,,Moricizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40745,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD559,,,Moricizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019571],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI40901,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD559,,,Moricizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100831],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41086,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD559,,,Moricizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43858,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD559,,,Moricizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002627508],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44011,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD559,,,Moricizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165707],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44176,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD559,,,Moricizine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40435,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD561,,,Moxalactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001829832],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40298,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.18E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40836,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.60E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41009,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.80E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41287,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41405,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41599,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41762,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41876,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42005,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42177,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42309,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.15E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42437,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42606,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42782,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42930,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43028,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43112,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43227,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43392,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168822],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43800,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43956,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44279,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44440,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44607,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000245651],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44807,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44960,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45108,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45280,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45403,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45548,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD561,,,Moxalactam disodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40112,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40241,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40371,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000267555],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40518,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40656,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40771,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40944,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41129,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41230,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41350,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41534,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41712,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.56E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41829,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41940,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42006,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083
PMDBI42120,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42247,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42372,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42542,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42719,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150075],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42869,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42993,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43077,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43163,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43328,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001400586],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43627,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43736,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43893,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44059,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44217,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44379,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00010614],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44542,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241328],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44745,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44895,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.50E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45045,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006468553],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45223,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45349,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45487,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD562,,,Moxifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12936,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12937,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.098 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12938,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12939,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI12940,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.89 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12942,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12943,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI12944,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12945,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12946,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12947,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12948,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.657 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12950,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12951,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12952,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI12953,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12954,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12955,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12956,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI12957,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.462 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12958,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.353 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI12959,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.799 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12960,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.044 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI12961,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.3 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12962,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12963,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12964,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12965,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12966,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12967,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12968,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12969,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.877 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12970,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12971,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.781 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12972,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12973,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12974,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12975,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12976,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.223 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12977,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12978,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12979,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12980,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12981,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12982,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.079 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12983,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12985,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12986,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12987,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12988,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12989,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.175 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12990,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12991,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.665 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12992,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12993,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12994,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12995,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12996,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12997,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12998,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12999,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13000,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13001,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD563,,,Mycophenolate mofetil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI10180,Microbes metabolize substances,PMDBM210,1322345,Escherichia coli ATCC 25922,PMDBD565,,,Nabumetone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,a reduced pharmacologically inactive metabolite,n.a.,n.a.,Decrease Efficacy,n.a.,n.a.,n.a.,n.a.,Cause lower absorbtion and lower bioavailability of the drug,PMID,PMID: 27485182
PMDBI40120,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.23E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40249,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.10E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40379,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40526,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40663,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40779,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40952,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41137,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41238,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41358,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41542,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000310041],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41719,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41837,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41948,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42127,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42255,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42380,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42550,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42877,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43001,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43085,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43171,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.04E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43336,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001837541],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43632,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43744,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43901,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44067,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44223,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000101163],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44387,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000114592],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44550,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000345801],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44753,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44903,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45053,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45231,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.83E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45357,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45495,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD566,,,Nadifloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40067,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40589,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003459073],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41307,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41419,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41618,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41886,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003996211],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42027,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42192,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007815455],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42327,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.79E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42457,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42628,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42801,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42948,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43246,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.61E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43413,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171186],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43684,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43818,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44299,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44459,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44628,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216356],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44826,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001070784],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44978,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45127,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45298,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45424,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD567,,,Nafcillin sodium salt monohydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10983,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD568,,,Nafronyl oxalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI10984,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD568,,,Nafronyl oxalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI10985,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD568,,,Nafronyl oxalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI10986,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD568,,,Nafronyl oxalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI10987,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD568,,,Nafronyl oxalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI10988,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD568,,,Nafronyl oxalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI10886,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD569,,,Naftopidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI10887,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD569,,,Naftopidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.006 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI41445,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD570,,,Naftopidil dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41206,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD571,,,Nalidixic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002768125],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42089,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD571,,,Nalidixic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008240679],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43052,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD571,,,Nalidixic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001295934],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43134,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD571,,,Nalidixic acid sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000480935],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11340,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11341,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11342,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11343,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11344,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11345,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11346,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11347,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11348,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11349,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11350,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11351,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD573,,,Naproxen(+),Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11716,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11717,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11719,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11720,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11721,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11722,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11723,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11724,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11725,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11726,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11727,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11728,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11729,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11730,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11731,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11732,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD576,,,Nateglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI44358,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD578,,,Nefazodone HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006634379],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42409,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1314,,,Nelarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42410,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1314,,,Nelarabine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42949,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1316,,,Neocarzinostatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vivo,Caenorhabditis elegans,n.a.,n.a.,No effect on Caenorhabditis elegans,PMID,PMID: 30890566; PMID: 28431244
PMDBI11352,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11353,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11354,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11355,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11356,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11357,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11358,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11359,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11360,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11361,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11362,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11363,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD581,,,Neostigmine bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI10888,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD582,,,Nevirapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11044,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD585,,,Nicergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11045,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD585,,,Nicergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11047,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD585,,,Nicergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11048,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD585,,,Nicergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.698 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11049,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD585,,,Nicergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.744 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11050,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD585,,,Nicergoline,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI40042,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40140,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40269,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.09E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40399,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40546,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40679,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.64E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40799,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40972,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41157,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41258,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41378,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41562,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.05E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41735,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00243064],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41849,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41968,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42145,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42275,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00181158],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42400,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42570,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42746,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00821249],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42897,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43355,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001492278],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43650,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43763,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43921,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44087,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44242,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44405,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002579406],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44570,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000190957],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44772,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44923,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164947],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45073,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404096],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45251,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.85E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45377,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45514,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD586,,,Niclosamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44872,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD587,,,Nicorandil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002266077],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40129,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000119893],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40258,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague-Dawley Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40388,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.90E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40535,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40672,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40788,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40961,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41146,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41247,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41367,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41551,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41728,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41842,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41957,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42134,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42264,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42389,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.63E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42559,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42735,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42886,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001029457],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43007,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43091,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43180,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43344,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000399703],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43639,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000473102],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43910,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.33E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44076,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44232,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005302486],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44395,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44559,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000309554],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44762,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00122221],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44912,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45062,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45240,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45366,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45504,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD589,,,Nifuroxazide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40058,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Primigravida ICR mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40167,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40290,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.45E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40425,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40570,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40695,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40826,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40999,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41173,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41398,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41589,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41754,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41869,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41995,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42170,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.25E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42300,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42427,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42596,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42772,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42922,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.14E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43217,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43382,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001055051],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43790,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43947,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44112,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44269,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44430,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44597,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000687091],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44797,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44950,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45099,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004828422],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45540,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD590,,,Nifurtimox,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42514,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD591,,,Nilutamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001197623],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45195,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD591,,,Nilutamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000442687],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45199,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD592,,,Nimesulide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001019344],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42521,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD593,,,Nimodipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009606651],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40023,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40117,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40246,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40376,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40523,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40661,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40776,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40949,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41134,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41235,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41355,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41539,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41717,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41834,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41945,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42124,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42252,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42377,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42547,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42724,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42874,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42998,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43082,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43168,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43333,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000265494],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43741,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43898,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44064,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44220,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.29E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44384,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.21E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44547,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000179511],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44750,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44900,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45050,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45228,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45354,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45492,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD594,,,Niridazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10181,Microbes metabolize substances,PMDBM152,1535,[Clostridium] leptum,PMDBD595,,,Nitrazepam,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,7-aminonitrazepam,n.a.,n.a.,n.a.,In vivo,Mouse; Rat,n.a.,Nitro reduction,Produce products with teratogenic effects,PMID,PMID: 27485182
PMDBI10588,Microbes metabolize substances,PMDBM152,1535,[Clostridium] leptum,PMDBD595,,,Nitrazepam,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,7-acetylaminonitrazepam,n.a.,n.a.,Decrease Toxicity,n.a.,n.a.,n.a.,Nitroreductase,"Produce teratogenic activity metabolites,Induce teratogenicity",PMID,PMID: 30227749
PMDBI12749,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.479 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12750,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.222 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12751,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.514 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12752,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.516 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI12753,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.868 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12755,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.569 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12756,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.556 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12757,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12758,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.631 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12759,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI12760,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.073 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12761,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12762,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.095 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12763,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.385 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12764,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.858 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12765,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.938 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12766,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.443 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12767,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.168 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12769,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.484 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12770,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.786 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12771,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.982 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12772,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.999 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12773,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.666 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12774,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.08 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12775,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12776,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.384 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12777,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.432 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12778,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.272 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12779,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.037 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12780,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.551 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12781,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.975 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12782,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.045 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12783,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.736 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12784,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.463 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12785,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.258 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12786,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.846 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12787,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.876 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12788,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.669 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12789,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.286 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12790,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.928 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12791,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.836 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12793,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.509 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12794,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.279 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12795,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.725 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12796,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12797,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.322 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12798,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.234 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12799,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.631 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12800,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.224 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12801,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.648 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12802,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.056 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12803,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.351 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12804,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.911 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12805,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.167 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12806,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.405 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12807,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.389 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12808,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD596,,,Nitrendipine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.722 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI10340,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD597,,,Nitrobenzodiazepine,Therapeutic Substance,Drug Class,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease Efficacy,n.a.,n.a.,n.a.,Bacterial nitroreductase(NfsB),n.a.,PMID,PMID: 26261284
PMDBI40150,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40276,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000124525],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40409,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001126779],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mice,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40556,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40684,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40809,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008278923],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40982,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141464],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41161,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41268,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691798],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41386,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41572,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41743,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41857,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103471],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41978,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42155,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42285,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42410,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42580,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42756,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42906,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43018,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43101,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43200,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.54E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43365,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000402648],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43773,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43931,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000453712],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44096,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.30E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44252,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355466],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44414,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44580,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000315934],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44782,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44933,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45083,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45524,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD598,,,Nitrofural,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40297,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40433,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000857592],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40578,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004295111],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40702,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40834,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41007,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000288543],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41180,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000677598],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41285,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41403,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41597,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41761,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42003,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42175,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42435,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42604,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42780,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42929,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110867],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43026,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.02E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43110,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.78E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43225,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003050721],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43390,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168706],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43798,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021442],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43954,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112269],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44277,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.33E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44438,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44605,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000148521],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44805,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000217512],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44958,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001363477],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45278,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45546,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD599,,,Nitrofurantoin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11441,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11442,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11443,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11444,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11445,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11446,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11447,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI11448,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11449,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11450,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11451,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11452,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11453,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD602,,,Nizatidine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI40751,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD606,,,Norcyclobenzaprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007567399],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43305,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD606,,,Norcyclobenzaprine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000421185],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40196,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001078837],n.a.,n.a.,n.a.,n.a.,In vitro,SHIME intestinal environment mimic model; Caco-2/TC7 human intestinal cells,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40460,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017055],n.a.,n.a.,n.a.,n.a.,In vivo,Fisher 344 rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40598,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007347466],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Prediabetic hyperglycemic state,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40869,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004551067],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41315,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41788,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41893,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002546255],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42034,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419
PMDBI42043,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42471,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42640,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000417653],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42959,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.25E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43043,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43126,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43695,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003173959],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43829,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44990,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003780078],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45139,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00358652],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45307,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00012336],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45436,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.84E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45567,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD607,,,Norfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44724,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD608,,,Norgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005430066],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40038,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40136,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40265,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109768],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40395,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001677974],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40542,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Marine medaka,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40795,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40968,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41153,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.42E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41254,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41374,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41558,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41732,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41847,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.28E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41964,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42141,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42271,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005906099],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42396,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42566,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42742,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42893,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43012,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43095,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.67E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43187,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43351,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43646,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43759,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43917,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44083,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44239,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.53E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44401,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44566,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44919,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45069,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45247,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45373,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD609,,,Novobiocin sodium salt,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42050,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD611,,,Ofloxacin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201
PMDBI10989,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD614,,,Olanzapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI10990,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD614,,,Olanzapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI10991,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD614,,,Olanzapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.057 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI10992,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD614,,,Olanzapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI10993,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD614,,,Olanzapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI10994,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD614,,,Olanzapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI12586,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.254 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12587,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12588,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.057 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12589,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.932 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12590,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.366 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12591,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12592,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12593,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.939 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12594,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.431 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12595,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.026 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12596,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI12597,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.139 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12598,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.106 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI12600,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.671 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12601,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI12602,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI12603,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI12604,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12605,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12606,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12607,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.818 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12608,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.556 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12609,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.06 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI12610,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.205 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12611,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.869 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI12612,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12613,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12614,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI12615,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.613 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI12616,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.21 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12617,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI12618,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.262 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12619,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.105 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI12620,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12621,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI12622,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12624,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12625,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.253 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12626,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.293 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12627,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.344 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12628,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.166 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12629,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.92 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI12630,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12631,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.756 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12632,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12633,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12634,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD617,,,Olmesartan medoxomil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.731 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13423,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.148 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13424,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.706 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13425,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.802 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13426,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.855 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13427,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.448 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13428,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.162 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13430,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.718 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13431,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.153 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13432,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.851 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13433,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.201 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13434,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.659 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13435,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.61 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13436,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.892 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13437,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.492 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13438,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.986 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13439,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.578 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13440,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.773 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13441,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.513 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13442,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.681 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13444,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.467 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13445,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.362 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13446,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.316 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13447,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.65 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13448,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.463 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13449,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.2 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13450,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13451,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.436 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13452,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.415 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13453,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13454,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.097 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI13455,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.775 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI13456,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.071 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI13457,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.503 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13458,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.67 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13459,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.396 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13460,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13461,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.628 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI13462,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.499 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13463,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.014 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13464,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.563 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13465,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.246 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI13466,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.067 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI13467,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI13468,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.804 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13469,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.496 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13470,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.786 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13471,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.449 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13472,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.045 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13473,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.212 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13474,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.419 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13475,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13476,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.679 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13477,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.287 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI13478,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.319 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13480,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.987 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13481,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.875 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13482,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.814 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13483,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13484,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.944 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13485,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.527 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13486,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.421 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13487,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.418 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13488,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.794 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13489,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.716 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13490,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.222 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13491,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.207 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13492,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.66 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI13493,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.531 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13494,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13495,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.654 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13496,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.87 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13497,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.612 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI41671,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42840,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43291,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004276717],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43475,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006471855],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44690,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44860,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000196508],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45169,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD619,,,Omeprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.29E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12474,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.202 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12475,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI12476,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.39 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12477,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12479,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.132 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12480,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12481,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.233 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12482,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12483,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.672 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12484,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.38 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12485,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.826 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12486,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.316 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12487,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12488,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12489,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.305 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12490,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.537 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12491,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.273 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12492,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.14 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12493,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12494,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.875 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI12495,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.369 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12496,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.404 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12497,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.04 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12498,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.159 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12499,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12500,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.859 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12501,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.981 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12502,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.76 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12503,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.89 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12504,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.799 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12505,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.489 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12506,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12507,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.91 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12508,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD620,,,Oorethindrone acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.97 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11065,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD621,,,Oorgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11066,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD621,,,Oorgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.162 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11068,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD621,,,Oorgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11069,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD621,,,Oorgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11070,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD621,,,Oorgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI11071,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD621,,,Oorgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.47 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11072,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD621,,,Oorgestimate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.287 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11058,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD622,,,Ooscapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11059,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD622,,,Ooscapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11060,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD622,,,Ooscapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11061,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD622,,,Ooscapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11062,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD622,,,Ooscapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11063,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD622,,,Ooscapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11064,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD622,,,Ooscapine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI40053,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001780397],n.a.,n.a.,n.a.,n.a.,In vivo,Enchytraeus crypticus,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40160,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40284,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40418,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40564,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40691,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40819,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.23E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40992,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41168,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41582,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41749,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41865,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41988,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42164,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42294,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42420,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42589,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42765,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42916,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43210,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43375,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000167548],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43783,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43941,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44106,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44262,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44423,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.89E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44590,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44790,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44943,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45092,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45534,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD624,,,Ornidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10853,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD625,,,Orphenadrine citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI40068,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40592,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001691631],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40858,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004605859],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41310,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41420,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41621,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.04E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41783,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001031773],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42031,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42196,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0078121],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42330,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42460,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42632,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42803,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43248,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43417,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169084],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43688,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43821,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44302,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.89E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44462,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44632,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000152121],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44829,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44981,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45129,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45301,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45427,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD626,,,Oxacillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12016,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12018,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12019,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI12020,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.323 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI12021,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI12022,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12023,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI12024,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12025,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.794 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12026,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12027,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12028,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.6 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12029,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.395 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12030,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI12031,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12032,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12033,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12034,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI12035,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12036,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12037,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI42696,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD628,,,Oxaprozin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005356222],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10854,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD629,,,Oxcarbazepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI40314,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006143524],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40717,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001797486],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40863,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000806109],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41039,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41190,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001467225],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41423,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41627,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42037,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42201,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42335,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42465,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42636,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42808,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43254,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43422,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166653],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43691,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43977,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44307,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44468,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44638,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019455],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44834,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44985,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45134,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45304,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45432,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD630,,,Oxethazaine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41692,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD631,,,Oxibendazol,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615387],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40319,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000617244],n.a.,n.a.,n.a.,n.a.,In vivo,Swiss mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40871,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001757589],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41047,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117632],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41633,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41791,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000530647],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42046,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42207,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42340,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.84E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42473,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42643,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42813,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43261,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43429,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000957735],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43697,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004700317],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44150,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003093329],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44474,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.42E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44644,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000543699],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44838,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44993,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45142,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45438,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD632,,,Oxiconazole Nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003427444],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41207,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD633,,,Oxolinic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003090159],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42090,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD633,,,Oxolinic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43053,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD633,,,Oxolinic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43135,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD633,,,Oxolinic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11174,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11176,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11177,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI11178,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11179,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11180,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11181,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11182,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11183,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD634,,,Oxybutynin chloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI40020,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40114,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40243,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.39E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40373,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40520,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Carassius auratus,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40658,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40773,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40946,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41131,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41232,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41352,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41536,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41714,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41831,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00061907],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41942,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42122,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42249,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42374,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42544,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42721,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42871,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42995,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43079,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43165,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43330,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214299],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43629,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43738,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43895,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44061,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44381,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000258893],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44544,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646073],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44747,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44897,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45047,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45225,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45351,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45489,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD635,,,Oxytetracycline dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42367,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD636,,,Paclitaxel,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vivo,Caenorhabditis elegans,n.a.,n.a.,developmental delay,PMID,PMID: 30890566; PMID: 28431244
PMDBI11788,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11789,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11790,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11791,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.104 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11792,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11793,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11794,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11795,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.963 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11796,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11797,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.777 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11798,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.94 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11799,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11800,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI11801,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.231 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11802,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.171 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11804,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.821 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11805,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI11806,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD638,,,Paliperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI42077,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD1342,,,Paracetamol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42079,Substances alter microbe abundance,PMDBM657,1689,Bifidobacterium dentium,PMDBD1342,,,Paracetamol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI41680,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD641,,,Parbendazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42846,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD641,,,Parbendazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003381699],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43488,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD641,,,Parbendazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005696752],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44706,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD641,,,Parbendazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00080764],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45179,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD641,,,Parbendazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.60E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40202,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000756371],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40323,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000560041],n.a.,n.a.,n.a.,n.a.,In vivo,Hawaiian green turtles,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40466,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40604,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000991397],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40726,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40877,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000201749],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41053,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000514387],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41195,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000878667],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41795,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001863675],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42053,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42478,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42648,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002624633],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42966,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.32E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43047,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43130,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43838,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.38E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45573,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD646,,,Pefloxacine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44038,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD647,,,Pemirolast potassium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006799706],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44195,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD647,,,Pemirolast potassium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003849058],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10937,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD648,,,Penbutolol sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI10938,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD648,,,Penbutolol sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI10939,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD648,,,Penbutolol sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI40173,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Wistar Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40431,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00759669],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40576,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001943],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40700,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40832,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41005,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.43E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41178,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.56E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41283,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41401,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41595,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42001,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42306,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42433,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138066],n.a.,n.a.,n.a.,n.a.,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42602,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42778,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42928,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009392496],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43223,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43388,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407731],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43670,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001427007],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43796,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43952,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44118,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44275,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00216796],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44436,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44603,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324492],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44803,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44956,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45105,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45276,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45401,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45545,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD649,,,Pentamidine isethionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42411,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1354,,,Pentostatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42412,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1354,,,Pentostatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40888,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004546858],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41653,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000345879],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41901,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005306086],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42490,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001915979],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42666,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00112447],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42831,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001634087],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43275,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43450,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001468787],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44326,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172153],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44492,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001652559],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44668,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000559087],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45015,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD652,,,Perhexiline maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001596797],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11116,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.937 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11117,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.453 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11118,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11119,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11120,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11121,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI11122,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11123,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11124,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD653,,,Pericyazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI40081,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD655,,,Perphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002509681],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43299,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD655,,,Perphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003200122],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44028,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD655,,,Perphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001361982],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44516,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD655,,,Perphenazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12690,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.764 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12691,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.178 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12693,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.872 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12694,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI12695,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.961 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12696,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.886 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12697,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.983 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12698,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.213 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12699,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12700,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12701,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.715 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12702,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.719 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12703,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12704,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.471 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12706,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.719 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12707,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.711 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12708,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI12709,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.977 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12710,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.813 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12711,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.98 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12712,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.047 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12713,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.105 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12714,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12715,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.52 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12716,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.531 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12717,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.243 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12718,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12719,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.536 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12720,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.164 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12721,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.581 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12722,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12723,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.825 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12724,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.806 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12725,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.878 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12726,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.017 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12727,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI12728,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12729,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.086 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12730,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12732,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.071 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12733,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.578 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12734,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.856 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12735,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.69 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12736,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.729 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12737,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12738,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.792 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12739,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.153 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12740,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12741,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.225 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12742,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.878 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12743,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.966 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12744,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.11 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12745,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.19 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12746,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.103 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12747,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.037 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12748,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD658,,,Phenazopyridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.173 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI40422,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD660,,,Phenethicillin potassium ,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000125508],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40056,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.59E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Primigravida ICR mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40164,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.11E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40567,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40823,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40996,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41279,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41397,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41586,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41867,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41992,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42168,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42297,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42424,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42593,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42769,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42919,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.64E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43214,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.70E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43379,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170885],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43666,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.23E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43787,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43944,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44109,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44266,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44427,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44594,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017552],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44794,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44947,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45096,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45271,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45396,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45537,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD660,,,Phenethicillin potassium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42108,Substances alter microbe abundance,PMDBM703,69824,Clostridium cocleatum,PMDBD1360,,,Phenformin,Therapeutic Substance,Approved Drug,6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 25038099
PMDBI42100,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD661,,,Phenindione,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00940513],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10096,Microbes metabolize substances,PMDBM261,577,Raoultella terrigena,PMDBD662,,,Phenoxyethanol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,cyanuric acid,n.a.,n.a.,n.a.,In vivo,Animal model,n.a.,n.a.,Lead to increased kidney damage,PMID,PMID: 26972811
PMDBI10097,Microbes metabolize substances,PMDBM261,577,Raoultella terrigena,PMDBD662,,,Phenoxyethanol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Metabolism by the bacteria,Lead to kidney stones,PMID,PMID: 26972811
PMDBI10961,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD663,,,Phenytoin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI10962,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD663,,,Phenytoin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI10963,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD663,,,Phenytoin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI10964,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD663,,,Phenytoin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI10965,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD663,,,Phenytoin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI10294,Microbes metabolize substances,PMDBM224,39491,[Eubacterium] rectale,PMDBD668,,,Picosulfuric acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,"free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol]",n.a.,n.a.,Increase Efficacy,n.a.,n.a.,n.a.,Arylsulfate sulfotransferase of bacteria,Have a laxative effect;drug interaction:antibiotics inhibits the transformation,PMID,PMID: 25926432
PMDBI11807,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.3 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11809,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11810,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11811,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11812,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11813,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11814,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11815,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.591 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11816,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11817,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.84 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11818,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11819,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11820,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.965 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11821,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11822,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11823,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11824,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.01 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11825,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD669,,,Pidotimod,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.072 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI40494,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD670,,,Pimethixene maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003050721],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40748,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD670,,,Pimethixene maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005767488],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40908,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD670,,,Pimethixene maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.26E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41094,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD670,,,Pimethixene maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44019,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD670,,,Pimethixene maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007677224],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44181,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD670,,,Pimethixene maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000120861],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10941,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.725 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI10942,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI10943,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI40904,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002355867],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41089,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704304],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43474,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000219214],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44014,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009098165],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44340,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004270959],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44504,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404048],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44689,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD671,,,Pimozide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001273328],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41077,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.57E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41436,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008178731],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41661,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42835,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005395687],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43281,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000919651],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43460,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00029395],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44497,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.08E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44676,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45164,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002561027],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45582,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD672,,,Pinaverium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40631,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD674,,,Pioglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000755608],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41209,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD674,,,Pioglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007046361],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40498,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD675,,,Pipemidic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001002675],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43055,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD675,,,Pipemidic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43137,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD675,,,Pipemidic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40033,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40131,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40260,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000427754],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague-Dawley Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40390,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.82E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40537,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40790,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40963,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41148,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.22E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41249,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41369,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41553,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41843,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001117861],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41959,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42136,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42266,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42391,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42561,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42737,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42888,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43009,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43093,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43182,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.11E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43346,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43641,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43754,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43912,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44078,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44234,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44397,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44561,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185636],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44764,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44914,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45064,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45242,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45368,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.62E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45506,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD676,,,Piperacillin sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41318,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41426,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000779058],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41634,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.43E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42048,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42209,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001023755],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42474,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.27E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42644,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42814,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42963,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002615896],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43262,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43430,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001224807],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43833,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44476,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44645,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000899543],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44839,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44995,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45310,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45440,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45570,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD677,,,Pivampicillin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43057,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD678,,,Pivmecillinam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43140,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD678,,,Pivmecillinam hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40924,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD679,,,Pizotifen malate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000111644],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44873,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD698,,,Pranlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007658516],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12204,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12205,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12207,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12208,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12209,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12210,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12211,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12212,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12213,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12214,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12215,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI12216,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI12217,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12218,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12219,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12220,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12221,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI12222,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12223,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI12224,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI12225,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12226,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12227,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12228,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12229,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI12230,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12231,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD699,,,Pranoprofen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI40351,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD701,,,Prenylamine lactate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001316391],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41098,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD701,,,Prenylamine lactate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000287651],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43297,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD701,,,Prenylamine lactate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001383791],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43486,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD701,,,Prenylamine lactate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006182585],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44704,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD701,,,Prenylamine lactate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004760197],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40920,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD702,,,Pridinol methanesulfonate salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103469],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41106,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD702,,,Pridinol methanesulfonate salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42517,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD703,,,Prilocaine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109489],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11125,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11126,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11127,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11128,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11129,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11130,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI11131,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.673 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11132,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11133,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD704,,,Primaquine phosphate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11618,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11619,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11620,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11621,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11622,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11623,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11624,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.542 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11625,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11626,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11627,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11628,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11629,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11630,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.829 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11631,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11632,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD707,,,Procarbazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.969 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI40909,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD708,,,Prochlorperazine dimaleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00869897],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41095,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD708,,,Prochlorperazine dimaleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007973156],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43481,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD708,,,Prochlorperazine dimaleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006409321],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44021,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD708,,,Prochlorperazine dimaleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008917598],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44345,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD708,,,Prochlorperazine dimaleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003039172],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44508,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD708,,,Prochlorperazine dimaleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005482844],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40073,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40213,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000488322],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40337,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000208434],n.a.,n.a.,n.a.,n.a.,In vitro,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40481,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003286927],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40615,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40739,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000835296],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40890,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.92E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41071,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.33E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43850,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006814855],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43998,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112711],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44166,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD709,,,Promazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40079,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD710,,,Promethazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003400942],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40495,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD710,,,Promethazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00641235],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40911,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD710,,,Promethazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41097,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD710,,,Promethazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44023,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD710,,,Promethazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44183,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD710,,,Promethazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42134,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42135,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42136,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42140,Substances alter microbe abundance,PMDBM791,729,Haemophilus parainfluenzae,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42142,Substances alter microbe abundance,PMDBM959,1305,Streptococcus sanguinis,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42143,Substances alter microbe abundance,PMDBM957,1309,Streptococcus mutans,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42144,Substances alter microbe abundance,PMDBM953,1328,Streptococcus anginosus,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42146,Substances alter microbe abundance,PMDBM657,1689,Bifidobacterium dentium,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42150,Substances alter microbe abundance,PMDBM771,39488,Eubacterium hallii,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42151,Substances alter microbe abundance,PMDBM774,39496,Eubacterium ventriosum,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42153,Substances alter microbe abundance,PMDBM746,88431,Dorea longicatena,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42154,Substances alter microbe abundance,PMDBM716,116085,Coprococcus catus,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42158,Substances alter microbe abundance,PMDBM766,n.a.,Erysipelotrichaceae noname,PMDBD1390,,,Proton pump inhibitors,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI40218,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005259467],n.a.,n.a.,n.a.,n.a.,n.a.,Medaka fishes,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40344,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00893217],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40492,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003451354],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40622,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000469925],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40744,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001072952],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI40900,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.59E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41085,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44175,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD713,,,Protriptyline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006955194],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40071,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000864218],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40200,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40321,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159762],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40464,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40602,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40724,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40874,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000532567],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41050,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001127486],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41193,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41319,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41427,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41793,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004374242],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42211,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.87E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42964,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004328366],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43432,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002168721],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43698,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686935],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43834,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45311,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000596883],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45571,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD715,,,Pyrimethamine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40206,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000301738],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40327,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00165225],n.a.,n.a.,n.a.,n.a.,In vitro,Bacterial strains from poultry,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40607,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40730,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40883,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131961],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41431,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42060,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000981233],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42484,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000275271],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42968,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43701,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004579591],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43842,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021713],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44158,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44485,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005257452],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45007,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007923075],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45576,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD716,,,Pyrvinium pamoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41108,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD719,,,Quetiapine hemifumarate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000472811],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41809,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD720,,,Quinacrine dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008674811],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42689,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD720,,,Quinacrine dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002051243],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43863,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD720,,,Quinacrine dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000154227],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44024,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD720,,,Quinacrine dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100254],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44511,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD720,,,Quinacrine dihydrochloride dihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000822814],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12379,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI12380,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12381,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12383,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.061 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12384,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.639 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI12385,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12386,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12387,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12388,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI12389,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12390,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12391,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12392,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12393,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.062 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12394,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.698 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12395,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12396,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12397,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI12399,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI12400,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12401,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12402,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12403,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12404,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.746 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12405,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12406,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI12407,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12408,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12409,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD721,,,Quinapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.948 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI42161,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1396,,,Quinupristin/dalfopristin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777
PMDBI44039,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD723,,,R(-) Apomorphine hydrochloride hemihydrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016442],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41675,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD724,,,Rabeprazole Sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42843,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD724,,,Rabeprazole Sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43479,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD724,,,Rabeprazole Sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00183633],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44697,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD724,,,Rabeprazole Sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000854305],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44863,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD724,,,Rabeprazole Sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001688439],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45174,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD724,,,Rabeprazole Sodium salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12546,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.071 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12547,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.164 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI12549,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12550,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.801 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI12551,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.567 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12552,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12553,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.715 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12554,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.804 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12555,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12556,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI12557,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.556 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12558,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.672 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12559,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.664 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI12560,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.684 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12561,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI12562,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.066 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12563,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.333 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12564,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.515 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12565,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12566,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.664 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12567,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.527 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12568,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12569,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.612 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12570,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12571,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12572,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.05],PMID,PMID: 31158845
PMDBI12573,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.566 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12574,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.885 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI12575,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12576,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.039 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12577,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.853 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI12578,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12579,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.728 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12580,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.386 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI12581,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.23 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12582,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.706 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12583,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.426 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12584,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.312 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12585,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD725,,,Racecadotril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.694 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI44037,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD726,,,Racepinephrine HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000111392],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44194,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD726,,,Racepinephrine HCl,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005817496],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40923,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD728,,,Raloxifene hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003432585],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11751,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.481 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11752,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11753,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.604 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11754,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11755,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11756,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11757,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11758,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11759,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11760,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11761,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI11762,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11763,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11764,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11765,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11766,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI11767,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11768,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD729,,,Ramelteon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11051,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD730,,,Ramipril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.41 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11052,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD730,,,Ramipril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11053,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD730,,,Ramipril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11054,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD730,,,Ramipril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11055,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD730,,,Ramipril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11056,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD730,,,Ramipril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11057,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD730,,,Ramipril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.692 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11246,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.852 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11247,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11248,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11249,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.069 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11250,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11251,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11252,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI11253,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11254,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11255,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI11256,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD732,,,Rebamipide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11194,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11195,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI11196,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11197,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11198,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI11199,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11200,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11201,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11202,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI11203,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD738,,,Repaglinide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI42167,Substances alter microbe abundance,PMDBM199,1351,Enterococcus faecalis,PMDBD740,,,Resveratrol,Therapeutic Substance,Approved Drug,resveratrol with 200 mg per kg per day,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 24722352; PMID: 31906281
PMDBI42455,Microbes metabolize substances,PMDBM103,1682,Bifidobacterium longum subsp. Infantis,PMDBD740,,,Resveratrol,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,piceid,n.a.,n.a.,Does not change activity,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 9784180; PMID: 27497981; PMID: 31906281
PMDBI42456,Microbes metabolize substances,PMDBM269,1579,Lactobacillus acidophilus,PMDBD740,,,Resveratrol,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,piceid,n.a.,n.a.,Does not change activity,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 9784180; PMID: 27497981; PMID: 31906281
PMDBI42457,Microbes metabolize substances,PMDBM639,1396,Bacillus cereus,PMDBD740,,,Resveratrol,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,piceid,n.a.,n.a.,Does not change activity,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 9784180; PMID: 27497981; PMID: 31906281
PMDBI40630,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD742,,,Ribavirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001080494],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41208,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD742,,,Ribavirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007617779],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44190,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD742,,,Ribavirin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003021836],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42515,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD743,,,Ribostamycin sulfate salt,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002052349],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40013,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40105,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40234,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40364,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40511,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40649,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40764,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40937,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41122,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41223,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41343,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41527,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41705,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.46E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41824,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41933,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42240,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.33E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42365,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42535,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42712,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42862,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42988,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.57E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43070,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.13E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43156,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43321,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000262719],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43620,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43729,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43886,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44052,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44211,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.50E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44372,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44535,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160919],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44738,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44888,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45038,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45216,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45342,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45480,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD746,,,Rifapentine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40026,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40123,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Cyprinus carpio,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40252,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40382,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40529,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40666,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40782,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40955,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.30E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41140,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41241,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41361,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41545,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41722,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41840,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001835278],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41951,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42258,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42383,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42553,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42729,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42880,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43004,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.88E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43088,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000751721],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43174,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43338,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165922],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43635,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.07E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43747,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43904,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44070,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44226,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001576716],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44389,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44553,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018963],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44756,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44906,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45056,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45234,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45360,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45498,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD747,,,Rifaximin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12410,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI12411,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12412,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12413,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12415,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12416,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12417,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI12418,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12419,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12420,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12421,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12422,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.002 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12423,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12424,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI12425,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI12426,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12427,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12428,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI12430,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI12431,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12432,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12433,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.418 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12434,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI12435,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12436,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12437,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.849 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12438,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12439,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI12440,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD748,,,Riluzole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI44722,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD749,,,Riluzole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00913864],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45192,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD749,,,Riluzole hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384151],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12441,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.03 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12442,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.342 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12444,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12445,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12446,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.949 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12447,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.962 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12448,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.505 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12449,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI12450,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.892 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12451,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12452,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI12453,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.178 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12454,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.073 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12455,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.515 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12456,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.735 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12457,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12458,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12459,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.054 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12460,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.949 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12461,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12462,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.898 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12464,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.476 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12465,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.901 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12466,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12467,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.134 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12468,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12469,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI12470,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12471,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.091 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12472,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.015 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12473,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD750,,,Risperidone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI42187,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1404,,,Ritipenem acoxil,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8300248
PMDBI11571,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11572,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11573,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11575,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11576,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11577,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11578,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.768 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11579,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.603 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11580,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI11581,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11582,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11583,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11584,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11585,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD751,,,Ritonavir,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI10857,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD752,,,Rizatriptan benzoate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI40049,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40153,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40279,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40412,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40559,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40687,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002379728],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40812,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40985,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41164,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41271,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41389,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41575,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41745,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001096791],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41860,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41981,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42158,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42288,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42413,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42582,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42759,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42909,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001088287],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43203,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43368,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000167597],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43776,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43934,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44099,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44255,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.87E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44417,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001497261],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44583,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126331],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44785,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44936,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45086,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45527,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD753,,,Ronidazole,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10766,Microbes metabolize substances,PMDBM280,1598,Lactobacillus reuteri,PMDBD755,,,Rosuvastatin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Human,Hyperlipidemia,Bile salt hydrolase activity,Reduce LDL-C levels,PMID,PMID: 31462078
PMDBI12509,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.794 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12510,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI12511,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.298 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12512,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.488 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12513,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.93 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12514,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.33 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12515,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.418 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12516,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.144 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12517,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.766 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12518,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.133 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12519,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.491 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12520,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12521,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.607 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12522,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12523,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12524,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.133 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12525,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.876 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12526,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI12527,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.379 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12528,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.033 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12529,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.37 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12530,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.251 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12531,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.435 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12532,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.493 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12534,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12535,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12536,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.811 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12537,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.766 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12538,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.382 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12539,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.362 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12540,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.313 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12541,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.428 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12542,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.922 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12543,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.831 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12544,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.629 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12545,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD757,,,Roxatidine acetate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.419 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI40034,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40132,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40261,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague-Dawley Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40391,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40538,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40673,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.48E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40791,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40964,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41149,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41250,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41370,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41554,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41729,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41960,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42137,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42267,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42392,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42562,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42738,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42889,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.74E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43183,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43347,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168726],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43642,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.60E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43755,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43913,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.09E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44079,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44235,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44398,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44562,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209985],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44765,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44915,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45065,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45243,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45369,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45507,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD758,,,Roxithromycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40159,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40283,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40417,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40563,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40690,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40818,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.82E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40991,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41167,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41581,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338291],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41748,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41864,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100702],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41987,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42293,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138652],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42419,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00692846],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42588,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42764,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002419759],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42915,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000779058],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43023,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43106,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43209,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002160053],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43374,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001080112],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43782,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43940,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.70E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44105,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.90E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44261,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000877737],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44422,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004555788],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44589,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001211448],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44942,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001636301],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45091,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008930242],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45267,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001734051],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45533,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD759,,,Rufloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45201,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD762,,,Salmeterol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002505954],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40749,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD764,,,Saquinavir mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009785517],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43489,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD764,,,Saquinavir mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003173408],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43866,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD764,,,Saquinavir mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003155935],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44515,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD764,,,Saquinavir mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00602832],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40122,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40251,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40381,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40528,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40665,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.52E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40781,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40954,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41139,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41240,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41360,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.96E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41544,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.97E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41721,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41839,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41950,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42129,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42257,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42382,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42552,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42728,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.68E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42879,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43003,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43087,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43173,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407513],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43337,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691821],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43634,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43746,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43903,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44069,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44225,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002363748],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44552,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001243714],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44755,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44905,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45055,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.48E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45233,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.18E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45359,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45497,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD765,,,Sarafloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40059,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006585507],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Primigravida ICR mice,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40168,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro; In vivo(Rat),Human; Rats,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40291,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40426,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40571,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Cirrhosis,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40696,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.55E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40827,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41000,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41174,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41590,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41755,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41870,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.29E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41996,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42171,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42301,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42428,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42597,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42773,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42923,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.89E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43218,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43383,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43791,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43948,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44113,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44270,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44431,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44598,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133324],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44798,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44951,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45100,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45541,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD771,,,Secnidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10122,Microbes metabolize substances,PMDBM199,n.a.,Enterococcus faecalis,PMDBD772,,,Secoisolariciresinol,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,enterodiol and entero lactone,n.a.,n.a.,Increase Efficacy,In vivo,Rat,"Germ-free,or germ-free colonized with a bacterial consortium",Metabolism by bacteria,Protective effects against breast cancer,PMID,PMID: 26972811
PMDBI10123,Microbes metabolize substances,PMDBM221,1736,Eubacterium limosum,PMDBD772,,,Secoisolariciresinol,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,enterodiol and entero lactone,n.a.,n.a.,Increase Efficacy,In vivo,Rat,"Germ-free,or germ-free colonized with a bacterial consortium",Metabolism by bacteria,Protective effects against breast cancer,PMID,PMID: 26972811
PMDBI10124,Microbes metabolize substances,PMDBM157,29347,[Clostridium] scindens,PMDBD772,,,Secoisolariciresinol,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,enterodiol and entero lactone,n.a.,n.a.,Increase Efficacy,In vivo,Rat,"Germ-free,or germ-free colonized with a bacterial consortium",Metabolism by bacteria,Protective effects against breast cancer,PMID,PMID: 26972811
PMDBI10125,Microbes metabolize substances,PMDBM117,n.a.,Blautia producta,PMDBD772,,,Secoisolariciresinol,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,enterodiol and entero lactone,n.a.,n.a.,Increase Efficacy,In vivo,Rat,"Germ-free,or germ-free colonized with a bacterial consortium",Metabolism by bacteria,Protective effects against breast cancer,PMID,PMID: 26972811
PMDBI10126,Microbes metabolize substances,PMDBM186,n.a.,Eggerthella lenta,PMDBD772,,,Secoisolariciresinol,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,enterodiol and entero lactone,n.a.,n.a.,Increase Efficacy,In vivo,Rat,"Germ-free,or germ-free colonized with a bacterial consortium",Metabolism by bacteria,Protective effects against breast cancer,PMID,PMID: 26972811
PMDBI10127,Microbes metabolize substances,PMDBM287,341220,Lactonifactor longoviformis,PMDBD772,,,Secoisolariciresinol,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,enterodiol and entero lactone,n.a.,n.a.,Increase Efficacy,In vivo,Rat,"Germ-free,or germ-free colonized with a bacterial consortium",Metabolism by bacteria,Protective effects against breast cancer,PMID,PMID: 26972811
PMDBI41643,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41799,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000327625],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42059,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42215,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000770567],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42483,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42657,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42823,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43267,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43439,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44320,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002796885],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44484,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44658,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000156512],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44844,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45006,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45151,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD777,,,Sertaconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100649],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40490,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000762503],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40897,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002066042],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43285,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003077566],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43465,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000282724],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44006,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44171,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002065448],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44334,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000955606],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44502,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44681,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD778,,,Sertindole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000223961],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10908,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD781,,,Sildenafil citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI10910,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD781,,,Sildenafil citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.424 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI44720,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD784,,,Sisomicin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005840765],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45187,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD784,,,Sisomicin sulfate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001018],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42209,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1419,,,Solithromycin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483
PMDBI10042,Microbes metabolize substances,PMDBM42,n.a.,Bacteroides fragilis,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil,Hydrolysis,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Metabolites can inactivate a key liver enzyme,Lead to lethal toxicity when co-administered with 5-fluorouracil,PMID,PMID: 26569070; PMID: 27591027
PMDBI10043,Microbes metabolize substances,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil,Hydrolysis,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Metabolites can inactivate a key liver enzyme,Lead to lethal toxicity when co-administered with 5-fluorouracil,PMID,PMID: 26569070; PMID: 27591027
PMDBI10044,Microbes metabolize substances,PMDBM72,820,Bacteroides uniformis,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil,Hydrolysis,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Metabolites can inactivate a key liver enzyme,Lead to lethal toxicity when co-administered with 5-fluorouracil,PMID,PMID: 26569070; PMID: 27591027
PMDBI10045,Microbes metabolize substances,PMDBM75,821,Bacteroides vulgatus,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil,Hydrolysis,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Metabolites can inactivate a key liver enzyme,Lead to lethal toxicity when co-administered with 5-fluorouracil,PMID,PMID: 26569070; PMID: 27591027
PMDBI10046,Microbes metabolize substances,PMDBM39,28111,Bacteroides eggerthii,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil,Hydrolysis,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,Metabolites can inactivate a key liver enzyme,Lead to lethal toxicity when co-administered with 5-fluorouracil,PMID,PMID: 26569070; PMID: 27591027
PMDBI10239,Microbes metabolize substances,PMDBM42,n.a.,Bacteroides fragilis,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil (BVU),n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Gut bacterial phosphorolytic enzyme,[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients,PMID,PMID: 28270698
PMDBI10240,Microbes metabolize substances,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil (BVU),n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Gut bacterial phosphorolytic enzyme,[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients,PMID,PMID: 28270698
PMDBI10241,Microbes metabolize substances,PMDBM72,820,Bacteroides uniformis,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil (BVU),n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Gut bacterial phosphorolytic enzyme,[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients,PMID,PMID: 28270698
PMDBI10242,Microbes metabolize substances,PMDBM75,821,Bacteroides vulgatus,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil (BVU),n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Gut bacterial phosphorolytic enzyme,[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients,PMID,PMID: 28270698
PMDBI10243,Microbes metabolize substances,PMDBM39,28111,Bacteroides eggerthii,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,(E)-5-(2-bromovinyl) uracil (BVU),n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Gut bacterial phosphorolytic enzyme,[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients,PMID,PMID: 28270698
PMDBI10250,Microbes metabolize substances,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,bromovinyluracil (BVU),n.a.,n.a.,Increase Toxicity,In vivo,Mouse,"Conventional(CV), germ-free(GF)",Microbial enzymes,Metabolized by members of this genus,PMID,PMID: 30733391
PMDBI10251,Microbes metabolize substances,PMDBM57,n.a.,Bacteroides ovatus,PMDBD788,,,Sorivudine,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,bromovinyluracil (BVU),n.a.,n.a.,Increase Toxicity,n.a.,n.a.,n.a.,n.a.,Metabolized by members of this genus,PMID,PMID: 30733391
PMDBI11204,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI11205,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11206,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11207,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11208,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11209,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI11210,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11211,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11212,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI11213,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD789,,,Sotalol,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI40155,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40280,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.43E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40413,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40561,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40688,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40814,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40987,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.21E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41165,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41273,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41391,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41577,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41746,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41862,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000638361],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41983,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42160,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000217474],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42217,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837
PMDBI42415,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42584,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.84E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42911,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43020,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43103,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43205,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.68E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43370,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001923597],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43662,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43778,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43936,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44101,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44257,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44585,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000602138],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44938,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.81E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45264,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45390,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45529,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD798,,,Sparfloxacin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41442,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD799,,,Spectinomycin dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42688,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD799,,,Spectinomycin dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43482,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD799,,,Spectinomycin dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008337197],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44699,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD799,,,Spectinomycin dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000311386],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45326,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD799,,,Spectinomycin dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000358033],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45591,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD800,,,Spiperone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133269],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40041,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000176808],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40139,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40268,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40398,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.67E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40545,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40678,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40798,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40971,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.30E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41156,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41257,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41377,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41561,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41734,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41967,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42144,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.90E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42274,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42399,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42569,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42745,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42896,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43190,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43354,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169084],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43649,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43762,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43920,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.47E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44086,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44241,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44404,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44569,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172121],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44771,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44922,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45072,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45250,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45376,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.60E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45513,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD801,,,Spiramycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41666,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.95E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42500,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008783433],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42676,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42836,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.27E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43284,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005291612],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43463,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000439773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44679,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000269858],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44857,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45165,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD803,,,Stanozolol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.55E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42238,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42240,Substances alter microbe abundance,PMDBM233,853,Faecalibacterium prausnitzii,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42244,Substances alter microbe abundance,PMDBM746,88431,Dorea longicatena,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42245,Substances alter microbe abundance,PMDBM838,n.a.,Methanobrevibacter unclassified,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42246,Substances alter microbe abundance,PMDBM878,n.a.,Peptostreptococcaceae noname,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42247,Substances alter microbe abundance,PMDBM879,n.a.,Peptostreptococcaceae noname unclassified,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42249,Substances alter microbe abundance,PMDBM811,n.a.,Lachnospiraceae bacterium 2 1 58FAA,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42250,Substances alter microbe abundance,PMDBM812,n.a.,Lachnospiraceae bacterium 3 1 57FAA CT1,PMDBD1424,,,Statins,Therapeutic Substance,Drug Class,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI42413,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1425,,,Streptonegrin,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI40194,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.41E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40317,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40458,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40596,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40719,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00040782],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40867,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41043,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.38E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41787,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41892,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000328272],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42041,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42204,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42337,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI42469,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42639,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43042,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43257,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43827,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43981,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44471,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44641,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000175664],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44988,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45137,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD805,,,Streptozotocin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43865,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD806,,,Sulbactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44348,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD806,,,Sulbactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000796508],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44514,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD806,,,Sulbactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000472372],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41647,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41800,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00575307],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42064,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42217,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00080865],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42487,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42660,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42826,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43271,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43442,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000162663],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44487,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44661,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000246537],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44848,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45009,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45154,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD807,,,Sulconazole nitrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40636,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD809,,,Sulfamonomethoxine,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129611],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10103,Microbes metabolize substances,PMDBM199,n.a.,Enterococcus faecalis,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Rat,Antibiotic-treated or germ-free;convention,n.a.,Result in drug cleavage,PMID,PMID: 26972811
PMDBI12809,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.247 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12810,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI12811,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.046 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12812,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12813,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.59 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12814,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.234 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12816,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.639 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12817,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.631 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12818,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.502 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12819,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.242 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12820,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.629 [FDR-adjusted p-Value=0.046],PMID,PMID: 31158845
PMDBI12821,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.679 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12822,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.826 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12823,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.064 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12824,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.088 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12825,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.113 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12826,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.256 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12827,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI12829,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.522 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12830,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12831,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.071 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12832,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.478 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12833,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.296 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12834,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.007 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12835,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.693 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12836,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.184 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12837,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12838,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.182 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12839,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.031 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI12840,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.585 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12841,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.384 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12842,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.184 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12843,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.663 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12844,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.888 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12845,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.605 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12846,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12847,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.916 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12848,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12849,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12850,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.892 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12851,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12852,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12853,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.002 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI12855,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.072 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12856,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.61 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12857,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.01 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12858,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.927 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12859,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.039 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12860,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12861,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.303 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12862,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12863,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12864,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI12865,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.844 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12866,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.252 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12867,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.327 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12868,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.522 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12869,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.398 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12870,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.576 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI42360,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,sulfapyridine; 5-aminosalicylate,Azo bond reduction,azoreductase,Activation of prodrug,In vitro,n.a.,n.a.,n.a.,Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes,PMID,PMID: 31675176
PMDBI42363,Microbes metabolize substances,PMDBM363,33038,Ruminococcus gnavus,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,sulfapyridine; 5-aminosalicylate,Azo bond reduction,azoreductase,Activation of prodrug,In vitro,n.a.,n.a.,n.a.,Sulfasalazine is prodrug converted to the active agent 3-ASA by gut microbes,PMID,PMID: 31675176
PMDBI42364,Microbes metabolize substances,PMDBM371,90371,Salmonella typhimurium,PMDBD812,,,Sulfasalazine,Therapeutic Substance,Approved Drug; Prodrug,n.a.,Gut,n.a.,n.a.,sulfapyridine; 5-aminosalicylate,Azo bond reduction,azoreductase,Activation of prodrug,In vitro,n.a.,n.a.,n.a.,Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes,PMID,PMID: 31675176
PMDBI11257,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11258,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.039],PMID,PMID: 31158845
PMDBI11259,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11260,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11261,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11262,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11263,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.912 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI11264,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11265,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11266,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI11267,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD813,,,Sulfinpyrazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI41668,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008448038],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42681,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000432177],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43288,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43469,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003364809],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44503,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44685,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00082887],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45167,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001171004],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45584,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD818,,,Suloctidil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149165],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10858,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD819,,,Sulpiride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI10911,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD820,,,Sumatriptan succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI10912,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD820,,,Sumatriptan succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI10913,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD820,,,Sumatriptan succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI40088,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD820,,,Sumatriptan succinate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008307524],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42951,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1431,,,Sunitinib,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vivo,Caenorhabditis elegans,n.a.,n.a.,No effect on Caenorhabditis elegans,PMID,PMID: 30890566; PMID: 28431244
PMDBI42464,Microbes metabolize substances,PMDBM233,853,Faecalibacterium prausnitzii,PMDBD821,,,Tacrolimus,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,M1,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,"Faecalibacterium prausnitzii metabolizes tacrolimus into less potent metabolites M1, which is 15-fold less potent than tacrolimus as an immunosuppressant.",PMID,PMID: 30598508
PMDBI10944,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD822,,,Tadalafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI10945,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD822,,,Tadalafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI10946,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD822,,,Tadalafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI10947,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD822,,,Tadalafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI40050,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000313055],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40154,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172932],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40560,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615579],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40813,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.85E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40986,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41272,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41390,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41576,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41861,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41982,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42159,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42289,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42414,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.37E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42583,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42760,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42910,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43019,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384468],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43102,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43204,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43369,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001040151],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43661,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181202],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43777,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43935,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44100,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44256,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44418,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44584,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00095505],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44786,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44937,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45087,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45263,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.11E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45389,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45528,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD823,,,Talampicillin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42953,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1433,,,Tamoxifen,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vivo,Caenorhabditis elegans,n.a.,n.a.,No effect on Caenorhabditis elegans,PMID,PMID: 30890566; PMID: 28431244
PMDBI40471,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000859086],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40882,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003377072],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41059,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00029395],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42345,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000631234],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42481,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003379116],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42655,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283328],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43266,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006847773],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43437,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003193652],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43991,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44157,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000403341],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44319,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003241269],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44482,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000341198],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44656,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000484892],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45004,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45149,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000360321],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45446,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD824,,,Tamoxifen citrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001510749],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40072,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00358652],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40208,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000249869],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40330,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.01E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40473,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40610,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324146],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40884,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001986996],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41061,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000325495],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41200,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41326,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43270,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003762061],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43844,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44160,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001688439],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44322,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44847,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD826,,,Tazobactam,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.83E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42414,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1436,,,Tegafur,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Increase activity,In vitro,n.a.,n.a.,n.a.,Increase hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42415,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1436,,,Tegafur,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42260,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1437,,,Teicoplanin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064
PMDBI42264,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1438,,,Telavancin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049
PMDBI42272,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1440,,,Telithromycin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193
PMDBI11364,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.999 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11365,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11366,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI11367,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11368,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.886 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11369,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11370,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.005 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11371,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI11372,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.035],PMID,PMID: 31158845
PMDBI11373,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI11374,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11375,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.615 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI41913,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42092,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007239027],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44029,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004467722],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45466,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD828,,,Telmisartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006928984],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42946,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD829,,,Temozolomide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Microbe does not metabolize drug,In vivo,Caenorhabditis elegans,n.a.,n.a.,No effect on Caenorhabditis elegans,PMID,PMID: 30890566; PMID: 28431244
PMDBI43871,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD829,,,Temozolomide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008274591],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI13206,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13207,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.763 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13208,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13209,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI13210,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.675 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI13211,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.823 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI13213,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.867 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI13214,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.32 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13215,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.068 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13216,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.1 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13217,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.523 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI13218,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.841 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13219,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.955 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI13220,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.708 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI13221,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.407 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI13222,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13223,Microbes metabolize substances,PMDBM339,n.a.,Proteus penneri ATCC35198,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.848 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13224,Microbes metabolize substances,PMDBM185,n.a.,Edwardsiella tarda ATCC23685,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.248 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13225,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.84 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13226,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13227,Microbes metabolize substances,PMDBM342,n.a.,Providencia stuartii ATCC25827,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.048 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13228,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.744 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13229,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.042 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI13230,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.687 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13231,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.783 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13232,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.833 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI13233,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.968 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13234,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.611 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI13235,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.32 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13236,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.227 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI13237,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.44 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI13238,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI13239,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.804 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13240,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.024 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI13241,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.912 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI13242,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.086 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI13243,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.877 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI13244,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.491 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13245,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.817 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13246,Microbes metabolize substances,PMDBM340,n.a.,Providencia alcalifaciens DSM30120,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.831 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13247,Microbes metabolize substances,PMDBM341,n.a.,Providencia rettgeri DSM1131,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.717 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13248,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.158 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13249,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.367 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13250,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13251,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.638 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13252,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.433 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13253,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.12 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13254,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.345 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13255,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.595 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI13256,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.46 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI13258,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.291 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI13259,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.178 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI13260,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.41 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13261,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI13262,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.138 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13263,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13264,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.67 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13265,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.406 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13266,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.404 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13267,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.57 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13268,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.716 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI13269,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.131 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI13270,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.916 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI13271,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.244 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13272,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.117 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI13273,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.334 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI13274,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.709 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI13275,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.928 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI41684,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42848,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000758779],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44714,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001487911],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45183,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD831,,,Tenatoprazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.91E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40875,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001694919],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41051,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001563951],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41428,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,non-Hodgkin's lymphoma,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41894,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00739182],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42050,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008990004],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42476,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001404915],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42646,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00052388],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42816,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004498],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43264,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575937],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43433,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001593325],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43835,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002107446],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43984,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000485641],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44152,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44314,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44478,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44647,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132871],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44997,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000740599],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45144,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000118131],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45572,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD834,,,Terfenadine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002974409],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44875,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD836,,,Testosterone propionate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000556732],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40017,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.32E-07],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40110,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40239,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.12E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40369,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40516,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40654,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.68E-06],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40769,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.83E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40942,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41127,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41228,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41348,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41532,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41710,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.19E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41827,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001313179],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41938,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42118,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42245,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42370,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42540,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42717,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42867,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42992,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43075,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43161,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43326,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43625,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43734,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43891,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.44E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44057,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44377,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.93E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44540,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133224],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44743,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44893,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45043,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45221,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45347,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45485,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD837,,,Tetracycline hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40019,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Rat,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40113,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40242,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40372,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.79E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40519,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40657,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40772,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40945,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41130,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41231,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41351,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41535,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41713,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41830,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41941,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42121,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000176723],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42248,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42373,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42543,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42720,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42870,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42994,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002697598],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43078,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43164,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.79E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43329,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169166],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43628,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43737,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43894,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44060,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44380,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44543,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018783],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44746,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44896,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45046,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45224,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45350,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45488,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD838,,,Thiamphenicol,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42690,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD840,,,Thiethylperazine dimalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004408996],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43490,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD840,,,Thiethylperazine dimalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001757155],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44350,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD840,,,Thiethylperazine dimalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000454427],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44709,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD840,,,Thiethylperazine dimalate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004535848],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40141,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000275861],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40270,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40400,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40547,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40680,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40800,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.98E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40973,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41259,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41563,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41736,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41850,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000234995],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41969,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42146,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.13E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42276,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42401,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42571,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.56E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42747,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.63E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43013,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000154779],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43096,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43191,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43356,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002294069],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43651,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.46E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43764,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001166423],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43922,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44088,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44243,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000862574],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44406,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000626908],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44571,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44773,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44924,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45074,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646322],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45252,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45378,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45515,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD841,,,Thimerosal,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42094,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD842,,,Thioguanosine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00037355],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43056,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD842,,,Thioguanosine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43139,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD842,,,Thioguanosine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42484,Microbes metabolize substances,PMDBM199,1351,Enterococcus faecalis,PMDBD1451,,,Thiopurines,Therapeutic Substance,Drug Class,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug activation,In vitro,n.a.,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI42485,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1451,,,Thiopurines,Therapeutic Substance,Drug Class,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Drug activation,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 31675176
PMDBI42486,Microbes metabolize substances,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD1451,,,Thiopurines,Therapeutic Substance,Drug Class,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Drug activation,In vitro,n.a.,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI40332,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000278128],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40476,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001913202],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40735,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000321751],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40886,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41065,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.31E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42068,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43273,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000354051],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43447,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003451354],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43996,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44163,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126222],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44325,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180705],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44489,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000342803],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44666,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD843,,,Thioridazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00089262],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40048,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40152,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40278,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40411,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Kunming mice,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40558,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40686,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40811,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40984,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.22E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41163,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41270,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41388,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41574,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41859,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41980,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42157,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42287,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42412,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42758,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42908,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43202,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.25E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43367,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008421756],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43660,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43775,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43933,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44098,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44254,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338971],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44416,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44582,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000346874],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44784,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44935,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45085,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45262,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45388,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45526,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD844,,,Thiostrepton,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10890,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD845,,,Thiothixene,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.043],PMID,PMID: 31158845
PMDBI40315,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824],n.a.,n.a.,n.a.,n.a.,In vivo,Swiss mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40456,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40865,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007399353],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41041,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41313,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41424,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Juvenile Idiopathic Arthritis (JIA),n.a.,n.a.,PMID,PMID: 29555994
PMDBI41629,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42039,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001820012],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42203,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001779948],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42467,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42638,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42810,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42956,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000320991],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43256,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43424,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169425],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43693,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001049058],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43979,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44147,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44309,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44470,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44640,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166653],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44987,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45136,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000331598],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45564,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD846,,,Thonzonium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42352,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD847,,,Thyroxine (L),Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001274877],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43304,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD847,,,Thyroxine (L),Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001698405],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43711,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD847,,,Thyroxine (L),Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009357149],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40039,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40137,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40266,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281647],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40396,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40543,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40796,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40969,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.68E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41154,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000495356],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41255,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41375,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41559,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41848,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41965,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42142,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42272,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42397,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42567,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42743,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42894,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43188,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.26E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43352,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43647,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.56E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43760,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43918,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44084,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44240,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44402,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232311],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44567,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000658811],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44769,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44920,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45070,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45248,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45374,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45511,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD848,,,Ticarcillin sodium,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42306,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD1457,,,Tigecycline,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820
PMDBI12871,Microbes metabolize substances,PMDBM34,n.a.,Bacteroides caccae ATCC43185,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.641 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI12872,Microbes metabolize substances,PMDBM154,n.a.,Clostridium ramosum DSM1402,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.756 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12873,Microbes metabolize substances,PMDBM89,n.a.,Bifidobacterium adolescentis ATCC 15703,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.211 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12874,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.21 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI12875,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.326 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12877,Microbes metabolize substances,PMDBM364,n.a.,Ruminococcus gnavus ATCC29149,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.355 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12878,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.221 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12879,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.879 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12880,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12881,Microbes metabolize substances,PMDBM168,n.a.,Collinsella aerofaciens ATCC25986,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.036],PMID,PMID: 31158845
PMDBI12882,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.51 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12883,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.402 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12884,Microbes metabolize substances,PMDBM158,n.a.,Clostridium scindens ATCC35704,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.773 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI12885,Microbes metabolize substances,PMDBM21,n.a.,Anaerotruncus colihominis DSM17241,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.078 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12886,Microbes metabolize substances,PMDBM144,n.a.,Clostridium bolteae ATCCBAA-613,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12887,Microbes metabolize substances,PMDBM164,n.a.,Clostridium symbiosum ATCC14940,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.163 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12888,Microbes metabolize substances,PMDBM41,n.a.,Bacteroides finegoldii DSM17565,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.325 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12889,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.75 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12891,Microbes metabolize substances,PMDBM230,n.a.,Eubacterium ventriosum ATCC27560,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.333 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12892,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12893,Microbes metabolize substances,PMDBM184,n.a.,Dorea formicigenerans ATCC27755,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.896 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12894,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.977 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12895,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.401 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12896,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.688 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12897,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.251 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12898,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.946 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12899,Microbes metabolize substances,PMDBM96,n.a.,Bifidobacterium breve DSM20213,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.152 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12900,Microbes metabolize substances,PMDBM172,n.a.,Coprococcus comes ATCC27758,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.03 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12901,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.863 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12902,Microbes metabolize substances,PMDBM104,n.a.,Bifidobacterium longum subsp. Infantis CCUG52486,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.098 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12903,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.082 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12904,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.527 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12905,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.682 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12906,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.753 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12907,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.781 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12908,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.021 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12909,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.284 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12910,Microbes metabolize substances,PMDBM169,n.a.,Collinsella intestinalis DSM13280,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.676 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12911,Microbes metabolize substances,PMDBM115,n.a.,Blautia luti DSM14534,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.668 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12912,Microbes metabolize substances,PMDBM356,n.a.,Roseburia intestinalis L1-82,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.134 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12913,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.536 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12914,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.592 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12915,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.624 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12916,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.053 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12917,Microbes metabolize substances,PMDBM225,n.a.,Eubacterium rectale ATCC33656,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.387 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12919,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12920,Microbes metabolize substances,PMDBM200,n.a.,Enterococcus faecalis V583,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.603 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12921,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.448 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12922,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.943 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12923,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.845 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12924,Microbes metabolize substances,PMDBM149,n.a.,Clostridium difficile 120,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.338 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI12925,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12926,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12927,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12928,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.31 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12929,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.418 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12930,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.685 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12931,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.839 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12932,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.07 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI12933,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.71 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12934,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.543 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI12935,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.994 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI40051,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000651143],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40157,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40282,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40415,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Hyline chicken,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40562,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40689,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40816,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40989,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41166,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41393,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41579,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.13E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41747,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.23E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41863,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41985,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42162,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42291,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42417,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42586,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42762,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42913,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.10E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43207,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43372,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000967328],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43780,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43938,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44103,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44259,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44420,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44587,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000604897],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44788,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44940,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45089,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45531,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD849,,,Tinidazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.93E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40454,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704304],n.a.,n.a.,n.a.,n.a.,In vivo,Broilers,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40862,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.94E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41038,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000182756],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41422,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922229],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41626,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41785,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.75E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41891,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00469744],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42036,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.98E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42200,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42334,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42464,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42635,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.77E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42807,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.17E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42954,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000445674],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43253,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43421,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000347934],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43976,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44145,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.63E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44306,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000660736],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44467,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.90E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44637,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133859],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44833,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.21E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44984,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45133,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45431,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD850,,,Tioconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001995732],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40611,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002723341],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41327,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.23E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41648,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41898,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126633],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42065,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42218,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000533178],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42349,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000314737],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42661,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944881],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42969,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006216034],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43845,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43993,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44161,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003190057],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44662,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008092593],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45449,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD851,,,"Tiratricol, 3,3',5-triiodothyroacetic acid",Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI12232,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI12233,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12235,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12236,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12237,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12238,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI12239,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12240,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI12241,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005],PMID,PMID: 31158845
PMDBI12242,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12243,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12244,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12245,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12246,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12247,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12248,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI12249,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12250,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12251,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12252,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12253,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI12254,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12255,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12256,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12257,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12258,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.766 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI12259,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD855,,,Tolazamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI40216,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005043812],n.a.,n.a.,n.a.,n.a.,n.a.,Medaka fishes,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40341,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000680623],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40486,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003731208],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40617,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40741,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003263891],n.a.,n.a.,n.a.,n.a.,In vivo,Human,Inflammatory bowel disease (IBD),n.a.,n.a.,PMID,PMID: 29555994
PMDBI41204,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000524332],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41662,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001470956],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43853,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001265417],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44002,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44169,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD856,,,Tolfenamic acid,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141002],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40348,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD857,,,Tolnaftate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009316771],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42087,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD857,,,Tolnaftate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007289477],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43709,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD857,,,Tolnaftate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003395954],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44700,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD857,,,Tolnaftate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007521944],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45176,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD857,,,Tolnaftate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000374146],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40345,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD858,,,Toltrazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001700046],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42082,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD858,,,Toltrazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007164988],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43861,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD858,,,Toltrazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003783935],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44017,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD858,,,Toltrazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44179,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD858,,,Toltrazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44343,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD858,,,Toltrazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001053227],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44691,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD858,,,Toltrazuril,Therapeutic Substance,Approved Drug (veterinary medicine),n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006747685],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40489,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003573495],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40896,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004974898],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41080,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003326216],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43464,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002310188],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44005,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000479833],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44333,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003764233],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44501,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428481],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44680,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000158052],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45020,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD859,,,Toremifene,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001890094],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40005,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000682966],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40096,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40225,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40355,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40502,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40640,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40755,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40928,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41113,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41214,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41334,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41518,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41696,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41815,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41924,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42105,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.56E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42231,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42356,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42526,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42703,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42853,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42979,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43061,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43147,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43312,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000306383],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43611,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43720,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43877,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44043,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44202,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.40E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44363,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.07E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44526,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164879],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44729,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44879,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45029,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45207,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45333,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45471,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD860,,,Tosufloxacin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11633,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11634,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.908 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI11635,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.037],PMID,PMID: 31158845
PMDBI11636,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.867 [FDR-adjusted p-Value=0.012],PMID,PMID: 31158845
PMDBI11637,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.66 [FDR-adjusted p-Value=0.034],PMID,PMID: 31158845
PMDBI11638,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11639,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11640,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11641,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11642,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11643,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11644,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.006],PMID,PMID: 31158845
PMDBI11645,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11646,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.637 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI11647,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.019],PMID,PMID: 31158845
PMDBI11648,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD863,,,Trandolapril,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.825 [FDR-adjusted p-Value=0.028],PMID,PMID: 31158845
PMDBI10892,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD864,,,Tranilast,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI10893,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD864,,,Tranilast,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI42487,Microbes metabolize substances,PMDBM379,498718,Slackia equolifaciens,PMDBD1470,,,Trans-resveratrol,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,dihydroresveratrol,n.a.,n.a.,Drug metabolism,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 23283496; PMID: 31906281
PMDBI42488,Microbes metabolize substances,PMDBM4,446660,Adlercreutzia equolifaciens,PMDBD1470,,,Trans-resveratrol,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,dihydroresveratrol,n.a.,n.a.,Drug metabolism,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 23283496; PMID: 31906281
PMDBI40089,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD865,,,Trazodone hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000277264],n.a.,n.a.,n.a.,n.a.,In vivo,Dog,Gonadectomized,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10347,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD866,,,Tretazicar,Therapeutic Substance,Investigational Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)),n.a.,PMID,PMID: 26261284
PMDBI41918,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD867,,,Tribenoside,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004733857],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43295,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD870,,,Trifluoperazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000767287],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43480,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD870,,,Trifluoperazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003095836],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44020,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD870,,,Trifluoperazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001621938],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44344,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD870,,,Trifluoperazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000746972],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44507,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD870,,,Trifluoperazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000360067],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44698,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD870,,,Trifluoperazine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002532969],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40086,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD871,,,Triflupromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000685478],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43500,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD871,,,Triflupromazine hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008014017],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10193,Microbes metabolize substances,PMDBM300,2100,Mycoplasma hyorhinis,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Bacterium encode a thymidine phosphorylase,Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds,PMID,PMID: 28270698
PMDBI40211,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000223955],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40335,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160215],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40478,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001921381],n.a.,n.a.,n.a.,n.a.,In vivo,BALB/c mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40614,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40738,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41068,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41202,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42223,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43848,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44327,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000600373],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44495,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD872,,,Trifluridine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10966,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD873,,,Trihexyphenidyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.017],PMID,PMID: 31158845
PMDBI10968,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD873,,,Trihexyphenidyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI10969,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD873,,,Trihexyphenidyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI10970,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD873,,,Trihexyphenidyl,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12107,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12109,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.023],PMID,PMID: 31158845
PMDBI12110,Microbes metabolize substances,PMDBM150,n.a.,Clostridium hathewayi DSM13479,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.04],PMID,PMID: 31158845
PMDBI12111,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI12112,Microbes metabolize substances,PMDBM366,n.a.,Ruminococcus lactaris ATCC29176,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI12113,Microbes metabolize substances,PMDBM192,n.a.,Enterobacter cancerogenus ATCC35316,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12114,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI12115,Microbes metabolize substances,PMDBM59,n.a.,Bacteroides pectinophilus ATCC43243,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI12116,Microbes metabolize substances,PMDBM142,n.a.,Clostridium asparagiforme DSM15981,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12117,Microbes metabolize substances,PMDBM220,n.a.,Eubacterium hallii DSM3353,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12118,Microbes metabolize substances,PMDBM370,n.a.,Ruminococcus torques ATCC27756,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12119,Microbes metabolize substances,PMDBM281,n.a.,Lactobacillus reuteri CF48-3A BEI HM-102,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12120,Microbes metabolize substances,PMDBM107,n.a.,Bifidobacterium ruminatum,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.027],PMID,PMID: 31158845
PMDBI12121,Microbes metabolize substances,PMDBM8,n.a.,Akkermansia muciniphila ATCC BAA-835,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.033],PMID,PMID: 31158845
PMDBI12122,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI12123,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.026],PMID,PMID: 31158845
PMDBI12124,Microbes metabolize substances,PMDBM119,n.a.,Bryantia formatexigens DSM 14469,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI12125,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI12126,Microbes metabolize substances,PMDBM218,n.a.,Eubacterium biforme DSM3989,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI12127,Microbes metabolize substances,PMDBM374,n.a.,Salmonella typhimurium LT2,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12128,Microbes metabolize substances,PMDBM187,n.a.,Eggerthella lenta ATCC25559,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.979 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI12129,Microbes metabolize substances,PMDBM410,n.a.,Victivallis vadensis ATCC BAA-548,PMDBD874,,,Trimebutine maleate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI40625,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD875,,,Trimeprazine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003354848],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40747,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD875,,,Trimeprazine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324701],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40905,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD875,,,Trimeprazine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000653747],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41090,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD875,,,Trimeprazine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43860,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD875,,,Trimeprazine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006969853],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44015,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD875,,,Trimeprazine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.92E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44178,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD875,,,Trimeprazine tartrate,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10859,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD876,,,Trimetazidine dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI40069,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.36E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40197,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244787],n.a.,n.a.,n.a.,n.a.,In vitro,SHIME intestinal environment mimic model,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40318,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00065096],n.a.,n.a.,n.a.,n.a.,In vivo,Sprague Dawley rat,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40461,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135733],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40599,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,CD1 (ICR) mouse,Prediabetic hyperglycemic state,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40721,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6J mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40870,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41045,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017654],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41316,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41425,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Rheumatoid arthritis,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41630,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181568],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41789,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42044,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004419677],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42206,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42960,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105176],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43044,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43127,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43426,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000449161],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43696,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43830,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44991,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD877,,,Trimethoprim,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40475,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00406747],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41651,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.43E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41900,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42067,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.87E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42219,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283823],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42664,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003892562],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43446,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003048825],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44324,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615387],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44665,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001020538],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44849,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001808803],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45012,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00446964],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45155,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001354778],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45451,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD878,,,Troglitazone,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.61E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40161,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40285,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Honeybees,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40419,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40565,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Zebrafish,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40692,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.67E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40820,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40993,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41169,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41276,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41395,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41583,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41750,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41989,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.33E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42165,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42295,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42421,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42590,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42766,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.11E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42917,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002482895],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43211,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43376,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000976862],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43665,Substances alter microbe abundance,PMDBM278,1597,Lactobacillus paracasei,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43784,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43942,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44107,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44263,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.40E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44424,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.29E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44591,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000925813],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44791,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44944,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000477981],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45093,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.91E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45268,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45393,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD879,,,Troleandomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42336,Substances alter microbe abundance,PMDBM209,562,Escherichia coli,PMDBD1485,,,Ustekinumab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,n.a.,n.a.,n.a.,n.a.,n.a.,In vivo,Human,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI42337,Substances alter microbe abundance,PMDBM233,853,Faecalibacterium prausnitzii,PMDBD1485,,,Ustekinumab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI42341,Substances alter microbe abundance,PMDBM912,301302,Roseburia faecis,PMDBD1485,,,Ustekinumab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI42416,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1486,,,Valacyclovir,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI11649,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI11650,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.024],PMID,PMID: 31158845
PMDBI11651,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.049],PMID,PMID: 31158845
PMDBI11652,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI11653,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.031],PMID,PMID: 31158845
PMDBI11654,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11655,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11656,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI11657,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11658,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI11659,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11660,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.021],PMID,PMID: 31158845
PMDBI11661,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11662,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI11663,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11664,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD887,,,Valsartan,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI40439,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD889,,,Vancomycin,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003903545],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42342,Substances alter microbe abundance,PMDBM140,1496,Clostridium difficile,PMDBD888,,,Vancomycin,Therapeutic Substance,Approved Drug; Antibiotics,n.a.,Gut,No significant change,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064
PMDBI40177,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40301,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40704,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001596639],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40841,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004873795],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41014,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41182,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009237436],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41292,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41408,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41604,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41767,Substances alter microbe abundance,PMDBM143,208479,Enterocloster bolteae,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41877,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-06],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42010,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42181,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42314,Substances alter microbe abundance,PMDBM156,84030,Lacrimispora saccharolytica,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42442,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42611,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42787,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.09E-06],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42934,Substances alter microbe abundance,PMDBM186,n.a.,Eggerthella lenta,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05],n.a.,n.a.,n.a.,n.a.,In vitro,Human,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43232,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43397,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000403341],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44125,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181202],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44284,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002799645],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44445,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44612,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000362476],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44812,Substances alter microbe abundance,PMDBM361,40518,Ruminococcus bromii,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44964,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45113,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45285,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45408,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD889,,,Vancomycin hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41682,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD890,,,Vardenafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001064221],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42691,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD890,,,Vardenafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006625292],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44711,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD890,,,Vardenafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000586538],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45182,Substances alter microbe abundance,PMDBM369,33039,[Ruminococcus] torques,PMDBD890,,,Vardenafil,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000390662],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41683,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD891,,,Vecuronium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000140478],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42847,Substances alter microbe abundance,PMDBM183,39486,Dorea formicigenerans,PMDBD891,,,Vecuronium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000745054],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43492,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD891,,,Vecuronium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000301514],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45023,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD891,,,Vecuronium bromide,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000543623],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42354,Substances alter microbe abundance,PMDBM913,360807,Roseburia inulinivorans,PMDBD1487,,,Vedolizumab,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Microbiota as IBD therapy response biomarker,PMID,PMID: 31675176
PMDBI42417,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1489,,,Vidarabine,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566
PMDBI42418,Microbes metabolize substances,PMDBM289,1643,Listeria welshimeri,PMDBD1489,,,Vidarabine,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI12289,Microbes metabolize substances,PMDBM40,n.a.,Bacteroides eggerthii DSM20697,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.737 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12290,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.699 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12291,Microbes metabolize substances,PMDBM35,n.a.,Bacteroides cellulosilyticus DSM14838,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.23 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12292,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.9 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12293,Microbes metabolize substances,PMDBM312,n.a.,Parabacteroides johnsonii DSM18315,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12294,Microbes metabolize substances,PMDBM161,n.a.,Clostridium spiroforme DSM1552,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.675 [FDR-adjusted p-Value=0.007],PMID,PMID: 31158845
PMDBI12295,Microbes metabolize substances,PMDBM54,n.a.,Bacteroides intestinalis DSM17393,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.287 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12296,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.602 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12297,Microbes metabolize substances,PMDBM327,n.a.,Pretovella copri DSM18205,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12298,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.304 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12299,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.4 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12300,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.075 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12301,Microbes metabolize substances,PMDBM66,n.a.,Bacteroides stercoris ATCC43183,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.163 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12302,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.091 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12303,Microbes metabolize substances,PMDBM58,n.a.,Bacteroides ovatus ATCC8483,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.049 [FDR-adjusted p-Value=0.01],PMID,PMID: 31158845
PMDBI12304,Microbes metabolize substances,PMDBM314,n.a.,Parabacteroides merdae ATCC43184,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.485 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12305,Microbes metabolize substances,PMDBM36,n.a.,Bacteroides coprophilus DSM18228,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.018 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12306,Microbes metabolize substances,PMDBM77,n.a.,Bacteroides WH2 WH2,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.449 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12307,Microbes metabolize substances,PMDBM163,n.a.,Clostridium sporogenes ATCC15579,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.025 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12308,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12309,Microbes metabolize substances,PMDBM71,n.a.,Bacteroides thetaiotaomicron VPI-5482,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.714 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12310,Microbes metabolize substances,PMDBM69,n.a.,Bacteroides thetaiotaomicron 3731,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12311,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.525 [FDR-adjusted p-Value=0.0],PMID,PMID: 31158845
PMDBI12312,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.985 [FDR-adjusted p-Value=0.002],PMID,PMID: 31158845
PMDBI12313,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12314,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.003],PMID,PMID: 31158845
PMDBI12315,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.198 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI12316,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.726 [FDR-adjusted p-Value=0.004],PMID,PMID: 31158845
PMDBI12317,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD895,,,Vilazodone,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.194 [FDR-adjusted p-Value=0.001],PMID,PMID: 31158845
PMDBI42419,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1490,,,Vinblastine,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,No change of activity,In vitro,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 26416623; PMID: 30890566
PMDBI10894,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD897,,,Vinpocetine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.018],PMID,PMID: 31158845
PMDBI42355,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD1492,,,Vitamin D,Therapeutic Substance,Approved Drug,n.a.,n.a.,Increase,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 32409589
PMDBI11428,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.025],PMID,PMID: 31158845
PMDBI11429,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI11430,Microbes metabolize substances,PMDBM310,n.a.,Parabacteroides distasonis ATCC8503,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042],PMID,PMID: 31158845
PMDBI11431,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.008],PMID,PMID: 31158845
PMDBI11432,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11433,Microbes metabolize substances,PMDBM304,n.a.,Odoribacter splanchnius,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044],PMID,PMID: 31158845
PMDBI11434,Microbes metabolize substances,PMDBM70,n.a.,Bacteroides thetaiotaomicron 7330,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI11435,Microbes metabolize substances,PMDBM43,n.a.,Bacteroides fragilis 3397 T10,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.038],PMID,PMID: 31158845
PMDBI11436,Microbes metabolize substances,PMDBM52,n.a.,Bacteroides fragilis T(B)9,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.048],PMID,PMID: 31158845
PMDBI11437,Microbes metabolize substances,PMDBM45,n.a.,Bacteroides fragilis DS-208,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.03],PMID,PMID: 31158845
PMDBI11438,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.02],PMID,PMID: 31158845
PMDBI11439,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11440,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD899,,,Voriconazole,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.727 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI40469,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0018713],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41198,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001974927],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41323,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006721124],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41430,Substances alter microbe abundance,PMDBM100,216816,Bifidobacterium longum,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41641,Substances alter microbe abundance,PMDBM116,40520,Blautia obeum,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.23E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41896,Substances alter microbe abundance,PMDBM140,n.a.,Clostridioides difficile,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05],n.a.,n.a.,n.a.,n.a.,n.a.,Human,Type 2 diabetes,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42056,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42214,Substances alter microbe abundance,PMDBM203,1547,Erysipelatoclostridium ramosum,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42653,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165081],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43436,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43989,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44155,Substances alter microbe abundance,PMDBM313,46503,Parabacteroides merdae,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007133259],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44317,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000548876],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44654,Substances alter microbe abundance,PMDBM355,166486,Roseburia intestinalis,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000925335],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45003,Substances alter microbe abundance,PMDBM363,33038,[Ruminococcus] gnavus,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.75E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45314,Substances alter microbe abundance,PMDBM388,1318,Streptococcus parasanguinis,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000240274],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45444,Substances alter microbe abundance,PMDBM391,1304,Streptococcus salivarius,PMDBD907,,,Zafirlukast,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI11214,Microbes metabolize substances,PMDBM114,n.a.,Blautia hansenii DSM20583,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.032],PMID,PMID: 31158845
PMDBI11216,Microbes metabolize substances,PMDBM38,n.a.,Bacteroides dorei DSM17855,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.013],PMID,PMID: 31158845
PMDBI11217,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.015],PMID,PMID: 31158845
PMDBI11218,Microbes metabolize substances,PMDBM49,n.a.,Bacteroides fragilis NCTC 9343,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.011],PMID,PMID: 31158845
PMDBI11219,Microbes metabolize substances,PMDBM79,n.a.,Bacteroides xylanisolvens DSM18836,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI11220,Microbes metabolize substances,PMDBM74,n.a.,Bacteroides uniformis ATCC8492,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045],PMID,PMID: 31158845
PMDBI11221,Microbes metabolize substances,PMDBM47,n.a.,Bacteroides fragilis HMW610,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.014],PMID,PMID: 31158845
PMDBI11222,Microbes metabolize substances,PMDBM48,n.a.,Bacteroides fragilis HMW615,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.016],PMID,PMID: 31158845
PMDBI11223,Microbes metabolize substances,PMDBM44,n.a.,Bacteroides fragilis ATCC43859,PMDBD908,,,Zaleplon,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.041],PMID,PMID: 31158845
PMDBI10861,Microbes metabolize substances,PMDBM16,n.a.,Anaerococcus hydrogenalis DSM7454,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.047],PMID,PMID: 31158845
PMDBI40210,Substances alter microbe abundance,PMDBM33,47678,Bacteroides caccae,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05],n.a.,n.a.,n.a.,n.a.,In vivo,Mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40333,Substances alter microbe abundance,PMDBM46,n.a.,Bacteroides fragilis enterotoxigenic,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005331174],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40477,Substances alter microbe abundance,PMDBM50,n.a.,Bacteroides fragilis nontoxigenic,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000343393],n.a.,n.a.,n.a.,n.a.,In vivo,Gadus Morhua,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40613,Substances alter microbe abundance,PMDBM57,n.a.,Bacteroides ovatus,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40736,Substances alter microbe abundance,PMDBM68,818,Bacteroides thetaiotaomicron,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41201,Substances alter microbe abundance,PMDBM78,371601,Bacteroides xylanisolvens,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41328,Substances alter microbe abundance,PMDBM88,1680,Bifidobacterium adolescentis,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005860626],n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42070,Substances alter microbe abundance,PMDBM153,n.a.,Clostridium perfringens,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000568494],n.a.,n.a.,n.a.,n.a.,n.a.,Human,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43048,Substances alter microbe abundance,PMDBM212,585397,Escherichia coli ED1a,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43131,Substances alter microbe abundance,PMDBM213,585034,Escherichia coli IAI1,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43847,Substances alter microbe abundance,PMDBM303,28118,Odoribacter splanchnicus,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44490,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD909,,,Zidovudine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.76E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI45590,Substances alter microbe abundance,PMDBM405,29466,Veillonella parvula,PMDBD910,,,Zileuton,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426281],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42698,Substances alter microbe abundance,PMDBM171,410072,Coprococcus comes,PMDBD912,,,Ziprasidone  Hydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003648773],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI10917,Microbes metabolize substances,PMDBM211,n.a.,Escherichia coli BW25113,PMDBD913,,,Ziprasidone mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.029],PMID,PMID: 31158845
PMDBI10918,Microbes metabolize substances,PMDBM76,n.a.,Bacteroides vulgatus ATCC8482,PMDBD913,,,Ziprasidone mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.009],PMID,PMID: 31158845
PMDBI10919,Microbes metabolize substances,PMDBM10,n.a.,Alistipes indistinctus DSM 22520,PMDBD913,,,Ziprasidone mesylate,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.022],PMID,PMID: 31158845
PMDBI10405,Microbes metabolize substances,PMDBM162,1509,Clostridium sporogenes,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,Benzisoxazole ring reduction,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,PMID,PMID: 27591027; PMID: 9231340; PMID: 1615700
PMDBI10592,Microbes metabolize substances,PMDBM162,1509,Clostridium sporogenes,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,2-sulphamoylacetylphenol,n.a.,n.a.,Increase Efficacy,n.a.,n.a.,n.a.,Zonisamide reductase,Increase activity,PMID,PMID: 30227749
PMDBI10593,Microbes metabolize substances,PMDBM348,294,Pseudomonas fluorescens,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI10594,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI10595,Microbes metabolize substances,PMDBM75,821,Bacteroides vulgatus,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI10596,Microbes metabolize substances,PMDBM199,n.a.,Enterococcus faecalis,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI10597,Microbes metabolize substances,PMDBM162,1509,Clostridium sporogenes,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI10598,Microbes metabolize substances,PMDBM93,1681,Bifidobacterium bifidum,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI10599,Microbes metabolize substances,PMDBM282,47715,Lactobacillus rhamnosus,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI10600,Microbes metabolize substances,PMDBM371,n.a.,Salmonella enterica subsp. enterica serovar Typhimurium,PMDBD915,,,Zonisamide,Therapeutic Substance,Approved Drug,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,n.a.,Reductive metabolism,n.a.,PMID,PMID: 30227749
PMDBI40076,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD916,,,Zotepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0056596],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40903,Substances alter microbe abundance,PMDBM72,820,Bacteroides uniformis,PMDBD916,,,Zotepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.84E-05],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41088,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD916,,,Zotepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-06],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43290,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD916,,,Zotepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001711794],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43473,Substances alter microbe abundance,PMDBM224,39491,[Eubacterium] rectale,PMDBD916,,,Zotepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001843987],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44013,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD916,,,Zotepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003256341],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44339,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD916,,,Zotepine,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004271679],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI40077,Substances alter microbe abundance,PMDBM7,239935,Akkermansia muciniphila,PMDBD917,,,Zuclopenthixol dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000933639],n.a.,n.a.,n.a.,n.a.,In vivo,C57BL/6 mouse,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI41091,Substances alter microbe abundance,PMDBM75,821,Bacteroides vulgatus,PMDBD917,,,Zuclopenthixol dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428916],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42504,Substances alter microbe abundance,PMDBM167,74426,Collinsella aerofaciens,PMDBD917,,,Zuclopenthixol dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004949573],n.a.,n.a.,n.a.,n.a.,In vitro,Human gut microbiota ex vivo mixed culturing system,Health,n.a.,n.a.,PMID,PMID: 29555994
PMDBI43292,Substances alter microbe abundance,PMDBM219,39485,[Eubacterium] eligens,PMDBD917,,,Zuclopenthixol dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005211733],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44016,Substances alter microbe abundance,PMDBM309,823,Parabacteroides distasonis,PMDBD917,,,Zuclopenthixol dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575241],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44342,Substances alter microbe abundance,PMDBM329,165179,Prevotella copri,PMDBD917,,,Zuclopenthixol dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI44505,Substances alter microbe abundance,PMDBM354,301301,Roseburia hominis,PMDBD917,,,Zuclopenthixol dihydrochloride,Therapeutic Substance,Approved Drug,n.a.,n.a.,Decrease,Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000835203],n.a.,n.a.,n.a.,n.a.,In vitro,High-throughput incubation assays,n.a.,n.a.,n.a.,PMID,PMID: 29555994
PMDBI42420,Microbes metabolize substances,PMDBM209,562,Escherichia coli,PMDBD1498,,,Β-Lapachone,Therapeutic Substance,Approved Drug,n.a.,Gut,n.a.,n.a.,n.a.,n.a.,n.a.,Decrease activity,In vitro,n.a.,n.a.,n.a.,Decrease hemotherapeutic drug cytotoxicity in vitro.,PMID,PMID: 26416623; PMID: 30890566